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 A vaccine to prevent infectious diseases associated with Epstein-Barr virus (EBV) 
has been put forward decades ago but has not made it to the clinic yet. EBV is a very 
complex herpes virus and its complexity, uncertainties about viral antigenic targets 
and technical difficulties to establish and mass-produce viral mutants are major 
obstacles. To mimic the complexity of the virus which encompasses more than 80 
proteins, virus-like particles (VLPs) have a high potential as a vaccine prototype. To 
explore conditions to optimize and improve virus production, I established and 
tested an EBV gene library with 78 expression plasmids and a set of designed shRNAs 
investigating the functions of individual viral genes in the context of virus synthesis. 
Engineered virus stocks were then systematically characterized with respect to virus 
titers, bioparticle and physical particle concentration and virus uptake by primary 
human B cells, EBV’s target cells in vivo. To quantitate virus uptake by these cells, I 
developed a novel ß-lactamase-based assay that can monitor fusion events of the 
viral envelope with membranes of recipient cells at the level of single cells by flow 
cytometry. Together, my results identified several EBV genes such as BALF4, BVLF1 
and BKRF4, encoding a viral glycoprotein, a regulator of transcription of late viral 
genes, and a possible tegument protein, respectively, that improve virus production 
regarding virus yield, virus composition and quality and virus uptake. My experi-
ments also indicated that EBV does not encode a master gene that governs EBV 
synthesis dampening virus production, contrary to my initial working hypothesis. 
Conditional expression of viral genes that improve EBV production as identified in my 
work will likely enhance and improve yield, assembly and important functional 
parameters of VLPs (such as their efficient uptake by antigen presenting immune 
cells, for example) supporting the development of a much improved EB-VLP based 




Epstein-Barr virus and its characteristics  
Epstein-Barr virus (EBV) was discovered by Michael Anthony Epstein, Bert 
Geoffrey Achong and Yvonne Barr in samples of Burkitt’s lymphoma biopsies in 1964 
(Epstein et al., 1964). EBV belongs to the large of herpesviruses and is also known as 
human herpesvirus 4 (HHV4) (Albà et al., 2001). Together with EBV, human 
herpesviruses encompass 9 members including herpes simplex 1 (HHV-1), herpes 
simplex 2 (HHV-2), varizella-zoster virus (VZV, HHV-3), human cytomegalovirus 
(HCMV, HHV-5), human herpesvirus 6A, 6B, (HHV-6A, HHV-6B), human herpesvirus 7 
(HHV-7) and Kaposi sarcoma-associated herpesvirus (KSHV, HHV-8) besides EBV, 
which are further classified into three subfamilies, alpha, beta and gamma. These 
pathogens can cause a wide range of different infectious diseases, but many 
infections in early childhood go unnoticed (Davison, 2007). A hallmark of all 
herpesviruses is their ‘lifestyle’ characterized by predominantly latent infections in 
vivo and in vitro. Latency means that the infected target cells carry viral genome 
copies, which are epigenetically repressed such that no or only a very restricted set 
of viral genes is expressed preventing immune recognition as well as virus de novo 
synthesis. Only upon reactivation, the latently infected cells turn into virus factories 
which release progeny.   
Since its discovery, EBV has been implicated in several life-threatening malignan-
cies, which include Burkitt’s lymphoma, Hodgkin’s lymphoma and nasopharyngeal 
carcinoma, among others. Primary infection with EBV usually takes place in early 
childhood and is asymptomatic. In industrialized countries, first encounter with EBV 
is often delayed until adolescence and young adulthood, but then infection with EBV 
can lead to Infectious Mononucleosis (IM) in up to 50 % of all individuals (Faulkner et 
al., 2000). EBV targets mainly mature human B cells and epithelial cells. The virus 
enters via a viral glycoprotein complex consisting of three members, gH/gL/gp42, 
which bind to HLA class II molecules after viral adhesion to the prevalent CD21 
surface receptor on B cells via gp350, a very abundant glycoprotein on the viral 
envelope. Paradoxically, entry of EBV into epithelial cells, which lack HLA class II 
molecules is hampered by gp42 and the expression of only gH/gL provides the 
tropism for epithelial cells (Möhl et al., 2016; Sathiyamoorthy et al., 2016).  
EBV’s canonical infection route starts with EB virions in the oropharynx that 
make their way through the mucosal layers of epithelial cells to infect B cells present 
in lymphoid tissues such as lymphnodes and tonsils. How EBV traverses the epithelial 
layer is controversial. The newly infected B cells express an incomplete set of lytic 
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and latent genes but are incapable of releasing infectious virions. This phase is 
termed pre-latent phase (Faulkner et al., 2000; Taylor et al., 2015; Buschle and 
Hammerschmidt, 2020) and leads to a stable latent infection in B cells, preferentially 
memory B cells with a long lifespan, eventually. Stable latent infection is supported 
by a very much reduced expression of viral antigens to evade immune recognition. In 
B cells, EBV persists lifelong in its human host. Only upon terminal differentiation of 
latently infected B cells to plasma cells, which can ensue upon antigen encounter, 
plasma cells turn into virus producing cells releasing infectious virions. 
 
The EBV genome, its replication and steps that lead to virus synthesis 
In latently infected B cells, several copies of the EBV genome are maintained as 
extrachromosomal plasmids or mini-chromosomes. The plasmid copies replicate in 
synchrony with the host cell in S phase. DNA replication of the EBV genomic copies 
initiates at the origin of DNA synthesis recognized as oriP which governs viral 
replication of the entire genome during latency (Aiyar et al., 1998). In this phase, the 
expression of viral genes is strictly limited. When the virus reactivates from latency 
and the lytic phase of infection initiates, viral genes such as BZLF1 and BRLF1 (also 
known as Zta and Rta, respectively) are expressed to start the expression of the early 
class of viral genes. Thus, BZLF1 and BRLF1 are categorized as immediate early genes 
(Murata and Tsurumi, 2014) and both gene products are able to switch on the lytic 
phase of EBV’s life cycle (Feederle et al., 2000). BZLF1 is a very interesting virally 
encoded transcription factor, which has properties of a pioneer factor (Zaret and 
Mango, 2016) and can revert epigenetic repression of EBV DNA fostering expression 
of viral lytic genes (Buschle et al., 2019; Schaeffner et al., 2019). Upon initial 
expression of BZLF1 and BRLF1, mainly BZLF1 induces the expression of the class of 
early viral genes, which are essential for autonomous viral DNA replication during 
EBV’s lytic phase. These genes include the viral DNA polymerase encoded by BALF5, a 
single-stranded DNA-binding protein encoded by BALF2, a DNA polymerase 
processivity factor encoded by BMRF1 and a primase-helicase complex, formed by 
three viral proteins encoded by BSLF1, BBLF4 and BBLF2/3 (Fixman et al., 1992; 
Sugimoto et al., 2019). Together with BZLF1 (Schepers et al., 1993), this group of 
replication factors initiates lytic DNA replication at oriLyt, the lytic origin of DNA 
replication (Hammerschmidt and Sugden, 1988) in a asynchronous manner to yield 
massive concatemers of newly replicated viral DNA, which serve as templates for 
transcription of late viral genes and are cleaved and subsequently packaged into 
preformed viral capsids in the nucleus.  
To support the following wave of late viral genes, which encompass mainly viral 
structural and tegument proteins, the viral BcRF1 gene product is essential. It 
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encodes a viral TATA-box like DNA binding protein, which binds to promoters of late 
viral genes to enable efficient expression of all late proteins (Wyrwicz and 
Rychlewski, 2007). Additionally, BGLF3, BDLF4, BVLF1, BDLF3.5 and BFRF2 are 
essential for supporting lytic gene expression (Aubry et al., 2014). The EBV structural 
proteins are critical for synthesizing viral components that sustain the integrity of 
virion morphogenesis. A complex, which comprises the major capsid protein (BcLF1), 
the minor capsid protein (BFRF3), a scaffold protein (BdRF1), a protease (BVRF2) 
together with two minor capsid proteins (BDLF1 and BORF1) was found to be 
essential for nucleocapsid assembly and maturation (Henson et al., 2009; Wang et 
al., 2011, 2015).  
Although many viral structural proteins are known, there are still multiple 
unsolved questions. Virus formation, nuclear export of DNA-filled capsids, their first 
and second envelopment at nuclear and cytoplasmic membranes, respectively, and 
the release and egress of mature virions from cells require many prior steps such as 
viral DNA packing and capsid assembly in the nucleus of lytically infected cells. BBRF1 
acts as a portal protein, which guides the amplified viral DNA into preformed, but 
empty capsids in the nucleus. In the absence of BBRF1 and BMRF1 viral DNA cannot 
be delivered and packaged (Pavlova et al., 2013; Sugimoto et al., 2019). Moreover, 
BFRF1A, BGRF1 and BVRF1 are directly or indirectly linked to viral DNA packing 
(Visalli et al., 2019) and BFLF2, BFRF1, BSRF1 and BBRF2 have been identified to be 
necessary for viral DNA loading and processing to unit length genomes (Farina et al., 
2005; Granato et al., 2008; Masud et al., 2019; Yanagi et al., 2019). Overall, the EBV 
genome encodes more than 80 proteins, which can be classified into different 
categories based on various criteria. Certain functions have been discovered and are 
known but the functions of many more viral gene products are still vague, 
hypothetical or completely unknown.  
 
Medical need of a preventive EBV vaccine  
Primary infection of EBV in childhood is mostly asymptomatic, but if primary 
infection takes place later during adulthood and adolescence, it can cause Infectious 
Mononucleosis (IM), leading to fever, fatigue and lymphadenopathy with a low rate 
of acute complications such as spleen rupture and airway obstructions. In addition, 
IM increases the risk of developing Burkitt ‘s lymphoma, Hodgkin’s lymphoma and 
multiple sclerosis later in life (Faulkner et al., 2000) and IM is also involved in pro-
gression of gastric cancer and nasopharyngeal carcinoma (Li et al., 2018). The post-
transplant lymphoproliferative disease (PTLD) is a major problem as EBV-negative 
organ transplant patients are vulnerable to PTLD because they are immuno-
suppressed and thus lack an efficient cellular immunity to control EBV infected B 
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cells. Clearly, the call for a prophylactic EBV vaccine to prevent IM and its sequelae 
and other EBV-associated consequences of infection is becoming more and more 
important.  
 
Different strategies of designing an EBV vaccines 
The glycoproteins of EBV play critical roles during virus infection and are 
interesting targets of virus-neutralizing antibodies. The major gp350 glycoprotein 
binds to CD21 on B cells to promote cell adhesion and the trimeric gH/gL/gp42 
complex interacts with MHC class II molecules initiating uptake of the virus into 
endosomes prior to membrane fusion. Moreover, gp42 has been identified to 
support infection of epithelial cells. Another glycoprotein encoded by the BALF4 gene 
is a gB homologue (Neuhierl et al., 2009) and promotes viral fusion. As the main 
target of a subunit vaccine, gp350 has been utilized as antigen and vaccine drug 
substance. Clinical studies showed that the recombinant gp350 vaccine can reduce 
the rate of IM, if the vaccine was applied prior to first infection with EBV. The 
recombinant gp350 vaccine proceeded to a phase 2 clinical trial by Glaxo Smith Kline 
(Cohen, 2015). Although the vaccine was found capable of reducing the incidence of 
IM, its lacking potency to prevent EBV infection led to a halt of its further clinical 
development (Sokal et al., 2007). So far, there have been many other approaches 
targeting different antigens of EBV. An EBNA3A epitope vaccine was found to be able 
to induce CD8+ T-cell response and is in a phase 1 trial (Elliott et al., 2008). Our group 
is currently in the process of developing an EBV vaccine with the primary indication 
to prevent IM. Its drug substance is virus-like particles (VLPs) that lack viral DNA and 
EBV oncogenes such that they cannot propagate infection and cellular transfor-
mation. EB-VLPs are morphologically and biochemically identical to EB virions and 
thus encompass about 50 different viral proteins and potential antigens (Johannsen 
et al., 2004). In a pre-clinical mouse model, VLPs could elicit strong CD4+ and CD8+ T-
cell responses besides antibodies reactive against a broad spectrum of viral proteins 
(Ruiss et al., 2011). These EB-VLPs were engineered by deleting essential packaging 
signal sequences on genomic viral DNA together with viral oncogenes that pose a 
risk. An alternative approach to generate EB-VLPs is the deletion of BFLF1/BFRF1A, 
which encode DNA packaging functions and gB to prevent infection together with 
enhanced BNRF1 expression. This experimental VLP vaccine demonstrated protec-
tion against EBV infection in a humanized mouse model (Zyl et al., 2018; van Zyl et 
al., 2019).  
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Studying EBV protein functions can contribute to EBV vaccine 
development  
Several approaches have been proposed to develop vaccines against EBV 
associated disease on the basis of virus-like particles (VLPs), but the key question of 
their efficient production has not been addressed and their practical availability and 
efficacy are uncertain. It is in particular unclear if the cellular host, the HEK293 cell 
line established a long time ago (Russell et al., 1977) optimally supports expression 
of all lytic EBV genes as well as morphogenesis and egress of viral particles as these 
cells are very distant to EBV’s genuine host cell. In an EBV infected human host, EBV 
infects resting B cells in a latent manner. Only upon terminal differentiation of 
latently infected B cells, plasma cells are thought to be the source of infectious virus 
(Laichalk and Thorley-Lawson, 2005). The selection of HEK293 cells as an EBV host 
and EBV synthesis in vitro dates back to pioneering work by my laboratory in 1998, 
when the entire EBV genome was cloned onto a bacterial artificial chromosome, a 
BACmid, which is also called maxi-EBV (Delecluse et al., 1998). Cloning of EBV as a 
BACmid was a technical achievement, but it was more challenging to identify a cell 
that would support virus synthesis upon induction of EBV’s lytic cycle. Among the 
many established cell lines tested, only HEK293 cells turned out to support virus de 
novo synthesis (personal communication). In fact, the search for a better suited cell 
that promotes efficient virus synthesis has failed so far (unpublished data).  
Moreover, the functions of most EBV genes and their products with respect to 
virus de novo synthesis and the biology of the host cell are not known or unclear. 
Consequently, my thesis is designed to study individual viral functions using a 
plasmid library of >75 EBV genes cloned into an expression plasmid. Single viral 
genes are tested upon their ectopic expression in the established 2089 EBV producer 
cell line and concomitant with induction of EBV’s lytic phase followed by detailed 
analyses of the resulting composition of viral particles and their functionality. 
Knowing the contribution of single EBV genes might open opportunities to enhance 
and improve virus yield and the quality of viral particles with respect to their 
function, fusion and antigenicity.  
Regarding one aspect of functional virions, their fusion with target cells is a 
critical and potentially limiting step. Thus, I devoted some of my PhD work 
developing means to monitor membrane fusion between the viral envelope and 
cellular membranes and adapted such an assay. Its principle was shown in the field of 
HIV research in 2002 (Cavrois et al., 2002; Jones and Padilla-Parra, 2016), but it has 
not been introduced into the field of herpesviruses. I developed this assay further to 
quantify EBV fusion events at the level of single cells as a new parameter of analysis.  
Clearly, vaccine preparations containing infectious EB virion are unsuitable as 
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vaccine candidates, but synthesis of intact, fully infectious EBV, its morphogenesis, 
egress and basic viral functions are proxies for VLP production. This is because 
production of both infectious virions and virus-like particles follow identical 
technical, cellular and viral principles. In contrast to infectious EB virions, studying 
VLPs is a rather cumbersome endeavor because a detailed investigation of their 
numbers, their biochemical composition and their uptake by target cells require 
sophisticated and very time-consuming assays.  
 
Scope and aim of my thesis  
 For more than 20 years now HEK293 cells have been instrumental to produce 
recombinant EBV stocks. The identification of this cell line as a source of infectious 
EB virions was pure serendipity since the cells are very distant to cells that produce 
EBV progeny in vivo. Nevertheless, HEK293 cells have remained the only usable 
source to generate recombinant EBV stocks so far. No systematic analysis has 
addressed the fundamental question whether virus yield with respect to virus 
concentration, virion composition and functionality can be improved while using 
these EBV producer cells. It was my task to tackle this question and to apply and 
establish (novel) assays to characterize these important parameters in the field of 
herpesvirology. 
Practically, I generated EB virus stocks from the 2089 EBV producer cells line 
2089 after ectopic expression of single EBV genes. They stem from an expression 
plasmid library that I curated for my particular needs here in this project. 
Alternatively, I adopted an shRNA technology to repress selected viral transcripts in 
the cells to knockdown specific viral genes of interest. The virus stocks were further 
characterized (Figure 1) regarding their physical particle concentration using a 
nanoparticle tracking analysis (NTA) instrument. The bioparticle concentrations were 
measured in an Elijah cell binding assay quantitating bound virion particles on the 
cell surface. Human primary B cells were incubated with engineered, CD63:ß-
lactamase-equipped EB virions and their fusogenic activities were subsequently 
analyzed by flow cytometry. Raji cells were utilized as a tool to determine the virus 
titer of the EB virus stocks. Flow cytometry detected the fraction of cells that express 
green fluorescence protein (GFP) encoded by recombinant EBV derivatives indicative 
of viral infection, the endpoint of the infectious route. Information derived from this 
PhD work is potentially useful to unravel the contributions of single viral genes and 
their encoded EBV proteins to efficient virus production. This information is also 
crucial to optimize EBV as well as VLP yield and the composition of infectious virions 






Figure 1. Overview of the experimental strategy of analyzing the composition of engineered EBV 
stocks and their virus-cell interactions.  
EBV stocks are obtained from the stable EBV producer cell line 2089 after transient transfection of an 
expression plasmid encoding the viral activator BZLF1. Supernatants of the cells containing infectious 
virus were collected after three days. Engineered EB viruses were obtained by co-transfection of BZLF1 
together with an individual expression plasmid from a panel of 76 different EBV genes to study their 
effects on quality and quantity of the ensuing EBV stocks. Alternatively, the EBV producer cell line was 
transfected with a plasmid encoding a reporter gene, CD63:ß-lactamase, to equip virus particles with 
an enzyme to study viral fusion with target cells. In yet another setting the EBV producer cell line was 
stably transduced with shRNAs to control certain selected viral transcripts and study the effects of their 
knockdown on virus production and composition. Different individual virus stocks were analyzed with 
the aid of three different target cells (Elijah cells, primary B cells, Raji cells) and their physical particle 
concentration was quantified using nanoparticle tracking analysis (NTA) instrument, ZetaView PMX110. 
Elijah cells were used to assess bioparticle concentration in the virus stocks via cell surface binding and 
subsequent analysis of bound particles by flow cytometry. Virus particles engineered to contain the 
CD63:ß-lactamase reporter protein were analyzed for their fusogenic activity with human primary B 
cells as targets again by flow cytometry. Finally, Raji cells were incubated with virus stocks to measure 
the virus titer, i.e., the concentration of infectious virus particles which confer expression of green 
fluorescence protein gene (GFP) in the infected cells as measured by flow cytometry. The four read-outs 

















A prophylactic EBV vaccine candidate under development and the 
question of its optimized production.  
 Since the first recombinant BLLF1 (gp350) subunit vaccine was developed to 
prevent EBV infection and EBV-associated diseases, there have been several attempts 
to develop alternative vaccines (Epstein et al., 1985). The most advanced vaccine 
development by Glaxo Smith Kline (GSK), also based on an adjuvanted gp350 protein 
formulation, reached phase II clinical testing with a medium efficacy preventing 
Infectious Mononucleosis. The trial was abandoned for unknown reasons in 2007, 
but several academic and commercial initiatives are known, which have announced 
pre-clinal and clinical testing of diverse candidate EBV vaccines (Moutschen et al., 
2007; Sokal et al., 2007; Cohen et al., 2013). All of them are based on subunit 
vaccines and many are centered on viral glycoproteins with the idea to evoke EBV-
neutralizing antibodies in the vaccinees. One of the most advanced vaccine 
candidates is probably by Moderna, Inc. and builds on this company’s mRNA 
technology according to a recent press release1. 
My laboratory and the laboratory of Henri-Jacques Delecluse put forward a very 
different idea of a preventive EBV vaccine that relies on virus-like particles (VLPs) of 
Epstein-Barr virus as the drug substance (Ruiss et al., 2011; van Zyl et al., 2019). EB-
VLPs mimic the composition of EB virions and their complexity which encompasses 
more than 50 viral proteins (Johannsen et al., 2004). In pre-clinical assays, 
formulations with EB-VLPs as a complex antigen cocktail induced both humoral and 
cellular immune responses directed against a multitude of viral antigens and 
epitopes (Ruiss et al., 2011). 
The generation of EB-VLPs is based on stable HEK293 cell-derived clones that 
carry an engineered EBV genome in a latent fashion. The cells can be propagated 
and expanded at will and can be induced to produce and release VLPs into the cells’ 
supernatant. Since the VLPs must not propagate viral infection, EBV genomes 
contained in such EB-VLP producer cells need to be genetically modified to meet this 
mandatory criterion. The genetic modifications are achieved by targeted genetic 
alterations in E. coli cells that carry a recombinant EBV genome as a bacterial 
artificial chromosome. The BACmid, which is also termed ‘maxi-EBV’ is maintained as 





(Delecluse et al., 1998), established the first EB-VLPs (Delecluse et al., 1999) and 
improved the recombineering technology (Pich et al., 2019) based on two genetic 
approaches in E. coli (Wang et al., 2009; Warming et al., 2005).  
With this technology at hand (Delecluse et al., 2008; Feederle et al., 2010) it is 
possible to alter the genetic composition of the EBV genome in E. coli such that it 
encodes all components of EB-VLPs but is non-infectious after its reconstitution in 
HEK293 cells. For example, the cis-acting packing signals of viral DNA can be deleted 
or essential viral genes that encode packaging functions can be disabled to achieve 
this aim (Hettich et al., 2006; Delecluse et al., 1999; Pavlova et al., 2013). The 
alterations of EBV’s genetic composition ensure that EB-VLPs will be devoid of viral 
genomic DNA (among other modifications that contribute to safety and 
immunogenicity) when reconstituted in the next step. The maxi-EBV DNA is then 
isolated and purified from E. coli and stably introduced into HEK293 cells, which give 
rise to EB-VLPs upon induction of EBV’s lytic phase. Lytic induction is generally 
achieved by transient transfection of an expression plasmid that encodes BZLF1, a 
viral gene and genetic switch that induces virus production in latently EBV infected 
cells upon its induced expression (Hammerschmidt and Sugden, 1988; Delecluse et 
al., 1998). 
Virus-like particles are ideal candidates for an EBV vaccine and are a promising 
strategy for EBV vaccine development (Hellebrand et al., 2006; Ruiss et al., 2011; 
Pavlova et al., 2013) because EB-VLPs likely induce robust immune responses against 
many EBV components and are capable of establishing antiviral effector T cells. To 
optimize VLP production, i.e., to increase their yield, improve their composition and 
uptake by EBV’s target cells and immune cells, it would be helpful to understand viral 
gene regulation, virion assembly, morphogenesis and egress during virus production. 
It is not clear, for example, if the process of EBV production is efficient or can be 
further improved because HEK293 cells are not the genuine viral host cells in a 
human organism. Therefore, my aim and plan were to identify possible means to 
improve EBV and VLP production in HEK293 cells. EBV as a fully infectious agent is 
clearly easier to trace and to quantify than EB-VLPs that lack the genetic information 
of the virus. Once identified in the EBV model working with infectious virus, means 
and measures to improve virus yield could similarly be applied to HEK293 cells that 
support EB-VLP production. This is because both EBV and EB-VLP production follow 
identical viral principles.   
My basic approach was first to test all known single EBV genes in a HEK293 cell 
line termed 2089 that carries the B95-8 strain of EBV as published earlier (Delecluse 
et al., 1998). Subsequently, I validated and refined my results using different read-
outs as shown in Figure 1 to characterize the functions of selected individual genes 
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further. Lastly, I adapted a fusion assay to the needs of my PhD work. Together with 
Manuel Albanese, I invented this general approach in a different project while 
working with extracellular vesicles (EVs) (Albanese et al., 2020). The source of all 
individual EBV genes cloned into a basic expression plasmid backbone was a library 
and repository of expression plasmids established by Dr. Josef Mautner. I used this 
library, modified the open reading frames to ensure proper expression of their 
unmodified viral genes and studied the consequences of introducing 78 individual 
expression plasmids in the platform cell line 2089 concomitantly with inducing EBV’s 
lytic cycle. I generated and tested the virus stocks to monitor the consequences of 
ectopic expression of all individual viral genes on the production of particles, 
concentration of infectious virions and viral characteristics using different functional 
analytical parameters as shown in Figure 1.  
 
EBV expression plasmids library with 78 individual viral genes 
 The 78 individual viral genes in the EBV expression library were provided by Dr. 
Josef Mautner (Table 1). Certain viral genes have attracted much interest by 
virologists and colleagues from the EBV field. For example, BZLF1, BALF4 and BLLF1 
have been studied intensively and their biological functions have been documented 
in detail (Janz et al., 2000; Neuhierl et al., 2002; Busse et al., 2010; Schaeffner et al., 
2019). Besides these very well-known and almost famous viral genes, there are still 
many EBV genes with unsettled, even enigmatic functions.  
With this EBV expression plasmid library, I was able to investigate potential 
functions of these genes using single gene expression plasmids. Since the plasmid 
library was established to express and purify single viral proteins from HEK293 cells 
after transient DNA transfection, all proteins are fused to epitope tags in the original 
plasmid library. This means that I had to remove these additional epitope tags, 
namely 6xHis and EBNA1 antibody tags, at the C-terminus of the open reading 
frames of all 76 expression plasmids as described in Materials and Methods in more 
detail. The purpose of this step was to express the original and unmodified viral 





Table 1. Overview of 78 EBV genes regarding their identity, classification in five 
functional classes and their expression timing 
Gene Identity Related Function Early/Late phase1 
A73 Protein A73 Unknown TBD 
BALF1 Apoptosis regulator BALF1 Non-structural protein E 
BALF2 Single-stranded DNA-binding protein DNA or Capsid associated  E 
BALF3 DNA packaging terminase subunit 2 DNA or Capsid associated  L 
BALF4 Envelope glycoprotein B Membrane protein L 
BALF5 DNA polymerase catalytic subunit DNA or Capsid associated  E 
BARF1 
Homolog of the human proto-oncogene c-
fms Membrane protein E 
BaRF1 Ribonucleotide reductase subunit 2 Non-structural protein E 
BBLF1 Myristylated tegument protein Tegument L 
BBLF2/BBLF3 Helicase-primase subunit DNA or Capsid associated  E 
BBLF4 Helicase-primase helicase subunit DNA or Capsid associated  E 
BBRF1 Capsid portal protein DNA or Capsid associated  L 
BBRF2 Tegument protein UL7 Tegument L 
BBRF3 Envelope glycoprotein M Membrane protein L 
BcLF1 Major capsid protein DNA or Capsid associated  L 
BCRF1 Interleukin-10 Non-structural protein TBD 
BcRF1 Viral TATA box binding protein DNA or Capsid associated  L 
BDLF1 Capsid triplex subunit 2 DNA or Capsid associated  L 
BDLF2 Envelope glycoprotein 48 Membrane protein L 
BDLF3 Envelope glycoprotein 150 Membrane protein L 
BDLF3.5 Protein UL91 Unknown TBD  
BDLF4 Protein UL92 Non-structural protein TBD  
BdRF1 Capsid scaffold protein DNA or Capsid associated  L 
BFLF1 DNA packaging protein UL32 DNA or Capsid associated  TBD  
BFLF2 Nuclear egress lamina protein DNA or Capsid associated  TBD  
BFRF1 Nuclear egress membrane protein DNA or Capsid associated  E 
BFRF1A DNA packaging protein UL33 DNA or Capsid associated  TBD  
BFRF2 Protein UL49 Unknown TBD  
BFRF3 Small capsid protein DNA or Capsid associated  L 
BGLF1 DNA packaging tegument protein UL17 DNA or Capsid associated  L 
BGLF2 Tegument protein UL16 Tegument L 
BGLF3 Protein UL95 Tegument TBD  
BGLF3.5 Tegument protein UL14 Tegument TBD  
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Gene Identity Related Function Early/Late phase1 
BGLF4 Tegument serine/threonine protein kinase DNA or Capsid associated  E 
BGLF5 Deoxyribonuclease DNA or Capsid associated  E 
BGRF1/BDRF1 DNA packaging terminase subunit 1 DNA or Capsid associated  TBD  
BHLF1 Protein BHLF1 DNA or Capsid associated  E 
BHRF1 Apoptosis regulator BHRF1 Non-structural protein E 
BILF1 Membrane protein BILF1 Membrane protein L 
BILF2 Membrane protein BILF2 Membrane protein L 
BKRF2 Envelope glycoprotein L Membrane protein L 
BKRF3 Uracil-DNA glycosylase Non-structural protein E 
BKRF4 Tegument protein G45 Tegument L 
BLLF1  Glycoprotein 350 Membrane protein L 
BLLF2  Protein BLLF2 Unknown TBD  
BLLF3 Deoxyuridine triphosphatase  Non-structural protein E 
BLRF1 Envelope glycoprotein N Membrane protein L 
BLRF2 Virion protein G52 Tegument L 
BLRF3 Unknown Unknown TBD  
BMLF1 EB2 DNA or Capsid associated  E 
BMRF1 DNA polymerase processivity subunit DNA or Capsid associated  E 
BMRF2 Envelope protein UL43 Membrane protein L 
BNLF2a Protein BNLF2a Non-structural protein E 
BNLF2b Protein BNLF2b Unknown TBD  
BNRF1 Tegument protein G75 Tegument L 
BOLF1 Tegument protein UL37 Tegument L 
BORF1 Capsid triplex subunit 1 DNA or Capsid associated  L 
BORF2 Ribonucleotide reductase subunit 1 Non-structural protein E 
BPLF1 Large tegument protein Tegument L 
BRLF1 Protein Rta DNA or Capsid associated  IE 
BRRF1 Protein G49 DNA or Capsid associated  E 
BRRF2 Tegument protein G48 Tegument TBD  
BSLF1 Helicase-primase primase subunit DNA or Capsid associated  E 
BSLF2/BMLF1 Multifunctional expression regulator DNA or Capsid associated  E 
BSRF1 Tegument protein UL51 Tegument L 
BTRF1 Tegument protein UL88 Tegument TBD  
BVLF1 Protein UL79 Unknown TBD  
BVRF1 DNA packaging tegument protein UL25 DNA or Capsid associated  L 
BVRF2 Capsid maturation protease DNA or Capsid associated  L 
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Gene Identity Related Function Early/Late phase1 
BXLF1 Thymidine kinase Non-structural protein E 
BXLF2 Envelope glycoprotein H Membrane protein L 
BXRF1 Nuclear protein UL24 Unknown TBD  
BZLF1 Protein Zta DNA or Capsid associated  IE 
BZLF2 Envelope glycoprotein 42 Membrane protein L 
LF1  Protein G10 Non-structural protein TBD  
LF2 Virion protein G11 Non-structural protein TBD  
RPMS1  Protein RPMS1 Unknown TBD  
sLF3  Protein LF3 Unknown TBD  
1: E, early; IE, immediate early; L, late; TBD: to be determined. 
 
The table was adapted according to overviews published in (Cai et al., 2017; Johannsen et al., 2004; 




Effects of individual EBV genes on virus titers 
 After restoring the integrity of 76 viral genes in the expression plasmid library, 
each plasmid was assigned a distinctive number in the institute’s database 
(Appendix, Table 6). To test all members of this plasmid library, 6.5x105 EBV producer 
cells of the 2089 cell line carrying a recombinant EBV B95-8 strain genome with a 
green fluorescence protein gene were seeded in 6-well cluster plates (Delecluse et 
al., 1998). After overnight cultivation, the medium was exchanged with 2 ml fresh 
exosome-depleted (ex-) medium (see Materials and Methods for its preparation and 
formulation). The cells were transiently co-transfected with 0.5 μg p509 plasmid DNA 
encoding the BZLF1 gene together with 0.5 μg plasmid DNA encoding one of the 76 
individual viral genes. 0.5 μg p509 and 0.5 μg pCMV vector DNAs, the ‘empty´ 
expression vector plasmid were co-transfected as control and reference for 
subsequent normalization. BZLF1 serves as the fundamental gene to induce EBV’s 
lytic cycle in the 2089 EBV producer cells. BALF4 encoded by the plasmid p6515 is 
the viral gB (glycoprotein B) homologue, which is found in all herpesviruses and was 
used as a positive control (Neuhierl et al., 2002). The standard protocol to produce 
virus stocks with the 2089 EBV producer cell line builds on transient transfection of 
the BZLF1 encoding expression plasmid p509, an approach which was established in 
my laboratory (Delecluse et al., 1998). After three days, the virus supernatants were 
harvested and partially purified using filters with 1.2 μm mesh size. 1x105 Raji cells, a 
human Burkitt’s lymphoma cell line, were incubated with 5 μl EBV virus stocks for 3 
days. EBV infected Raji cells were identified by green fluorescence protein expression 
and quantified by flow cytometry. All experiments were done in triplicates. The 
results from infection experiments with three independent sets of virus stocks were 
normalized to the respective controls, which were set to one. The ratios of the 76 
tested combinations plus the two controls were arranged in descending order (Fig. 
2). The viral BALF4 gene, which encodes the gB glycoprotein of EBV was co-
transfected with BZLF1 served as a positive control. BALF4 has been shown 
previously to generate highly infectious virus stocks in a similar experimental setup 
(Neuhierl et al., 2002). As shown in Figure 2A the genes contained in the plasmid 
library were sub-grouped according to viral functional classes as in Table 1 and color-
coded as follows – green: DNA or capsid-associated protein; red: membrane protein; 
brown: tegument protein; blue: non-structural protein; grey: protein with unknown 
functions (Fig. 2A). To relate the results to expression timing of the individual genes, 
the readouts were color-coded according to three criteria as follows – red: early viral 
gene; blue: late viral gene; grey: viral gene with unknown temporal expression 




Fig. 2 Comparison of the virus titer of samples generated by co-transfection of BZLF1 together with 
expression plasmids from a panel of 76 EBV genes plus two controls.  




























































































































































































































































































































































































































































































































































































































cell medium was exchanged with 2 ml exosome-depleted (ex-) medium (see Materials and Methods) 
followed by transient transfection of the cells with the BZLF1 expression plasmid p509 in combination 
with single expression plasmids from a panel of 76 individual EBV genes cloned into the pCMV plasmid 
backbone. The virus supernatants were harvested 3 days after transfection and filtrated using 1.2-
micron filters. 1x105 Raji cells were incubated with 5 μl harvested virus supernatants. After three days, 
the infected Raji cells were investigated by flow cytometry (BD FACSCanto™) analyzing the expression 
of green fluorescence protein. The x-axes list the individual EBV genes transfected in combination with 
BZLF1. The BZLF1 (p509) expression plasmid co-transfected with p6816, an empty pCMV vector plasmid 
served as reference and control (Ctrl). The titers of infectious EBV stocks according to the percentage of 
GFP-positive Raji cells (GRU) were normalized to the reference sample (Ctrl), which was set to 1. The 
results are listed in descending order. (A) EBV genes are color-coded according to five functional groups. 
(i) green: DNA or capsid-associated proteins, (ii) red: membrane proteins, (iii) brown: tegument proteins, 
(iv) blue: non-structural proteins, and (v) grey: proteins with unknown functions. (B) The EBV genes are 
marked according to their early or late expression characteristics. (i) red: early, (ii) blue: late, and (iii) 
grey: viral genes with unknown expression timing. Mean and standard deviation of three biological 
replicates are shown. Horizontal 0.5- and 1.5-fold line are indicated. Dotted vertical lines indicate groups 
of 10 viral genes for better visualization. 
 
Certain viral genes increase or decrease virus titers 
 The results in Figure 2 indicated that co-transfection of BMRF1, BGRF1/BDRF1, 
LF1, BLRF3, BDLF2 or BDLF3.5 together with BZLF1 yielded mean virus titers, which 
were at or exceeding a factor of 1.5 indicating that only six genes yielded slightly 
higher virus titers than the negative control. Two genes encode DNA or capsid-
associated proteins, one is a membrane protein, one is a non-structural protein, and 
two genes have unknown functions. No tegument protein encoding gene is among 
this list. According to expression timing among the six proteins that enhanced virus 
titers one is expressed early, one is expressed late and four have no known 
expression timing. It seems as if there is no clear attributable functional role nor a 
discrete expression timing within this group of six viral genes that led to higher virus 
infectivity of the virus stocks. The majority of viral genes tested, about 60 in total, are 
in a neutral zone with little variations to virus titers at around control level. In 
contrast, the last 15 plasmids co-transfected with BZLF1 and encoding BGLF5, BTRF1, 
BBRF1, BFRF1, BSLF2/BMLF1, BBRF3, BNRF1, BBLF1, BRLF1, BMRF2, BGLF4, BBRF2, 
BMLF1, LF2, and BALF1 led to virus titers lower than the control and reduced by a 
factor of 2 and more (Fig. 2). Seven genes in this group of viral factors with repressive 
functionality encode DNA or capsid-associated proteins, two are membrane proteins, 
four are tegument proteins and two are non-structural proteins suggesting that their 
presumably higher expression is contra-productive. Seven genes are expressed in the 
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early phase, whereas six genes are expressed in the late phase and two have no 
known expression timing. Again, there is no clear attributable functionality nor does 
expression timing seems to be a notable criterion.  
Taken together, ectopic expression of the 76 individual viral genes resulted in 
small differences in the concentration of the virus stocks, only. The positive control 
BALF4 is clearly superior compared to the remaining tested viral genes and increases 
the infectivity of the virus stocks by a factor of 6.5. The viral BMRF1, BGRF1/BDRF1, 
LF1, BLRF3, and BDLF2 genes also support infectivity but only between 1.5- to 1.8-
fold (Fig. 2). Remarkably, the B95-8 laboratory strain lacks the viral LF1 gene 
suggesting that it contributes a previously unknown but supportive functions during 
virus synthesis or enhances viral infectivity. A larger group of genes (n=15) exhibits 
repressive functions and shows a clear negative impact on virus synthesis or virus 
infectivity in this set of experiments. 
 
Measuring viral bioparticle concentrations using Elijah cells 
 Viral infectivity as measured in Figure 2 is the successful endpoint of the 
infectious route, which initiates with virus binding to targets cells as the very first 
step. I measured this key function using a cellular binding assays as shown schemati-
cally in Figure 1 using Elijah cells, a human B cell line derived from a case of Burkitt’s 
lymphoma (Rowe et al., 1985). 
The previously tested 76 EBV virus stocks plus appropriate controls were ana-
lyzed for viral particles binding to the surface of Elijah cells followed by flow cytome-
try using a fluorochrome-coupled monoclonal antibody with a superior specificity 
against gp350, the abundant glycoprotein in the viral envelope (obtained from 
Helmholtz Zentrum Muenchen antibody core facility; unpublished). The data 
expressed as mean fluorescence intensity (MFI) values were calculated and 
normalized to the control and standard reference and termed ‘bioparticle concentra-
tion’ as illustrated in Figure 1. Elijah cells and individual virus stocks were incubated 
for a limited time at low temperature to allow rigid viral binding to the cells via 
glycoproteins on the viral envelope and Elijah cell surface receptors. Virus binding 
was detected with an gp350-specific, fluorochrome-coupled monoclonal antibody on 
life cells. Practically, 2x105 Elijah cells were incubated with 20 μl virus stocks at 4 °C 
for 3 h. The fluorochrome-coupled gp350-specific antibody was added and the cells 
were analyzed by flow cytometry after appropriate washing steps. The raw values of 
MFI were recorded. Virus stocks generated with the 2089 EBV producer cells after 
co-transfection of an empty vector plasmid together with BZLF1 (p509) served as the 
reference control (Ctrl) and standard for calculating the ratios of MFI values as 
shown in Figure 3A. Virus stocks generated by co-transfection of the BALF4 encoding 
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expression plasmid p6515 together with p509 served as an additional control.  
 
Fig. 3 Comparison of the bioparticle concentration in virus samples generated by BZLF1 transfection 
together with expression plasmids from a panel of 76 EBV genes and two controls.  
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Virus production and generation of samples were identical as described in Figure 2. The number of viral 
particles bound to Elijah cells was determined, which is an indirect measure of bound virions. The read-
out is based on the binding of EBV particles to Elijah cells, a cancerous human B cell line, and the 
quantification of bound virus using a gp350-specific, fluorochrome-coupled monoclonal antibody by 
flow cytometry as described in Materials and Methods. The ratios of mean fluorescence intensity (MFI) 
values of individual samples versus the MFI value of the reference sample (Ctrl) were calculated and are 
provided on the y-axes. The x-axes list the transfected individual EBV genes in combination with BZLF1. 
An empty pCMV vector plasmid co-transfected with the BZLF1 plasmid p509 served as reference (Ctrl). 
Ratios are arranged in descending order. An expression plasmid encoding BALF4 served as a positive 
control. Shaded areas on the left and right flanks highlight groups of viral genes termed ‘high bin’ and 
‘low bin’, respectively, encompassing 12 and 14 group members. Three singly highlighted genes (BPLF1, 
BBRF1, BGLF4) were randomly picked as further candidates tested later. (A) EBV genes are classified 
according to five functional groups and are color-coded. (i) green: DNA or capsid-associated proteins, 
(ii) red: membrane proteins, (iii) brown: tegument proteins, (iv) blue: non-structural proteins, and (v) 
grey: proteins with unknown function. (B) EBV genes are color-coded according to their early or late 
expression characteristics. (i) red: early, (ii) blue: late, and (iii) grey: viral genes with unknown expression 
timing. Mean and standard deviation of three biological replicates are shown. The horizontal lines 
indicate 0.5- and 1.5-fold ratios. Dotted vertical lines indicate groups of 10 viral genes for better 
visualization. 
 
The most interesting result is the finding with a virus stock produced by co-
transfection of BALF4 and BZLF1, which showed absolutely no difference in this assay 
(Fig. 3) in contrast to the previous set of experiments in Figure 2, when this virus 
stock revealed a substantially higher virus infectivity. The results prove that BALF4 is 
limiting in virions when virus synthesis is induced by transient expression of BZLF1, 
only, in 2089 EBV producer cells. The results also documented that BALF4 increased 
the quality of EBV virions but did not contribute to virion quantity. As I will show 
later, BALF4, which is EBV’s glycoprotein B (gB) homologue present in all herpes-
viruses, is the essential fusogenic viral protein that promotes fusion of the virus 
envelope with membranes of the target cells.  
The other virus stocks showed a very similar trend as already seen in Figure 2. 
Variances between differently produced virus stocks were detectable and ranged 
from about a factor of 1.5 to 0.5. Only a small group of 13 virus stocks (BSLF1 -> 
BMLF1) showed a reduction below a factor of 0.5. Identical to Figure 2, the color 
codes in Figure 3A illustrate the five functional groups of viral proteins. Again, no 
discrete functional characteristics was obvious suggesting that various gene 
functions contribute to viral bioparticles synthesis. When the results were color-
coded according to gene expression timing regarding early, late genes or genes with 
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unknown timing, no special contribution of the three different classes could be 
found (Fig. 3B). This result suggests that various viral genes expressed throughout 
the entire lytic phase of virus production contribute to viral bioparticles biosynthesis. 
Certain viral genes can even reduce and repress bioparticle production. 
 
Subgroups of viral genes increase or decrease the concentration of 
bioparticles upon ectopic expression  
 After data normalization, 60 virus stocks locate within a broad middle range in 
between factors of 0.5 to 1.5 with subtle differences among the different virus stocks 
(Fig. 3). BKRF4, BVLF1 and BNLF2a, which represent a tegument protein, a protein 
with unknown function and a non-structural protein, respectively, are top candidates 
here and are part of the ‘high bin’ group. BKRF4, BVLF1 and BNLF2a all belong to 
different groups regarding expression timing (Fig. 3B), but the three genes show a 
similar effect and increase bioparticle production by about 50 % compared to the 
control. Thirteen viral genes that decrease bioparticle concentration by a factor of 
0.5 encompass BSLF1, BTRF1, LF1, BSLF2/BMLF1, BMRF2, BBRF3, BNRF1, BBLF1, 
BRLF1, BALF1, BBRF2, LF2 and BMLF1. Four genes among this class belong to DNA or 
capsid-associated proteins, two are membrane proteins, four are tegument proteins 
and three belong to the group of non-structural proteins. Based on expression 
timing, five genes are expressed early, five are expressed late and three have no 
known expression timing. Remarkably, virus stocks generated by ectopic expression 
of BALF1, BBRF2, LF2 and BMLF1 genes have a considerably reduced viral bioparticle 
concentrations in the order of 0.1, only, and lead the ‘low bin’ group of viral genes 
(Figure 3).  
 
Physical particle concentration of virus stocks  
 The same virus stocks analyzed in Figure 2 and 3 were investigated for their 
absolute number of physical particles by nanoparticle tracking analysis (NTA) using a 
ZetaView PMX110 instrument. All virus supernatant stocks were first diluted 50-fold 
with PBS to obtain a concentration in between 107 and 108 particles per ml. During 
analysis of the particles their movement by diffusion was recorded within 11 distinct 
spots in the chamber. Particle concentration of virus supernatant stocks was 
recorded and normalized to the control generated by co-transfection of BZLF1 and 
DNA of an empty plasmid vector (Fig. 4). Particle concentration in supernatants 
obtained after expression of the 76 viral genes plus two controls are arranged in 
descending order and the results are separated by vertical lines to obtain bins of 10 
genes each for better visualization.  
 Remarkably and in accordance with results shown in Figure 3 (bioparticle 
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concentration), virus stocks obtained after co-transfection of BALF4 and BZLF1 
contained identical numbers of physical particles (Fig. 4). Particle concentration in 
the different virus stocks varied in between factors of 1.3 to 0.3. Certain virus stocks 
showed an inconsistent number of physical particles from one experiment to the 
next documented by their standard deviation (e.g., BcLF1, BVRF1, BGLF3.5, LF1 
among others) for unknown reasons. At the low end of the data, reduction of 
physical particle concentration was moderate, only, very much in contrast to the 
results obtained in Figures 2 and 3, which depict viral infectivity and bioparticle 
concentration, respectively. It thus appears as if physical particle concentration and 
viral functions correlate moderately, only.  
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Fig. 4 Comparison of physical particle concentrations in virus samples generated by co-transfection of 




















































































































































































































































































































































































































































































































































































































Samples investigated in Figure 2 and 3 were analyzed here for their physical particle concentration by 
nanoparticle tracking analysis (NTA). NTA was performed with the ZetaView PMX110 instrument and 
the images were analyzed with the ZetaView 8.04.02 software. Standard calibration beads (102.7±1.3 
nm) were used to confirm the range of linearity. 1 ml diluted supernatant samples were injected for 
analysis. Particle concentration and size were measured and documented. The x-axes list the transfected 
individual EBV genes in combination with BZLF1. An empty pCMV vector plasmid (p6816) plus the BZLF1 
plasmid (p509) were co-transfected as reference (Ctrl). The positive control encompasses supernatants 
obtained after co-transfection of both BZLF1 and BALF4 expression plasmids. The number of physical 
particles in the range of 100 – 200 nm contained in the supernatants of cells were analyzed and 
normalized to the reference sample. The readouts are arranged in descending order. (A) EBV genes are 
classified according to five functional groups and color-coded. (i) green: DNA or capsid-associated 
proteins, (ii) red: membrane proteins, (iii) brown: tegument proteins, (iv) blue: non-structural proteins, 
and (v) grey: proteins with unknown functions. (B) EBV genes are marked according to their early or late 
expression characteristics. (i) red: early, (ii) blue: late, and (iii) grey: viral genes with unknown expression 
timing. Mean and standard deviation of three biological replicates are shown. The 0.5- and 1.5-fold line 
are indicated. Dotted vertical lines indicate groups of 10 viral genes for better visualization. 
 
Notably, the virus stocks contained not only virus particles but also cell debris, 
sizeable protein aggregates as well as an unknown fraction of extracellular vesicles 
(EVs), all of which potentially contribute to physical particle numbers in this analysis. 
The instrument cannot distinguish real virus particles from other particle within the 
same size range and its dynamic range of measuring is limited to 107 to 108 
particles/ml.  
 
Certain viral genes increase or decrease particles numbers  
 The read-outs in the two panels of Figure 4 are color-coded as in Figures 2 and 
3. Ten genes are at the high end, five of which are associated with DNA or capsid 
functions, one is a membrane protein, one gene is a tegument protein, one is a non-
structural protein and two have unknown functions. At the low end are 16 genes, 
eight of which are associated with DNA or capsid functions, two give rise to 
membrane proteins, four encode tegument proteins and two are non-structural 
proteins. Regarding expression timing, within the top 10 genes, 2 are expressed early, 
4 are expressed late and the remaining have no known expression timing (Fig. 4B). In 
the group of 16 virus stocks, which have the lowest number of physical particles 7 
are expressed early, 5 are expressed late and the expression timing of the remining 
genes is unknown. No particular function appears to cluster in the virus stocks 
arranged in descending order. Also, expression timing does not yield an obvious color 
pattern suggesting that various viral genes expressed throughout the entire lytic 
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phase of virus production and egress can modulate the biosynthesis of physical 
particles as measured by the NTA instrument. 
 
Statistical analysis and correlation of three parameters characterizing 
functional virus release, bioparticles and physical particles 
The finding so far shown in Figures 2 to 4 document the characteristics of three 
distinctive parameters obtained from 76 individual EBV stocks plus two controls. 
Figure 2 shows infectious virus titers of stocks after co-transfection of BZLF1 and 76 
individual EBV gene expression plasmids. Figure 3 demonstrates the bioparticle 
concentration of these virus stocks whereas Figure 4 indicates their physical particle 
concentration.  
 
Fig. 5 Statistical analysis and comparison of individual virus supernatants according to their virus titer, 
bioparticle concentration, physical particle concentration, functional group category and expressing 
timing classification.  





DNA or capsid associated 
Virus titers

























































Three characteristic measurements of 76 harvested individual virus supernatants plus two controls are 
shown summarizing the data in Figures 2-4: (i) virus titer (green Raji units, GRU, Figure 2); (ii) bioparticle 
concentration (Elijah ratios, Figure 3); and (iii) physical particle concentration (ZetaView, Figure 4). 
Possible overall correlation of the data and their statistical significance are provided in panel A together 
with specific correlation within functional groups and expression timing shown in panel B and C. (A) 
Mean values of the three functional tests (virus titer, bioparticle concentration, and the physical particle 
concentration data) were set as rank order and the statistical correlation was assessed using the 
Spearman rank correlation method. Correlations between two groups were analyzed and the 
correlation coefficients (R2) are shown in the grids of the heatmap. (i) bioparticle concentration versus 
virus titer: 0.7651; (ii) physical particle concentration versus virus titer: 0.7396; (iii) physical particle 
concentration versus bioparticle concentration: 0.8338. The color scale bar on the right indicates the 
intensity of the value. 1.0 is red and 0.7 is set to yellow. (B) Virus samples generated by individual co-
expression of 76 expression plasmids encoding viral genes together with BZLF1 (Figure 2A) were parted 
according to their functional groups (DNA or capsid-associated proteins, membrane proteins, tegument 
proteins, non-structural proteins and unknown). The x-axes show the fold changes compared to the 
references. The left, middle and right panel show the results of the three assays as indicated. The data 
are provided as box plots and each point represents the mean value of individual virus samples. The 
single red dots indicate the mean value of the virus sample generated by co-transfection of BZLF1 with 
BALF4. The statistical numerical results are presented in Table 2. (C) Results obtained with 76 virus 
supernatants are displayed according to their expression timing: early, late, and ‘to be determined’ and 
arranged as in panel B. The x-axes indicate the fold change. The red dots indicate BALF4. The unpaired 
Wilcoxon rank sum test was conducted in the statistical analysis between the early and late groups, the 
group labeled ‘to be determined’ was excluded from the statistical test. The median of the different 
populations is shown and the p-values are provided. 
 
The mean values of three measurements of the 76 virus stocks were taken and 
set as rank order to investigate a possible (and likely) correlation of these 
measurements. I assessed the mutual relationship using the Spearman rank 
correlation method. The values are provided in a heatmap shown in Figure 5A. The 
parameters are placed on the x- and y-axis of the grids of the heatmap. The color 
scale on the right indicates the intensity and the correlativity between two 
parameters ranging from 0.7 to 1.0. The correlativity of bioparticle concentration 
versus virus titer was found to be 0.7651 (dark yellow) the physical particle 
concentration versus virus titer was slightly lower at 0.7396 (light yellow) while the 
correlation between physical particle concentration and bioparticle concentration 
was highest at 0.8338 (orange).  
 To look for correlative details in my data, mean values derived from the three 
quantitative parameters (virus infectious titers, bioparticle and physical particle 
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concentration) were sorted according to functional groups or grouped according to 
expression timing criteria. To analyze the data from the three quantitative 
parameters, the data of Figures 2 to 4 were transformed into three box plots (Fig. 
5B). The y-axis denotes functional groups (DNA or capsid-associated proteins, 
membrane proteins, tegument proteins, non-structural proteins and unknown) and 
the x-axes show the fold change of each parameter (left: virus titer [GRU]; middle: 
bioparticle concentration [Elijah]; right: physical particle concentration [Zetaview]). 
The dots represent the mean values of the corresponding individual measurements 
and the single red dot in each panel indicates the results obtained with the BALF4 
gene encoding the viral glycoprotein gB. The statistics are summarized in Table 2. The 
means of virus titers, bioparticle concentration and physical particle concentration of 
the EBV virus stocks were grouped by biological functions and genes encoding viral 
proteins of unknown functionality were excluded from the test. The Kruskal Wallis 
rank sum test of one-way ANOVA was applied. The p-value adjustment method by 
Benjamini-Hochberg was applied to calculate the statistical significance between two 
functional groups in a pair-wise comparison. For example, the p-value of the Kruskal-
Wallis rank sum test is 0.7328 for the parameter of infectious viral titers (GRU in 
Table. 2) showing the statistical significance that prevent rejecting the null 
hypothesis of the overall test. This result indicated that all protein functions 
contribute to the GRU parameter as they do not significantly differ. The same 
statistical test was applied to the two remaining parameters as shown in Table 2. The 
p-value of the Kruskal-Wallis rank sum test is 0.7519 of bioparticle concentration 
among functional groups. P-values between groups are shown in the second part of 
the table. Additionally, 0.4194 is the p-value of the Kruskal-Wallis rank sum test of 
physical particle concentration and other p-values are also given. Again, no 
statistically significant contribution of proteins with different functions was found to 




Table 2. Statistical analysis of the correlation of the three read-out categories 
Virus titers 
Kruskal-Wallis rank sum test  
Kruskal-Wallis chi-squared = 1.2844, df = 3, p-value = 0.7328 
Pairwise comparisons using Wilcoxon rank sum test 
P value adjustment method: BH 
 DNA or capsid 
associated proteins 
Membrane proteins Non-structural 
proteins 
Membrane proteins 0.74 - - 
Non-structural 
proteins 
0.74 0.74 - 
Tegument  
proteins 
0.74 0.74 0.74 
Bioparticles 
Kruskal-Wallis rank sum test 
Kruskal-Wallis chi-squared = 1.2047, df = 3, p-value = 0.7519 
Pairwise comparisons using Wilcoxon rank sum test 
P value adjustment method: BH 
 DNA or capsid 
associated proteins 
Membrane proteins Non-structural 
proteins 
Membrane proteins 0.96 - - 
Non-structural 
proteins 
0.96 0.96 - 
Tegument  
proteins 
0.96 0.96 0.96 
Physical particles 
Kruskal-Wallis rank sum test 
Kruskal-Wallis chi-squared = 2.825, df = 3, p-value = 0.4194 
Pairwise comparisons using Wilcoxon rank sum test 
P value adjustment method: BH 
 DNA or capsid 
associated proteins 
Membrane proteins Non-structural 
proteins 
Membrane proteins 0.60 - - 
Non-structural 
proteins 
0.87 0.60 - 
Tegument  
proteins 
0.60 0.60 0.60 
BH: Benjamini-Hochberg (p-value adjustment method) 
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Expression timing of viral genes does not affect the three analyzed 
parameters of virus stocks  
 Mean values of the three measured parameters (virus titer [GRU]; bioparticle 
concentration [Elijah]; physical particle concentration [Zetaview]) were transformed 
into dots and displayed according to the criterion ‘expression timing’ of the viral 
genes, which are known to be expressed early or late or which have no known 
expression time (Fig. 5C). The left panel shows box plots of mean values of virus titer 
versus expression timing derived from Figure 2B. The middle panel transforms data 
shown in Figure 3B into box plots of bioparticle concentration versus expression 
timing. The right panel of box plots states physical particle concentration versus 
expression timing as in Figure 4B. The y-axes mark the groups of expression timing 
and the x-axes display the ratios of mean values of the three parameters. The red dot 
in each panel points to the mean value of virus stocks obtained by ectopic expression 
of BALF4. I used the unpaired Wilcoxon rank sum statistical test to analyze expression 
timing versus the three parameters. Data obtained with genes of unknown 
expression timing were excluded from the analysis. The two classes of viral genes 
with early or late expression timing had p-values of 0.5677, 0.7065 and 0.7065 from 
the left to the right panel documenting that expression timing of viral genes is also 
not a criterion that contributes significantly to the three analyzed parameters. 
 
Only one out of ten selected viral genes associated with elevated 
bioparticle numbers improves infectivity of viral stocks together with 
BALF4 
 In this and in the next chapters, I concentrated on subgroups of selected viral 
genes that enhance (or reduce) mean values of certain parameters.  
BALF4 is the only viral gene that boosts viral infectivity (Fig. 2) but it does not 
affect bioparticle concentration (Fig. 3) nor the concentration of physical particles in 
virus stocks generated by co-transfection of BALF4 and BZLF1 (Fig. 4). On the 
contrary, certain viral genes seem to increase the concentration of bioparticles as 
shown in Figure 3 but in the order of 1.5-fold, only. In this chapter I asked if these 
single viral genes associated with higher bioparticle concentration could yield better 
virus stocks when co-expressed with together BALF4 than virus stocks obtained by 
co-transfection of BALF4 and BZLF1, only. 
Ten EBV gene expression plasmids, BKRF4, BVLF1, BNLF2a, BXRF1, BFLF2, 
BMRF1, BHLF1, BXLF1, BVRF2 and BALF2, were chosen based primarily on their 
elevated viral bioparticle concentration as shown in the left grey block in Figure 3, 
which encompasses members of the ‘high bin’ group. In this ranking, the ten genes 
caused a higher bioparticle concentration in the supernatants.  
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To investigate a possible additive or synergistic effect, I co-transfected the 
individual ten expression plasmids together with p509 and p6515, which encode 
BZLF1 and BALF4, respectively, into 2089 EBV producer cells. The virus supernatant 
stocks were collected and 5 μl was used to infect Raji cells to determine the virus 
titers as in Figure 2. An empty pCMV vector was co-transfected with BZLF1 and 
BALF4 as a control (Ctrl) and used as standard for normalization (Fig. 6). The results 
showed that only in case of the BVLF1 expression plasmid an additive effect could be 
observed in the range of 1.5-fold, which was also observed with BVLF1 in 
experiments shown in Figure 3. Co-transfection of BKRF4, BVRF2 or BALF2 seemed to 
reduce the virus titer and BNLF2a, BXRF1, BFLF2, BMRF1, BHLF1 and BXLF1 did not 
influence the virus titers.  
 
Fig. 6 Comparison of viral titers in virus stocks generated by co-transfection of the EBV genes BZLF1, 
BALF4 and 10 single expression plasmids encoding selected viral genes of the ‘high bin’ group.  
The 2089 EBV producer cells were seeded and transiently transfected with 0.25 μg BZLF1 (p509), 0.25 
μg BALF4 (p6515) and 0.5 μg of 10 selected EBV expression plasmids as indicated and described in Figure 
2 and Materials and Methods. The virus supernatants were harvested 3 days after transfection and 
partially purified using 1.2-micron filters. 1x105 Raji cells were incubated with 5 μl of the harvested virus 
supernatants. After three days, the infected Raji cells were investigated by flow cytometry (BD 
FACSCanto™) analyzing the fraction of cells expressing green fluorescence protein. Mean and standard 
deviation of three biological replicates are shown. 
 
Selection of 24 viral genes that elevate or repress bioparticle 
concentration 









































chose candidates from the high and low ends of genes identified in the experiments 
in Figure 3 in which I studied bioparticle concentration in Elijah cell binding assays. I 
asked if members of the top group of genes are essential for virus production as 
measured in infection experiments with Raji cells in Figure 2. On the contrary I asked 
if members of the bottom group of viral genes might regulate virus synthesis 
negatively and hence repress virus infectious titers, because some could act as 
master regulators controlling and thus limiting virus production.  
To investigate these scenarios, the top 10 genes and the bottom 11 genes in the 
ranking order in Figure 3 were selected and termed ‘high bin’ and ‘low bin’ genes, 
respectively. Certain genes were excluded for various reasons. LF1 and LF2 were 
excluded since the B95-8 EBV strain, which is contained in the 2089 EBV producer cell 
line does not encompass these two genes. Their ectopic expression in the 2089 
producer cells was informative but their lack precludes a knockdown strategy as 
explained below. BSLF2/BMLF1 was excluded because BMLF1 was also in the ‘low 
bin’ group and could be the cause of low bioparticle number. BLLF1 (gp350) ectopic 
expression directly affected the read-out since the gp350-specific antibody was 
utilized to detect bioparticles. Therefore, BLLF1 (gp350) was excluded as well. Also, 
BLRF3 was excluded from the ‘high bin’ group as it is part of EBNA3 and likely not 
directly involved in virus production. Eventually, the ‘high bin’ group contains BKRF4, 
BVLF1, BNLF2a, BXRF1, BFLF2, BMRF1, BHLF1, BXLF1, BVRF2 and BALF2 and genes of 
the ‘low bin’ group encompass BFRF1, BSLF1, BTRF1, BMRF2, BBRF3, BNRF1, BBLF1, 
BRLF1, BALF1, BBRF2 and BMLF1. Additionally, I randomly selected three genes 
BPLF1, BBRF1 and BGLF4 from the large middle group as shown in Figure 3. The rank 
order of bioparticle concentrations was copied from Figure 3 and is summarized in 
Figure 8A. The color codes of functional groups in this figure panel and in Figure 3B 
are identical. 11 genes encode DNA or capsid-associated proteins (green), 2 genes 
encode membrane proteins (red), 6 genes give rise to tegument proteins (brown), 3 
genes code for non-structural proteins (blue) and 2 gene have unknown functions 
(grey).  
 
Design and validation of 78 shRNA candidates targeting 24 viral and 
control genes 
 To test the 24 selected viral genes for their possible essential or regulatory roles 
in EBV’s lytic phase, I developed an shRNA knockdown strategy to repress individual 
viral genes and to study their contribution during virus production. Towards this end, 
the DNA sequences of the 24 viral genes in FASTA format were used as input for 
splashRNA, a search and design tool website for shRNA sequence candidates 
(http://splashrna.mskcc.org) (Pelossof et al., 2017). Several candidates with their 
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predicted efficiency scores were obtained for all 24 selected viral genes. Three 
promising shRNA antisense guides were chosen for each EBV gene target to establish 
a knockdown shRNA pool for all selected genes and controls. Altogether, 72 
individual synthetic sequences (plus 6 for additional control shRNAs) were cloned 
into the miR-3G frame shRNA construct (Watanabe et al., 2016). Subsequently, the 
miR-3G frames were introduced into the lentivirus pCDH vector plasmid (p6924), 
which also encodes puromycin resistance to allow selecting the lentivirally 
transduced 2089 EBV producer cells. Six control shRNA were also introduced into this 
vector to target GFP and BALF4 as positive controls. In total, I constructed 78 shRNA 
expression vectors to establish 26 shRNA knockdown pools with three shRNAs each. 
To pretest the many shRNA expression vectors, I also cloned the three sequences of 
the three shRNAs per target gene in complementary strand orientation into 
psiCHECK2, a standard dual luciferase reporter (p5264) that expresses firefly and 
Renilla luciferase proteins. To evaluate shRNA knockdown efficiencies, 293T cells 
were co-transfected with the 78 single shRNA vector plasmids to express the shRNAs 
together with one of the 26 corresponding luciferase reporter plasmids. The 
experimental setup is shown schematically in Figure 7A. After 24 h, the luciferase 
activities were measured. An ‘empty’ lentiviral pCDH vector (p6924) was co-
transfected with the luciferase reporter as a negative control. Using firefly and Renilla 
luciferase measurements for internal data correction, the Renilla luciferase ratios 
were normalized to the negative control and the results are shown in Figure 7A. 
Every shRNA expression vector demonstrated excellent knockdown efficiency of at 
least 90 % of the luciferase target. An unpaired two-tailed t tests proved the potent 






Fig. 7 Functional analysis of 72 shRNA constructs directed against 24 selected viral transcripts plus 
controls. 
Based on results obtained from bioparticle quantification (Elijah cell binding assay) in Figure 3, two 
groups of viral genes termed ‘high bin’ and ‘low bin’ encompassing 10 and 11 members (shaded areas), 
respectively, were selected that profoundly increased or decreased the number of EBV particles in viral 
supernatants. shRNA antisense guides for each EBV gene were generated (http://splashrna.mskcc.org) 
and three shRNA sequences per EBV target gene were individually cloned into the miR-3G frame of the 
basic shRNA vector (pCDH; p6924) that also encodes resistance against puromycin. A set of 
corresponding EBV target genes cloned into the psiCHECK2 dual luciferase reporter allows functional 
testing. (A) The flow chart depicts the experimental setup of the reporter assay shown in this panel. 
Transient reporter assays were conducted in 24-well cluster plates seeded with 2x105 293T cells, which 
were co-transfected with the individual reporter plasmids (26 in total including controls) together with 
single matching lentiviral shRNA expression plasmids. As reference and control, an empty pCDH 
lentiviral plasmid (p6924) was co-transfected with the indicated luciferase reporter (Ctrl). As additional 
controls, luciferase reporter plasmid with GFP and BALF4 as target genes were used in combination with 
three individual lentiviral vectors encoding GFP- and BALF4-specific shRNAs. After 24 h, luciferase 
activities were recorded and normalized to the reference. ‘High bin’ and ‘low bin’ samples are indicated. 
(B) The flow chart shows the experimental setup of introducing sets of three shRNA encoding 
lentiviruses into the 2089 EBV producer cell line and the selection with puromycin. The individual cell 
lines stably transduced with three shRNA vectors each were analyzed by transient transfection with 
matching dual luciferase reporter plasmids encoding corresponding viral targets as in panel A. Mean 
and standard deviation of three biological replicates are shown. Asterisks indicate statistical significance 
as determined by using the unpaired two-tailed t test with Welch’s correction (**P≤ 0.01; ***P≤ 0.001). 
(C) The effect of three shRNAs stably introduced into the 2089 EBV producer cell line and directed 
against GFP was analyzed by flow cytometry. GFP-negative cells were used as control. GFP expression 
of parental 2089 EBV producer cells (2089) and a derivative stably transduced with an empty pCDH 












Validation of knockdown efficacies of 24 transcript mimics representing 
viral targets in stably shRNA-transduced 2089 EBV producer cells  
 2089 EBV producer cells were stably transduced with the set of 24 shRNA 
expressing lentiviral vectors. In addition, two control vectors encoding shRNAs 
directed against GFP (the viral genome in 2089 EBV producer cells expresses GFP 
stably) and BALF4 transcripts were included. Lentiviral vector stocks were generated 
by transfecting packaging and envelope plasmids (p4502 and p5451) together with 
discrete pools of three shRNA encoding lentiviral vector plasmids directed against 
one viral transcript target. The EBV producer cells were incubated with the lentivirus-
containing medium for 3 days (schematic diagram in Fig. 7B). The transduced cells 
were further expanded and 10 μg/ml puromycin was added for the initial selection of 
the transduced cells. To test the knockdown efficacies, the 24 stably transduced 2089 
EBV producer cell lines together with two control cell lines transduced with shRNAs 
against GFP and BALF4 were transiently transfected with the matching luciferase 
reporter plasmids or an empty luciferase reporter (p5264) as a negative control. 
After 24 h, the luciferase activities were measured, and the efficacies were calculated 
and depicted in Figure 7B. Overall, the 26 transduced cell lines, including the two 
controls indicated a very convincing knockdown efficacy and documented high 
functional levels of shRNAs constitutively expressed in the different cell lines 
including the shRNA mediated knockdown of GFP expression at protein level (Fig. 
7C) . Convincingly, a statistical analysis using the unpaired two-tailed t test supported 
the almost complete repression of the luciferase reporter activities (Fig. 7A,B).  
 
Analysis of virus titers in supernatants from 2089 EBV producer cell lines 
stably transduced with 24 sets of shRNAs directed against selected EBV 
transcripts 
 The EBV producer cell lines each stably transduced with a set of three shRNA 
vectors were expanded under co-selection using 3 μg/ml puromycin and 100 μg/ml 
hygromycin B to ensure shRNA expression and maintenance of the EBV genome 
2089, respectively. Controls included 2089 EBV producer cells transduced with the 
empty lentivirus pCDH shRNA vector backbone (p6924), only, as well as cells encod-
ing triple set of shRNAs directed against GFP and BALF4 transcripts as tested in 
Figure 7. The 24 shRNA specific viral targets were selected, including the ‘high bin’ 
and ‘low bin’ groups of genes identified in previous Elijah assays monitoring bioparti-
cle concentration marked with grey shaded areas in Figure 3. The 10 candidate genes 
in the ‘high bin’ group have higher bioparticle concentration whereas in the ‘low bin’ 
group ectopic expression of 11 viral genes reduced bioparticle concentration consid-
erably (Fig. 3). The two panels in Figure 8A recapitulate these previous findings. In 
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addition, I randomly selected three targets from the large group of viral genes with 
no discrete functionality to include BPLF1, BBRF1 and BGLF4 in my study (Fig. 8A). 
Virus stocks from the different 2089 EBV producer cell lines were generated by 
transient transfection of BZLF1 (p509) followed by infecting Raji cells and quantifying 
virus titers by flow cytometry. The results were separated according to the ‘high bin’ 
and ‘low bin’ groups of candidates in Figure 8B (black columns). To allow a 
comparison also with supernatants from cells co-transfected with both BZLF1 (p509) 
and BALF4 (p6515) plasmids, I repeated the experiments measuring virus infectivity. 
Figure 8B also depicts the analysis of virus titers obtained from these experiments 

























































































































































































































































































Fig. 8 Analysis of viral titers in supernatants generated with 2089 EBV producer cell lines stably 
transduced with sets of three shRNAs directed against 24 individual viral transcripts plus controls. 
(A) Recapitulation of selected data shown in Figure 3. Three groups of viral genes are shown that 
increased (‘high bin’ group, left panel) or decreased (‘high bin’ group, right panel) the yield of 
bioparticles (viral particles). In addition, three genes were randomly selected as measured in the Elijah 
cell binding assay (single grey columns in Fig. 3) when co-transfected together with BZLF1 into the EBV 
producer cell line 2089. The EBV genes are arranged in descending order and the color codes depict the 
different functions of viral proteins as in Figure 3. The color codes indicate (i) green: DNA or capsid-
associated proteins, (ii) red: membrane proteins, (iii) brown: tegument proteins, (iv) blue: non-
structural proteins, and (v) grey: proteins with unknown functions. (B) Newly established EBV producer 
cell lines based on the parental producer cells 2089 were stably transduced with 24 sets of three shRNAs 
each, together with matching control cell lines. Controls encompass the EBV producer cell line 2089 
stably transduced with the empty pCDH shRNA expression vector (Ctrl) or two sets of three shRNAs 
each directed against GFP or BALF4. The viral genes termed ‘high bin’ and ‘low bin’ groups are shown 
in the left and right panels, respectively. The individual cell lines were transiently transfected with the 
p509 expression plasmid coding for BZLF1 alone or in combination with the p6515 expression plasmid 
coding for BALF4 as indicated. The virus supernatants were harvested 3 days after transfection, filtered 
(1.2 μm pore size) and 10 μl were used to infect 1x105 Raji cells for three days. The Raji cells were 
analyzed for the fraction of GFP-positive cells by flow cytometry and their virus titers (GRU titers) were 
calculated. Supernatants harvested from the control cell lines are shown on the left side of the graph 
with the ‘high bin’ group of genes separated by a vertical dotted line from the test samples. The ‘low 
bin’ group is shown on the right separated from the control and the other three genes by dotted lines. 
(C) Virus titers of supernatants obtained from the 24 individual shRNA expressing EBV producer cell 
lines (black columns; shRNA knockdown) analyzed in panel B are compared with virus titers found in 
supernatants from the parental EBV producer cell line 2089 upon transient expression of viral genes 
(red columns; ectopic expression). The latter data are selected and copied from Fig. 2. Mean and 
standard deviation of three biological replicates are shown. 
 
Controls included 2089 EBV producer cells transduced with the empty lentiviral 
vector (Ctrl) and cells transduced with the triple set of shRNA directed against GFP 
transcripts. The two controls revealed that this manipulation did not change virus 
titers in the supernatants of 2089 EBV producer cells induced with BZLF1 alone or in 
conjunction with BALF4 as expected (data not shown). The data from the two sets of 
experiments were normalized (black and white columns) and set to one (Fig. 8B). The 
horizontal dotted lines indicate the virus titer of the reference (Ctrl). All virus titers 
were normalized to this control, which stems from supernatants of 2089 EBV 
producer cells transduced with the empty shRNA expression vector pCDH (p6924). 
The vertical line separates the controls and remaining genes are arranged in the 
 41 
same order as Figure 8A.  
Virus titers obtained after BZLF1 transfection of shBALF4 transduced EBV 
producer cells showed considerable reduction of infectivity as expected but co-
transfection of both BZLF1 and BALF4 partially rescued the loss of virus titer from the 
shBALF4 transduced cells (Fig. 8B, left panel) when BALF4 was re-introduced. This 
experiment demonstrated that shRNA pools can successfully repress lytic viral genes 
causing a substantial phenotype indicative of functional repression.  
 
Changes of virus titers in supernatants from EBV producer cell lines stably 
transduced with shRNAs directed against ‘high bin’ and ‘low bin’ viral 
transcripts  
As expected, certain shRNA sets decreased virus titers dramatically but not all 
shRNA sets caused a serious phenotype (Fig. 8B). Basically, shRNAs directed against 
transcripts of BXRF1, BMRF1, BVRF2 and BALF2 (left panel) and BMRF2 (right panel) 
induced a complete or almost complete failure to produce infectious EBV stocks. 
Other shRNAs had a weak repressive phenotype (BKRF4, BHLF1, BXLF1, BFRF1, 
BSLF1, BNRF1, BMLF1) or did not or did hardly affect production of infectious virus 
(BNLF2a, BPLF1, BTRF1, BBRF3 and BALF1). Others showed in-between phenotypes 
(Fig. 8B). Remarkably, the shRNA mediated knockdown of BFLF2 seemed to induce 
virus titers to some degree (Fig. 8B, left panel). Induction of the 2089 EBV producer 
cell lines carrying the different shRNA sets with both BZLF1 and BALF4 did not reveal 
a convincing function or contribution of BALF4 in this series of experiments (white 
columns in Fig. 8B), which is in line with results presented in Figure 3. 
The results obtained so far support the conclusion that certain viral genes seem 
to be absolutely essential (BXRF1, BMRF1, BVRF2, BALF2, BMRF2) or, conversely, are 
entirely dispensable (BNLF2a, BFLF2, BTRF1, BBRF3 and BALF1) for the production of 
infectious virus stocks. Importantly, the results did not support my hypothesis that 
EBV encodes a gene that controls production of infectious virus. This is because the 
knockdown of any of the 11 transcript candidates in the ‘low bin’ group did not 
increase virus production as I had hoped (right panel in Fig. 8B). In this set of 
experimentation, only the shRNA knockdown of BFLF2 seemed to yield elevated virus 
titers (Fig. 8B) in a range similar to the gene’s ectopic expression in Figure 2 and 
Figure 3 experiments, which appears contradictive. 
I also compared virus titers obtained in experiments shown in Figure 2 (ectopic 
expression of single viral genes in BZLF1 induced 2089 EBV producer cells) with virus 
titers of the 24 selected shRNA knockdown EBV producer cell lines (also induced by 
BZLF1 transduction) as in Figure 8B. The direct comparison is provided in Figure 8C. 
Normalized virus titers obtained after ectopic expression of the 24 single viral genes 
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are marked in red and the corresponding virus titers from the shRNA knockdown 
producer cells are depicted in black (Fig. 8C). BALF4 expression yielded maximal virus 
titers but its knockdown repressed virus titers to about 10 % compared to the 
normalized control value. These results also validate the shRNA knockdown strategy 
and confirm BALF4’s role as an essential gene that boost viral infectivity upon ectopic 
expression (Fig. 8C) (Neuhierl et al., 2002). In the ‘high bin’ group, the majority of 
viral genes that yielded higher virus titers upon ectopic expression of viral genes 
provides critical lytic products because their shRNA mediated knockdown repressed 
virus titers considerably (BVLF1, BXRF1, BMRF1, BVRF2, BALF2) or moderately 
(BXLF1, for example). The knockdown of BFLF2 is an exception because it increased 
the virus titer slightly. In the ‘low bin’ group (Fig. 8C, right panel), the knockdown of 
certain viral transcripts reduced virus titers even further (BGLF4, BMRF2, BBLF1 and 
BRLF1) indicating their regulatory function, which is disturbed upon overexpression 
of these genes as well as upon their repression. Their proper function seems to 
require a certain homeostatic or fine-tuned level of expression. A similar 
interpretation might apply for BTRF1, BBRF3 and BALF1. Their ectopic expression or 
their shRNA mediated knockdown reduced or restored virus titers, respectively, as 
seen in Figure 8C. 
 
Ectopic expression and shRNA knockdown of viral genes and transcripts – 
comparing bioparticle concentration of 24 viral targets 
Virus stocks from experiments in which I tested the virus stocks for their 
infectivity in Raji cells in Figure 8B were also analyzed for their bioparticle 
concentrations using the Elijah cell binding assay as in shown in Figure 3. Virus stocks 
were added to Elijah cells and bound bioparticles were quantified. The results are 
summarized in Figure 9A.  
The 2089 producer cell line transduced with the set of three shRNA directed 
against the GFP transcript did not affect bioparticle concentration much (Fig. 9A, left 
panel). The shRNA mediated knockdown of BALF4 showed a minor decrease of 
bioparticle concentration, which was partially rescued when BALF4 was transfected 
into this shRNA knockdown producer cell line (Fig. 9A, left panel). The bioparticle 
concentrations of BVLF1 and BALF2 indicated a substantial reduction in the shRNA 
expressing EBV producer cell lines which is in agreement with their low virus titers in 
Figure 9B and C. In the right panel of Figure 9A, BBRF3 and BALF1 had equivalent 
bioparticle concentrations comparable with their virus titers in Figure 8B. Moreover, 
the concentration of bioparticles was considerably low in supernatants from BGLF4, 
BBLF1 and BRLF1 knockdown cells reminiscent of their virus titers (Fig. 8C). Interest-
ingly, expression of BALF4 upon lytic induction of the 24 shRNAs carrying EBV 
 43 
producer cell lines did not lead to considerable deviations regarding bioparticle 
concentration in the supernatants (Fig. 9A). 
 
 
Fig. 9 Analysis and comparison of bioparticles in supernatants from the 2089 EBV producer cell line 
stably transduced with sets of three shRNAs directed against 24 viral transcripts in the Elijah cell 
binding assay. 
Supernatants analyzed in Figure 8 were tested for their bioparticle concentration in the Elijah cell 
binding assay. (A) Following the setup in panel B of Figure 8, 20 μl supernatants from the 24 EBV 
producer cell lines stably transduced with 24 sets of three shRNAs together with matching controls were 
analyzed for bioparticle concentration after transfection of only BZLF1 (p509) or after co-transfection 
with both p509 and BALF4 (p6515) expression plasmids. (B) Bioparticle concentrations found in 
supernatants from 2089 EBV producer cells upon expression of single viral genes as analyzed in Figure 
3 (red columns; ectopic expression) are compared with results shown in panel A of this figure (black 
columns; shRNA knockdown). Mean and standard deviation of three biological replicates are shown. 
 
Finally, I compared supernatants obtained after ectopic expression of single viral 
genes analyzed in Figure 3 with corresponding supernatants from the 24 shRNA 
expressing EBV producer cell lines for their bioparticle concentration in the Elijah cell 





































































































































































































expression of single viral genes and the matching shRNA knockdown experiments are 
shown in red and black, respectively (Fig. 9B). Bioparticle concentration declined to a 
bout 50% upon knockdown of BALF4 suggesting that BALF4 might also be involved in 
bioparticle generation. Bioparticle concentration from supernatants of shRNA 
knockdown cells of the ‘high bin’ group were severely or moderately reduced (Fig. 
9B, left panel). In the right panel of Figure 9B, ectopic expression of single viral genes 
showed lower bioparticle concentrations initially. The majority of supernatants from 
shRNA expressing EBV producer cell lines did not show very different bioparticle 
concentrations (BBRF1, BFRF1, BTRF1, BMRF2, BNRF1) whereas some had reduced 
numbers of bioparticles (BGLF4, BSLF1, BBLF1, BRLF1). The shRNA mediated 
knockdown of BBRF3, BALF1, BBRF2 and BMLF1 transcripts increased bioparticle 
production reaching levels similar with or identical to the control (Fig. 9B, right 
panel). 
 
Analysis of the fusogenic activity of 24 virus stocks upon ectopic 
expression of individual viral genes from the ‘high bin’ and ‘low bin’ 
groups 
 Together with my colleague Manuel Albanese, I developed a novel assay to 
measure the fusogenic activity of engineered extracellular vesicles (EVs) (Albanese et 
al., 2020). Here I adapted the principle of this assay to analyze the fusogenicity of EB 
virions using primary human B cells, EBV’s primary target cells. 
The enzyme ß-lactamase (BlaM) is utilized by bacteria to cleave the ß-lactam 
ring of antibiotics of the penicillin group, e.g., ampicillin, such that the bacteria 
become resistant. The principle was employed to synthesize a compound, termed 
CCF4 with a ß-lactam ring in its center, which links two separate fluorochromes, 
hydroxycoumarin and fluorescein, located at opposite ends. The concept is based on 
fluorescence (or Förster) resonance energy transfer (FRET). When light of 409 nm 
wavelength excites hydroxycoumarin in the compound, the energy is transferred to 
fluorescein, which emits light with a wavelength of 520 nm. If the ß-lactam ring is 
cleaved, excitation causes hydroxycoumarin to emit light with 447 nm wavelength 
directly without an energy transfer because the hydroxycoumarin moiety is absent. 
The difference between the two wavelengths and their intensities can be detected 
and differentiated by flow cytometry. The ß-lactamase (BlaM) assay has been 
developed in the HIV field to detect fusion of HIV particles with T cells (Cavrois et al., 
2002; Jones and Padilla-Parra, 2016). In the BlaM assay, ß-lactamase enzyme is 
introduced into recipient cells by virus-mediated transfer and then the modified 
substrate CCF4-AM is added to cells. After the substrate is taken up by cells, it is cut 
by endogenous cytoplasmatic esterases to the negatively charged CCF4 product 
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locking it in the cytoplasm of the CCF4-loaded cell. Once BlaM is also introduced into 
the cells, the enzyme cuts the ß-lactam ring of CCF4 and altering its emission 
wavelength. The protocol has been constantly improved (Cavrois et al., 2014) and it 
is applicable to detect transduction of BlaM linked to viruses or other entities.  
As demonstrated in a pre-print with Manuel Albanese and me as shared first 
authors (Albanese et al., 2020), we investigated extracellular vesicles (EVs) also 
termed exosomes, which range in size from 30 nm to 1000 nm and which could play 
an essential role in signal transduction. Many papers claim that EVs contribute to 
cell-to-cell communication and deliver cargos from donor to recipient cells. It is 
believed that four major routes deliver messengers to target cells, e.g., receptor 
binding and activation, fusion, endocytosis and ligand cleavage from extracellular 
vesicles (Meckes and Raab-Traub, 2011). In their lumen and on their surface EVs can 
contain many proteins and DNA and RNA molecules that originate from donor cells. 
Viral proteins such as the EBV encoded LMP1 protein, cytoskeletal proteins, myosin 
and tetraspanin protein CD63 can be found incorporated and enriched in EVs. Based 
on this knowledge, a codon-optimized ß-lactamase gene was fused to the carboxy 
terminus of the human CD63 protein, which is enriched in EVs, via a conventional G4S 
linker (Albanese et al., 2020). Subsequently, the fusion protein was cloned into a 
pcDNA3.1(+) (p5267) expression vector, which was transiently introduced into 
different cell types. They readily gave rise to EVs that contain CD63:ß-lactamase 
(subsequently termed CD63:BlaM) in their vesicle membrane. Upon EV delivery to 
CCF4-loaded cells the BlaM assay is an easy method to evaluate a successful EV-
mediated transfer of CD63:BlaM to target cells (Albanese et al., 2020).  
 To evaluate EBV fusion with the virus’ genuine target cells, human primary B 
cells, I developed this novel assay shown schematically in Figure 10A. The aim was to 
study virus fusion separately and independent of viral infectivity (Fig. 1). The latter 
summarizes the entire infection process including de novo gene expression of 
infectious EBV particles (detecting GFP expression in Raji cells as shown in Figure 2).  
2089 EBV producer cells were co-transfected with an expression plasmid 
encoding CD63:BlaM (p7200) together with BZLF1 (p509) and single expression 
plasmids that encode the 21 individual viral genes of the ‘high bin’ and ‘low bin’ 
groups plus controls as defined in Figure 8A. Human primary B cells isolated from 
adenoid tissue (nasal polyps biopsies) were incubated with 20 μl CD63:BlaM-
containing virus stocks for 4 h. Subsequently, the cells were loaded with the CCF4-
AM substrate and incubated at room temperature for 16 h. During this period, the 
cytoplasmic CCF4 substrate is cleaved in infected but not in non-infected cells. The 
fraction of cells with emission light shift was determined by flow cytometry. The 
same virus stocks were used to infect Raji cells and the virus titers were recorded as 
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in my experiments shown in Figure 2. A virus stock generated by transient 
transfection of the 2089 EBV producer cells with BZLF1 (p509), only, served as 
control. Yet another control was a virus stock generated by co-transfection of BZLF1, 
an empty expression vector plasmid and CD63:BlaM to normalize the data depicted 
in Figure 10B.  
The left panel shows the fusogenic activities of 10 EBV stocks obtained by 
ectopic expression of viral genes of the ‘high bin’ group. With the prominent 
exception of the single virus stock generated by ectopic expression of BALF4 all other 
virus stocks did not show changes in their fusogenicity activity. The BALF4 virus stock 
showed a four-fold increase in this assay and another virus stock generated with 
BMRF1 had a somewhat improved fusogenic activity, probably because this virus 
stock also scored better with respect to its bioparticle concentration (Fig. 3). Within 
the members of the ‘low bin’ group of genes, all virus stocks showed medium 
(BFRF1, BSLF1, BTRF1) or much reduced fusogenic activities probably following a 
similarly reduced bioparticle concentration (Fig. 3) in this group of genes. 
Interestingly, while the fusogenicity of the BGLF4 virus stock was clearly 
compromised, the two virus stocks belonging to the ‘middle bin’ group, BPLF1 and 
BBRF1, had comparable fusion activity at the level of the control stock (Fig. 10B, right 
panel). The BBRF1 virus stock is interesting, because its infectivity is reduced by more 
than 50 % (Fig. 2) while its fusogenic activity is wild-type. 
 Taken together, the assay demonstrates that BALF4 is the driver of viral fusion 
with target cells as thought previously (Neuhierl et al., 2002). In addition, the assay 
unveils that virus stocks generated by ectopic expression of certain viral genes such 
as BBRF1 are not compromised with respect to virus fusion (Fig. 10B, right panel) but 
impaired in their infectivity (Fig. 8C). This observation shows that measuring virus 
fusion independent of virus infectivity can be a valuable new parameter in the 
herpesvirus field. BBRF1 is a prime example, because it encodes the capsid portal 
protein (Table 1) indispensable for loading EBV DNA into viral capsids. Upon BBRF1 
knockdown, the virus stocks probably contain fewer infectious virions (they lack the 
viral DNA genome), but the virus stocks nevertheless show the identical fusogenic 
activity compared with wildtype virus indicating that fusion and viral gene expression 




Fig. 10 Analysis of engineered EBVs obtained from 2089 EBV producer cells transiently transfected 
with 24 individual expression plasmids and their fusion with primary human B cells using the novel 
ß-lactamase fusion assay. 
(A) The flow chart depicts the experimental steps of the fusion assay (top pathway) and its comparison 
with the Raji cell-based test for infectivity (below). (B) Results of the ß-lactamase fusion assay with 
supernatants of the 2089 EBV producer cell line transiently transfected with 24 individual expression 
plasmids encoding viral genes of the ‘high bin’, ‘low bin’ groups and three control genes. The cells were 
co-transfected with three plasmids as shown in panel A (plasmids encode BZLF1 [p509], CD63:ß-
lactamase [p7200] and one of the 24 selected EBV genes or controls) and the supernatants were tested 
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on primary human B cells as targets. The read-outs are based on determining the fraction of ‘blue’ B 
cells with cleaved CCF4 substrate by flow cytometry. Shown are the results from the ‘high bin’, ‘low bin’ 
groups and three controls separated by vertical dotted lines. (C) The supernatants analyzed in panel B 
were also tested for their infectivity of Raji cells using GFP expression as indicator of viral infection as 
schematically shown in panel A. For comparison, the 2089 EBV producer cell line was transiently 
transfected with 24 individual expression plasmids encoding viral genes of the ‘high bin’, ‘low bin’ 
groups and three control genes together with BZLF1 p509, only, omitting the CD63:ß-lactamase 
expression plasmid p7200. The pairwise comparison of supernatants generated with and without 
CD63:ß-lactamase (BlaM) is shown and the results from the ‘high bin’ and ‘low bin’ groups in the left 
and right graphs, respectively, are provided as in panel B. 
 
Incorporation of CD63:BlaM slightly improves the virus titer  
 To study possible consequences of CD63:BlaM expression during EBV’s lytic 
phase or upon incorporation of the fusion protein into EBV particles I compared two 
sets of virus stocks in Raji cell infection experiments. One set of virus stocks was 
generated by co-transfection of individual expression plasmids encoding the 21 
members of ‘high bin’ and ‘low bin’ groups of viral genes (plus controls) with BZLF1 
and CD63:BlaM into 2089 EBV producer cells. For comparison, the same set of 
plasmids excluding CD63:BlaM was co-transfected in parallel. The infectivity of the 
two sets of virus stocks was analyzed by infecting Raji cells. The fraction of infected 
Raji cells shown in Figure 10C followed my previous results depicted in Figures 2 and 
8C. As shown in Figure 2, virus stocks generated with BALF4 had the highest virus 
titer. Other ectopically expressed viral genes of the ‘high bin’ group had moderately 
higher virus titers in terms of infectivity comparable with my findings in Figure 2. 
Similarly, virus stocks generated with individual members of the ‘low bin’ group 
showed considerably lower infectious virus titers (Fig. 10C, right panel). Virus stocks 
generated by the concomitant expression of the CD63:BlaM fusion proteins had a 
slight tendency to higher virus titers (Fig. 10C). This was a very consistent 
observation suggesting that the incorporation of CD63:BlaM is somewhat 
advantageous and can enhance virus titer but to a rather limited degree, only. More 
importantly, this results indicates that CD63:BlaM does not interfere or even 
compromise infectivity of EBV particles. 
 
A novel assay to detect and quantify cellular fusion of extracellular 
particles with primary human cells and various established cell lines 
 The novel assay, which I introduced in the previous chapter is based on viral 
fusion events with targets cells and the reporter protein CD63:BlaM with which viral 
particles can be equipped. Examples such as BALF4 and BBRF1 demonstrate that viral 
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fusion can be monitored directly. The examples also show that viral fusion and viral 
infectivity are independent parameters that both contribute to viral success.  
This opportunity allowed me to address a very related question in the field of 
extracellular vesicles (EVs). They are continuously released from probably all cells 
and EVs are believed to be messengers between cells supporting cell-to-cell 
communication. Moreover, there is strong belief that EVs can fuse with recipient cells 
(similar to viruses) such that the content of EVs, their cargos, can be physically 
delivered to recipient cells. The content can be microRNAs (miRNAs), for example, 
which could regulate gene expression in recipient cells. This hypothesis has never 
been convincingly demonstrated directly. Hence, I used my novel assay to prove (or 
refute) this long-standing hypothesis. Towards this end, I prepared generic EVs 
equipped with CD63:BlaM as effectors from supernatants of 293T cells and 
incubated various types of recipient cells with these EVs to test this hypothesis.  
 
Subpopulations of peripheral blood mononuclear cells differ in their 
uptake of the CD63:BlaM reporter protein delivered by engineered EVs  
 293T cells were transfected either with CD63:BlaM (p7200) or co-transfected 
with CD63:BlaM and an expression plasmid encoding VSV-G (p5451). VSV-G is a 
glycoprotein of vesicular stomatitis virus (VSV) with a broad, almost universal 
fusogenic, cell-targeting function reflecting VSV’s broad tropism. Consequently, VSV-
G is widely used in combination with lentiviral or retroviral vectors to ensure their 
efficient fusion with target cells and delivery of the vector’s genetic information. 
Here, I co-transfected VSV-G together with CD63:BlaM to generate fusogenic EVs as a 
positive control to demonstrate the reliable delivery of the CD63:BlaM reporter 
protein.  
One day after transfecting 293T cells with expression plasmid DNAs, the 
medium was changed to plain DMEM (without FBS) and the cells were cultivated for 
three more days. The cell supernatants were harvested and purified by two times 
low speed centrifugation to remove cell debris and apoptotic bodies. Human 
peripheral blood mononuclear cells (PBMCs) were purified from blood donor and the 
cells were incubated with EV containing supernatants at 37 °C for 4 h. CCF4-AM 
substrate was added to the cells, which were incubated at room temperature for 16 
h. Prior to their analysis by flow cytometry, the cells were stained with antibodies to 
specify subpopulation of cells using conventional cell markers to identify T cells, B 
cells, monocytes, dendritic cells (DC) and plasmacytoid dendritic cells (pDCs) (Fig. 
11A). Supernatants with EV equipped with CD63:BlaM, only, barely delivered the 
reporter protein to recipient cells (Fig. 11A). However, EVs equipped with both 
CD63:BlaM and VSV-G are able to deliver the reporter protein very efficiently to up 
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to 10 % PBMCs (Fig. 11A). VSV-G decorated EVs led to 8 % positive T cells and about 
2 % of all B cells were targeted. Monocytes showed the highest rate of fusion 
reaching almost 100 %, DCs showed 55 % and, lastly, pDCs showed 5 % to 10 % 
positive cells.  
 
Without VSV glycoprotein, EVs can barely deliver the CD63:BlaM reporter 
protein to 17 different cell lines 
 I wanted to clarify whether my initial results with PBMCs also applied to other 
cells. Towards this end, two classes of EVs equipped with only CD63:BlaM or 
equipped with both CD63:BlaM and VSV-G were generated from supernatants of 
293T, Calu-3, Caco-2, HepG2 and Huh7 donor cells by transient transfection of the 
respective expression plasmids. As recipient cells I employed 293T, Caco-2, A549, 
Calu-3, MDA-MB-231, HepG2, Huh7, LN-18, U-251MG, HEL, Mono-mac-6, THP-1, 
BJAB, DG-75, Elijah, Raji and lymphoblastoid cells (LCL) reflecting a broad spectrum 
of diverse cell types. Identical volumes of EV preparations collected from the 5 
different donor cells were used to incubate the 17 recipient cell types. After addition 
of the CCF4-AM substrate the fractions of BlaM positive recipient cells were 
quantified by flow cytometry. The results are presented in five panels in Figure 11B 
summarizing results with EVs from the five different donor cells. Compared to the 
extremely low or mostly undetectable uptake of EVs equipped with CD63:BlaM, only, 
(white columns), EVs equipped with both CD63:BlaM and VSV-G led to medium and 
high BlaM signals (black columns) in almost all donor-recipient combinations. 
Supernatants from 293T and HepG2 donor cells performed very well in this assay. 
Caco-2 derived EVs showed a moderate ability of delivering the CD63:BlaM reporter. 
As recipients, U-251MG cells had the highest rate of uptake among all cells tested 
whereas Caco-2, A549, Calu-3, HepG2, Huh7 and LCL showed lower fractions of 
BlaM-positive cells (Fig. 11B). 
 Taken together, my results provide a convincing example of applying this novel 
fusion assay not only to virus stocks but also to physiological extracellular vesicles 
which all cells release. Virus-like particles, which share aspects of both types of 
particles, i.e., infectious EBV and EBV-derived EVs, can be investigated for their 
fusogenic activities and delivery of their antigenic components to immune cells 
demonstrating their efficacy of antigen presentation.  

























































































































































































































































































































































































































































































Fig. 11 A novel assay for measuring the fusogenic activity of ß-lactamase-containing extracellular 
vesicles (EVs) generated from five different types of cells.  
293T cells were transiently transfected with 12 μg expression plasmid p7200 encoding CD63:ß-
lactamase with or without 8 μg expression plasmid p5451 encoding VSV-G, a glycoprotein of 
vesicular stomatitis virus. One day after transfection, the medium was exchanged with plain DMEM 
without FBS. The conditioned medium was harvested after 3 days as described in Materials and 
Methods. (A) 500 μl conditioned medium containing CD63:ß-lactamase with or without VSV-G was 
incubated with 2x105 peripheral blood mononuclear cells (PBMCs) for 4 h. The incubated medium 
was removed and cells were incubated with CO2-independent medium containing CCF4-AM 
substrate at room temperature in the dark for 16 h. Antigen-specific antibodies to identify T cells, 
B cells, monocytes, DCs or pDCs contained in PBMCs were added and the cells were analyzed by 
flow cytometry. Upon ß-lactamase cleavage positive cells emit light of 447 nm wavelength. 
Conditioned medium, which contained CD63:ß-lactamase equipped EVs, only, was used as control. 
The percentage of ß-lactamase positive cells is indicated as BlaM positive recipient cells (%). (B) 
293T, Calu-3, Caco-2, HepG2 and Huh7 cells were used to generated supernatants with EVs 
containing CD63:ß-lactamase with or without VSV-G. 500 μl conditioned medium obtained from 
the five donor cells was incubated with recipient cells as indicated for 4 h. The conditioned medium 
was subsequently removed and CCF4-AM substrate was added. After 16 h, the percentage of ß-
lactamase-positive recipient cells was determined by flow cytometry (black columns). ß-lactamase-





The problem of EBV yield and virus quality 
 EBV is a member of the γ-herpes virus family, which typically does not give yield 
to progeny when these viruses are amplified via traditional techniques. In fact, EBV 
(and its closest relative Kaposi sarcoma-associated herpes virus, KSHV) cannot be 
simply propagated in cell culture. Instead, cell lines latently infected with EBV are the 
source of infectious virus, which the cells produce spontaneously at low level or after 
induction of EBV’s lytic productive phase. In many cell lines, the lytic phase can be 
induced upon ectopic expression of BZLF1, an immediate-early EBV gene and 
molecular switch (Buschle and Hammerschmidt, 2020). Almost all latently EBV 
infected cell lines are B cells established from Burkitt’s lymphoma biopsies. Induced 
expression of BZLF1 in these cells is often inefficient, which results in low titer EBV 
stocks and inconsistent yields.  
Another hurdle while working with EBV (as well as KSHV) has been the lack of 
viral genetics. Genetic manipulation of EBV’s genomic DNA has not been possible for 
decades after its discovery in the sixties (Epstein et al., 1964) very much in contrast 
to other herpes virus such as herpes simplex virus 1. Its genetic era started more 
than 40 years ago in the Roizman lab using forward selection in virus infected cell 
cultures (Mocarski et al., 1980). 
Pioneering work of my laboratory introduced a very different technology of 
cloning the entire EBV genome of 172 kbp in size in E. coli onto a single copy mini-F-
factor plasmid backbone to gain access to recombinant EBVs and genetically 
modified EBV mutant derivatives (Delecluse et al., 1998). Genetic manipulation is 
done in E. coli using homologous recombination techniques. From E. coli cells, 
mutated genomic EBV DNA is prepared and introduced into HEK293 cells in which 
the virus adopts a state reminiscent of latent infection. Virus synthesis is induced in 
these cells by transfecting an expression plasmid coding for BZLF1 (also known as Zta, 
Z or EB1) and progeny is harvested from the supernatant of induced cells. This is a 
practical and breakthrough approach, but one obstacle of this technology was and 
still is suboptimal virus yield.  
 
The impact of individual EBV genes on virus yield and virus quality 
 Using this system, Delecluse et al. obtained the first recombinant EBV stock 
from the supernatant of a HEK293 cell line derivative later termed 2089 EBV 
producer cells (Delecluse et al., 1998). EB virus supernatants were generated by 
transiently transfecting an expression plasmid (p509) encoding BZLF1. I used this cell 
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line throughout my work, because it yields more than 5×106 infectious particles per 
ml when Raji cells are used as EBV’s target cells as I did (Figs. 1, 2). Infected Raji cells, 
which express green fluorescence protein upon infection are used to provide ‘green 
Raji units’, termed GRU, which determine the virus titer (infectivity) as indicated in 
my experiments. Despite this proven approach and reliable source of infectious EBV 
stocks, it has always been questionable, if the HEK293 cell is the ideal host to 
propagate the virus. The nature of these cells is probably a neuronal cell, a cell type 
never linked to EBV infection or synthesis. Therefore, certain viral genes might be 
insufficiently expressed such that virus production in HEK293 cells is suboptimal at 
best. Conversely, certain non-identified viral genes could exist that act as regulators 
of cellular or viral gene expression dampening or restricting virus production when 
expressed in an untimely fashion and/or at inadequately high levels. As the 
continuous search for another established cells that supports EBV production has not 
been successful, it was my task to test all available viral genes whether their single 
ectopic expression during virus synthesis in the 2089 EBV producer cells might yield 
higher yields (indicative of an insufficient expression of this particular gene of 
interest) or if viral genes repress virus production, which could be an indication of a 
negative regulator of virus production. If true, the identification of such a viral 
regulatory function would help to design techniques to improve virus yield from 
HEK293 cells. Alternatively, the identification of a viral gene that boost virus 
production during its enhanced expression in 2089 EBV producer cells will be 
another chance to improve virus yield. In case of the planned VLP-based vaccine, 
production of (non-infectious, harmless) virions is THE key parameter of optimal 
yield during the upstream GMP process of VLP manufacturing.    
Interestingly, in a single study from my lab in 2002, the function of a viral 
glycoprotein encoded by the EBV open reading frame BALF4 was investigated. 
Neuhierl et al. made a genetic knockout of this gene and found that production of 
infectious EBV came to a full halt indicating that BALF4 is an essential gene. When 
Neuhierl et al. expressed BALF4 in the HEK293 cell line carrying the BALF4 knockout 
they observed a considerable improvement of virus titers (Neuhierl et al., 2002). 
They went on and found that co-transfection of BZLF1 (p509) together with BALF4 
(p6515) in the parental 2089 EBV producer cell line yielded substantially higher virus 
titers compared to the same cells transfected with BZLF1 alone (Neuhierl et al., 
2002), indicating that BALF4 is a limiting gene product during EBV production in 
HEK293 cells. 
In my work I used this basic experimental design (with BALF4 as a proven 
positive control) and transfected BZLF1 together with 76 individual expression 
plasmids encoding single EBV genes into 2089 EBV producer cells. Supernatants from 
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these experiments were investigated in four different analytic schemes as shown in 
Figure 1. The results from these analyses encompassing the parameters of virus titers 
(Fig. 2), bioparticle concentration (Fig. 3) and physical particle concentration (Fig. 4) 
showed a very good overall correlation (Fig. 5). All the values obtained were 
arranged in descending order and the genes were color-coded based on their 
functional categories or, alternatively, on their expression timing (if known).  
 
76 EBV genes and their contribution to virus titers 
 BALF4 scored best with regard to virus titers while the next ten top genes 
(BMRF1, BGRF1/BDRF1, LF1, BLRF3, BDLF2, BDLF3.5, BLLF2, BHLF1, BVLF1, BNLF2a) 
showed a moderate increase of virus titer, only. The role of BALF4 has been 
addressed previously by my laboratory and Richard Longnecker’s group (Herrold et 
al., 1996; Neuhierl et al., 2002) and more recently by Henri-Jacques Delecluse in 
Heidelberg (Neuhierl et al., 2009). Together, the literature agrees on the essential 
role of the BALF4 encoded gB homologue of herpesviruses (also called gp110 in the 
EBV field) during B cell infection. My novel virus fusion assays presented in Figure 10 
demonstrates its true function as it is essential for fusion of the virus envelope with 
cell membranes, which commonly takes place in endosomes after receptor-
mediated uptake of the virus (Chesnokova et al., 2015).  
 The known functions of the top ten genes down the list in Figure 2 do not offer 
an immediate answer how they could contribute to the (mild) increase in virus titer. 
The genes fall into different functional categories and only BDLF2 and BILF1 belong 
to the class of membrane proteins similar to BALF4. BILF1 encodes a constitutively 
active G protein-coupled receptor presumably involved in signaling whereas BDLF2, 
one out at least 11 EBV glycoprotein is a type II envelope protein with uncertain 
functions (Gore and Hutt-Fletcher, 2009). 
 Down the lanes in Figure 2 ectopic expression of 16 viral genes reduced virus 
titers by half at least with some reducing it by a factor of 10 (BLRF1, BGLF5, BTRF1, 
BBRF1, BFRF1, BSLF2/BMLF1, BBRF3, BNRF1, BBLF1, BRLF1, BMRF2, BGLF4, BBRF2, 
BMLF1, LF2 and BALF1). Infection with EBV includes several discernable steps, i.e., 
virus binding, endocytosis, envelope fusion, viral transcription and translation of viral 
proteins. The Raji cell infection assay monitors all these steps leading to the 
expression of green fluorescence protein, which serves as a virally encoded surrogate 
marker of successful infection. Therefore, virus-cell binding, virus fusion, 
transcription and translation could be regarded as indicators evaluating the quantity 
of infectious viruses in a given volume and the quality of virus stocks. Whereas 
quantity is an obvious feature, quality is a rather vague parameter as it describes the 
virus fraction of a virus stock that is fully functional, i.e., infectious, whereas the 
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remaining virus particles are not. This is, because they have not been properly 
assembled, they became damaged or essential virion components are 
underrepresented or entirely missing for various reasons. These particles are 
commonly called defective interfering particles. 
 It is not obvious how those EBV genes, which repress virus titer could act and, 
to my knowledge, there is no example in the literature that fits my experiments and 
data. There are seven DNA or capsid-associated early genes within the group of 16 
genes that lead to a reduce virus titer. This and remaining classifications do not 
indicate how the viral genes could cause a trend to lower titers. Their expression 
could be toxic to the cell or cause problems in assembling virus components during 
morphogenesis as their unbalanced levels could alter protein stoichiometry (Fig. 2).  
 
Bioparticle concentration profiles after ectopic expression of 76 single 
EBV genes  
 The same virus stocks were tested for their bioparticle concentrations by 
binding to Elijah cells. The bioparticles adhere to the Elijah cell surface and are 
detected using a gp350-specific antibody. The bioparticle concentrations were 
quantified and aligned (Fig. 3). BKRF4, BVLF1, BNLF2a, BXRF1, BFLF2, BMRF1, BLLF1, 
BHLF1, BLRF3, BXLF1, BVRF2 and BALF2 expression seemed to enhance bioparticle 
concentration to some degree. They are called the ‘high bin’ group (n=12). 
Expression of BFRF1, BSLF1, BTRF1, LF1, BSLF2/BMLF1, BMRF2, BBRF3, BNRF1, 
BBLF1, BRLF1, BALF1, BBRF2, LF2 and BMLF1, the ‘low bin’ group of genes (n=14) led 
to a reduction of bioparticle concentration. Technically, the assay measures bound 
particles on the surface of Elijah cells, an established human B cell line from a case of 
Burkitt’s lymphoma (Rowe et al., 1985; Baker et al., 1998). Binding is probably 
mediated by the interaction of gp350 with CD21 on the cell surface, but this is 
speculation (Feederle et al., 2005; Pavlova et al., 2013). Operationally, I consider 
particle binding as a proxy for the amount of biologically active, i.e., cell binding virus 
particles contained in virus stocks. A functional classification of the genes of the ‘high 
bin’ and ‘low bin’ groups were classified according accepted criteria was not very 
informative nor was expression timing (Fig. 3A,B). Among the 26 genes, ten gene 
products are DNA or capsid associated, three are membrane proteins, five are 
tegument proteins, five are non-structural proteins and three proteins have no 
known function. It remains unclear which specific function might enhance or reduce 
the capacity of producing bioparticles as measured in the Elijah cell binding assay.  
 
Quantification of physical particle concentration of the 76 EB virus stocks 
Besides measuring virus titer and bioparticle concentration, identical virus 
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stocks were quantified using the NTA instrument that can detect and record the 
particles in a predefined size range (100 nm – 200 nm) by their zeta charges. The 
normalized results were arranged in rank order from highest to lowest. The top ten 
genes are BFLF2, BILF1, BcLF1, BKRF4, BHLF1, BVRF1, BVLF1, BORF2, BLRF3 and 
BGRF1/BDRF1. BRRF2, BCRF1, BRLF1, BFRF1A, BFRF1, BSLF2/BMLF1, BGLF5, BBRF3, 
BBLF1, BKRF2, BNRF1, BSLF1, LF2, BBRF2, BALF1 and BMLF1 have the lowest physical 
particle concentrations (Fig. 4). The quantification inevitably included cell debris, 
protein aggregates, cellular fragments and any sort of cellular particles such as 
extracellular vesicles and exosomes that fall into the same size range causing 
background interference. This parameter, however, can define real physical particles 
compared to bioparticles. Among the 26 genes selected, 13 encode DNA or capsid-
associated proteins, three are membrane proteins, five are tegument proteins, three 
are non-structural proteins and two are proteins of unknown function (Fig. 4A). By 
the definition of expression timing, nine are expressed early, nine are expressed late 
and eight have unknown expression timings (Fig. 4B). Again, there is no obvious 
correlation between functional groups or expression timing versus a gain or loss of 
the number of physical particles.   
 
High correlation between the three characteristic parameters of virus 
stocks  
 Since the virus titers, bioparticle concentrations and physical particle 
concentrations were recorded, it is worth to investigate the interrelation between 
each pair of characteristics and examine the reliability of the measurements. Mean 
values of Figure 2-4 were transformed to rank orders and listed in parallel. The 
ordinal table was assessed by Spearman rank method and the result is shown as a 
heatmap and the correlation coefficients (R2) were indicated in the grids (Fig. 5A). 
Bioparticle concentration vs. virus titer is 0.7651; physical particle concentration vs. 
virus titer is 0.7396; physical particle concentration vs. bioparticle concentration is 
0.8338. The coefficients clearly point to a strong positive correlation. Similarly, the 
value of 0.8338 between physical particle concentration and bioparticle 
concentration is highest suggesting that physical particle numbers mostly reflect the 
number of intact virus particles that bind to the surface of Elijah cells.  
 
No distinct category of protein function contributes significantly to virus 
titer, bioparticle concentration or number of physical particles. 
 The contributions of all genes investigated to the three measured parameters 
are listed in Table 1. Mean values of three characteristics (Fig 2A-4A) were extracted 
and provided as box plots (Fig. 5B). Each dot represented an EBV gene and red dots 
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stand for values obtained by ectopic expression of BALF4. Virus titers, bioparticle and 
physical particles were analyzed by the Kruskal-Wallis rank sum test (Table 2). The 
overall p values indicated that there were no significant differences among groups 
and also a pairwise comparisons using the Wilcoxon rank sum test suggested no 
statistically firm difference regarding attributed protein functions, virus titers, 
bioparticles and physical particles of the virus stocks. Similarly, examining a possible 
significant contribution by the category expression timing was not informative.  
 I interpret the outcome of these analyses to mean that many of the selected 
viral genes contribute to various aspects of virus production. Hence, there is no clear 
direction towards a certain group of protein function or time window of gene 
expression as documented here. 
 
Expression of BALF4 together with selected viral genes does not enhance 
virus titers with one exception 
 In Figure 2 the ectopic expression of BALF4 together with BZLF1 led to a 
substantial increase in virus titer but not to an increase in bioparticles or physical 
particle concentration (Fig. 3 resp. 4). Together, this finding suggests that the 
expression of BALF4 improved the quality of single infectious virions in the virus 
stock but did nothing to change the concentration of virions per se. No other EBV 
genes showed a similar level of superior infectivity compared with BALF4 but certain 
EBV genes enhanced it to a limited degree (Figure 2). Intriguingly, it was unclear 
whether co-expression of BALF4 together with these viral genes might further boost 
virus titers (or infectivity) beyond BALF4 levels. Among the top ten viral genes tested 
only BVLF1 showed a 1.5-fold increase in virus titer compared with the BALF 4 only 
control and the remaining nine candidates. BALF4 in combination with BVLF1 raised 
the virus titer 12-fold. Ectopic expression of BVLF1 led to more virus particles (Figs. 3 
and 4) in contrast to BALF4 pointing to a combination of two different effects which 
together improve virion quality (BALF4) and quantity (BVLF1). Other viral genes 
tested in this experiment in combination with BALF4 did not have a discernable 
contribution suggesting that BALF4 is probably the only fusogenic EBV protein. 
 
shRNA mediated knockdown of 24 selected viral transcripts identifies 
essential and dispensable viral genes 
 To further investigate the role of certain EBV genes during virus production, I 
employed the shRNA technology to knockdown selected viral transcripts (using sets 
of three shRNAs per target) of 10 genes that enhanced (BKRF4, BVLF1, BNLF2a, 
BXRF1, BFLF2, BMRF1, BHLF1, BXLF1, BVRF2, BALF2; the ‘high group’) or decreased 
bioparticle concentration (BFRF1, BSLF1, BTRF1, BMRF2, BBRF3, BNRF1, BBLF1, 
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BRLF1, BALF1, BBRF2, BMLF1; the ‘low bin’ group) together with three viral genes 
and controls (BPLF1, BBRF1, BGLF4, GFP, Ctrl) (Fig. 8A). Knockdown efficiencies as 
determined by co-expression of individual shRNAs together with the corresponding 
luciferase reporters in 293T cells were excellent (Fig. 7A). Contrary to expectations of 
lab members, the functionality of the stably expressed shRNAs was also perfect (Fig. 
7B). Upon induction of virus production in the 24 shRNA expressing EBV producer 
cell lines some shRNA sets caused severe consequences with respect to virus titers 
(Fig. 8B,C) and bioparticle concentration (Fig. 9). The results supports the validity of 
this experimental approach despite the abundance of viral lytic transcripts during the 
productive lytic phase in 2089 EBV producer cells.  
 As expected, EBV production was not affected in shGFP producer cells (Fig. 8B) 
but many stably expressed shRNAs caused a severe reduction of virus titers (Fig. 8C) 
documenting anticipated consequences of the shRNA knockdown approach. Virus 
stocks obtained from shBALF4 cells revealed a dramatic decrease in virus titer, which 
is in agreement with a BALF4 knockout EBV derivative (Neuhierl et al., 2002). Ectopic 
expression of BALF4 in shBALF4 EBV producer cells partially restored the virus titer as 
expected from the essential function of EBV’s gB homologue during virus fusion (Fig. 
10C).  
Noticeably, the virus stock of shBFLF2 EBV producer cells had a roughly 1.9-fold 
increased virus titer, but, after transfection of BALF4 the virus titer dropped to the 
level of the reference (Fig. 8B). BFLF2, which was reported to be essential for viral 
nuclear egress and DNA packaging interacts with BFRF1 (Granato et al., 2008; Dai et 
al., 2020). While both BFLF2 and BFRF1 have partially overlapping function, they 
have opposite effects on regulating virus titer, bioparticle concentration and physical 
concentration (Figs. 8B, 9B). Furthermore, BFLF2 was classified to belong to the ‘high 
bin’ group, while BFRF1 was found to be a member of the ‘low bin’ group. The results 
can be interpreted to mean that both genes are critical for virus production but their 
expression in 2089 EBV producer cells is not optimally regulated. 
The shRNA mediated knockdown of BKRF4, BNLF2a, BHLF1 and BXLF1, which 
are members of the ‘high bin’ group demonstrated a similar and moderate reduction 
of virus titers. The Murata group found that BKRF4 is able to increase virus titers 
(Masud et al., 2017), which my measurement confirmed as bioparticle concentration 
increased upon ectopic expression of this gene (Fig. 3). BNLF2a was shown to be 
upregulated by BZLF1 and is involved in immune invasion from cytotoxic T cells 
(Almohammed et al., 2018), but has no reported function in virion biogenesis. 
Currently, a BHLF1 knockout EBV demonstrated its limited capacity of transforming B 
cells (Yetming et al., 2020). BXLF1 has been identified as the viral thymidine kinase 
and, consequently, its knockdown reduced the virus titer, supporting its supportive 
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role during ribonucleotide synthesis in EBV producing cells. Similarly, the knockdown 
of BALF2 and BMRF1, EBV’s major DNA binding protein and the DNA polymerase 
processivity factor, respectively, repressed the function of two viral proteins that are 
essential during lytic DNA replication (Fixman et al., 1992). During EBV replication, 
BMRF1 was also found to have a role in late gene transcription (Sugimoto et al., 
2013). The ectopic expression of BMRF1 increased the virus titer slightly (Fig. 2 and 
8C), suggesting that it could limit virus production, whereas ectopic expression of 
BALF2 had no measurable effect in my experiments. A very similar trend was 
observed with BVRF2, which is involved in capsid maturation and folding (Sugimoto 
et al., 2019). 
For EBV late genes transcription, a group of genes form the pre-initiation 
complex (vPIC) consisting of BVLF1, BGLF3 and BFRF2 which, together with others 
viral components is involved in very efficient transcription of late genes encoding 
structural proteins (Aubry et al., 2014; Gruffat et al., 2016; Li et al., 2019). It was 
therefore not surprising to note that the shRNA mediated knockdown of BVLF1 
reduced the virus titer (Fig. 8B), which, on the contrary, was substantially higher, 
when BVLF1 was ectopically expressed (Fig. 2 and 8C). BXRF1 showed the same trend 
as BVLF1. BXRF1 is a homologue of HHV1 UL24 and a nuclear egress protein critically 
involved in cytoplasmic capsid export. Consequently, its knockdown was detrimental 
to virus titer (Fig. 8B), while its ectopic expression increased it (Fig. 2 and 8C).   
 
The shRNA strategy directed against genes of the ‘low bin’ group fails to 
identify a viral gene with regulatory functions controlling EBV’s lytic phase 
In the ‘low bin’ group and in case of the three viral control targets (BPLF1, 
BBRF1, BGLF4) a knockdown of certain gene products (BBRF1, BGLF4, BFRF1, BMRF2, 
BBLF1, BRLF1, BBRF2, BMFL1) had an expected severe or devastating effect on virus 
titer and a similar but less pronounced effect on bioparticle concentration (Figs. 8 
and 9). This loss of virus production is in line with an essential function of these eight 
genes, a conclusion that is supported by the known roles of some of these viral gene 
products. For example, the BBLF1 protein was reported to be involved in virus 
budding and shown to be colocalized with gp350 to trans-Golgi network (TGN) (Chiu 
et al., 2012). Another example is BBRF2, which encodes an EBV tegument protein 
involved in secondary envelopment with the final viral envelope (He et al., 2020). 
Upon the knockout of BBRF2 in EBV genomic DNA by the CRISPR/Cas9 technique, 
viral infectivity subsequently dropped substantially (Masud et al., 2019). A third 
example is BMRF2, a glycoprotein, which is reported to facilitate virion binding to ß1 
family integrins on target cells contributing to EBV infection. It is somewhat 
surprising to observe this effect with Raji cells, a human B cell line, because BMRF2 
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was claimed to play this role with polarized oral epithelial cells, only (Xiao et al., 
2007, 2008). 
In the ‘low bin’ group, a knockdown of BTRF1, BBRF3 or BALF1 had no 
measurable effects on virus titers or bioparticle concentration suggesting that their 
undisturbed expression levels are concordant with optimal gene expression or that 
these proteins are not limiting for virus production. However, their ectopic 
expression was counterproductive (Figs. 2 and 8).   
Unexpectedly, the knockdown of all 11 viral transcripts failed to reveal a 
phenotype compatible with a viral function that acts as a repressor or controller of 
virus production. This expectation was based on the ectopic, probably unphysio-
logical expression of 11 EBV genes which reduced bioparticle concentration and, 
concomitantly, virus titers (Fig. 2 and 3). Besides adverse effects of different nature, 
the unadjusted, probably elevated expression of a viral repressor of lytic functions 
could reduce virus titers or compromise bioparticle production. Conversely, a 
knockdown of such a repressor should yield the opposite effect increasing virus titers 
along with bioparticle concentration substantially. The results in Figure 8B and C 
clearly speak against the existence of such a viral factor.   
 
Comparison of bioparticle concentration of virus stocks generated by 
ectopic expression of viral genes and stocks from shRNA expressing EBV 
producer cells  
 Virus stocks generated by ectopic expression of individual genes in the parental 
2089 EBV producer cells were compared with virus stocks generated from shRNA 
knockdown producers. Obviously, the knockdown of BALF4 produced fewer 
bioparticles than its ectopic expression in the parental producer cells, which showed 
no effect on bioparticle numbers (Figs. 4 and 9B). Consistently, the ability of 
producing bioparticles from shRNA knockdown cells was impaired in all 10 selected 
genes of the ‘high bin’ group. In the ‘low bin’ group, bioparticle concentrations 
increased after knocking down BBRF3, BALF1, and BMLF1 but declined in shBGLF4 
producer cells consistent with the trend seen with virus titers (with BMLF1 as an 
exception regarding this parameter). Variations of virus titers and bioparticle 
concentrations were small in shBPLF1, shBBRF1, shBFRF1, shBTRF1, shBMRF2, 
shBNRF1, and shBBRF2 EBV producer cells, which indicate a co-regulation of virus 
titer and bioparticle concentration.  
 
Quantitation of the fusogenic activity of EBV virions  
 An analysis of the fusion event that takes place when the viral membrane of an 
enveloped virus and membranes of the virus’ target cell intersect is very difficult 
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because of the transient nature of the fusion event and the very local disturbance of 
the cellular membrane. A common surrogate model consists of two established cell 
lines that are co-cultivated. One of which encodes a viral fusion moiety expressed on 
its plasma membrane, the other cell line serves as target cell expressing the cognate 
receptor of the virus-encoded fusogenic protein(s) or the assembled protein com-
plex. In this simple model cellular fusion mediated by the action of the fusogenic viral 
effector is believed to mimic fusion events during viral infection. Clearly, this is an 
artificial model that relies on syncytia formation, which can be monitored with dyes 
or microscopically. Often, and in particular in case of herpesviruses such as EBV, 
multiple viral glycoproteins contribute to the final fusion such that it is difficult to 
reconstruct all these viral components in their correct composition and stoichiome-
try in such a model. 
My alternative is shown in Figure 10A. The technology is based on the bacterial 
enzyme ß-lactamase (BlaM), which was introduced to detect fusion of HIV virions 
with CD4 T cells and other possible HIV target cells a rather long time ago (Cavrois et 
al., 2002). The authors used a chimeric BlaM-Vpr enzyme which targets the enzyme 
into the lumen of the HIV envelope as about 100 to 200 Vpr molecules associate 
strongly with the HIV nucleocapsid protein (Muriaux and Darlix, 2010). The enzyme, 
when delivered to substrate-containing target cells cleaves the ß-ring of the CCF4 
substrate, causing the emission wavelength shift based on fluorescence (Förster) 
resonance energy transfer, FRET. It has been used for analysis of viral fusion and the 
method has also been improved (Jones and Padilla-Parra, 2016; Cavrois et al., 2014). 
I adopted this technology to make it work with EBV. The diagram in panel A of Figure 
10 depicts the preparation of modified complete EBVs encompassing a protein 
reporter (here a fusion protein consisting of CD63 and ß-lactamase assembled into 
the virus’ envelope) to measure fusogenic activity of virions directly and quantita-
tively. To measure the impact of certain ectopically expressed viral genes, virus stocks 
were generated by co-transfecting plasmids encoding BZLF1 (p509), CD63:BlaM 
(p7200) and individual, selected EBV gene into 2089 EBV producer cells. The virus 
stocks were harvested and incubated with human primary B cells, the primary target 
of EBV. After loading the CCF4 substrate into recipient cells, the fusogenic activity 
could be measured by detecting the percentage of cleaved substrate in these cells by 
flow cytometry. The results are shown in panel B of Figure 10. In parallel, the same 
virus stocks were incubated with Raji cells to measure their virus titers. For compari-
son, the virus stocks were prepared without the CD63:BlaM expression plasmid 
which were quantified in parallel as well.  
BALF4 has been regarded as EBV’s gB homologue, which in other herpes viruses 
is known to mediate viral fusion. In my assay, ectopic expression of BALF4 showed 
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outstanding fusogenic activity compared with the control (Fig. 10B). Very much in 
contrast, co-expression of all other viral genes of the ‘high bin’ or ‘low bin’ groups did 
not increase viral fusion beyond control levels indicating that BALF4 is the only viral 
protein that mediates fusion. Its genetic deletion abrogates viral infectivity (Neuhierl 
et al., 2002) supporting my finding nicely.  
 
Alternative application of the CD63:BlaM fusion assay  
 My colleagues and I made use of the CD63:BlaM reporter protein in a virus-
related context investigating the function and transport of EBV miRNAs when 
contained in extracellular vesicles (EVs) (Albanese et al., 2020). The key question here 
differed from my work with EBV because I wanted to enumerate the rate of EV-cell 
fusion to learn whether EV-borne miRNAs can be delivered to recipient cells to 
regulate cellular transcripts. This hypothesis has been maintained in the EV field ever 
since a landmark publication using EVs from latently EBV infected B cell lines 
provided circumstantial evidence supporting this idea (Pegtel et al., 2011). To detect 
EV-cell fusion events and quantify them, EV donor cells were transfected with 
CD63:BlaM (p7200) alone or were co-transfected with CD63:BlaM and VSV-G 
(p5451). VSV-G is a highly fusogenic glycoprotein from vesicular stomatitis virus. EVs 
released into the cell supernatant were harvested and peripheral blood mononuclear 
cells (PBMCs) (Fig. 11A) were incubated and measured by flow cytometry. Cell 
subpopulations were identified with specific antibodies to differentiate them 
according to their cell surface markers. Barely any EV fusion was detected in total 
PBMCs or PBMC subpopulations (T cells, B cells, monocytes, dendritic cells (DCs) and 
plasmacytoid dendritic cells (pDCs)). On the other hand, when EVs were used from 
donor cells co-transfected with CD63:BlaM and VSV-G these EVs readily delivered the 
reporter protein to different target cells as demonstrated by flow cytometry (Fig. 
11A). EVs generated using five different donor cell lines with or without VSV-G and 
tested with 17 different recipient cells showed exactly the same phenotype (Fig. 
11B).  
In conclusion, the novel fusion assay with a protein reporter that can consist of 
a membrane protein (such as CD63 or gp350 of cellular and viral origin, respectively) 
and an enzyme of prokaryotic origin (BlaM) can be broadly applied to detect fusion 
events between EVs or enveloped viruses with any recipient cell type such as primary 
or established cells from any species. Given the failure to observe any fusion of EVs 
with all recipient cells tested it is very likely that no cellular protein exists with 
fusogenic functions reminiscent of viral glycoproteins such as VSV-G or gB encoded 
by EBV and studied here. My work also suggests that ‘fusogenic’ proteins have no 
cellular precedent but instead have evolved together with enveloped viruses.   
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Materials and Methods  
Cell culture and cell lines  
RPMI 1640 medium supplemented with 10% FBS, 100 U/ml penicillin-streptomycin, 1 
mM sodium pyruvate, 100 pM sodium selenite, and 0.04% α-thioglycerols is used as 
universal cell culture medium. HEK293T cells were cultivated in DMEM supple-
mented with 10% FBS and 100 U/ml penicillin-streptomycin. CD63:BlaM transduced- 
293T, Calu-3, Caco-2, HepG2 and Huh7 cells were cultivated with 10% FBS, 100 U/ml 
penicillin-streptomycin, and 1% non-essential amino acid (NEAA) DMEM. (1) 
Peripheral blood mononuclear cells (PBMCs), (2) BJAB, (3) DG-75, (4) Elijah, (5) a 
lymphoblastoid cell line (LCL), which was human primary B cells infected with EBV, 
(6) Raji, (7) Mono-mac-6, (8) THP-1, (9) HEL, (10) LN-18, (11) U-251MG, (12) A549, 
(13) Calu-3, (14) HepG2, (15) Huh7, (16) MDA-MB-231, and (17) Caco-2 were 
cultivated with supplemented RPMI 1640 culture medium. 2089 carrying HEK293 
EBV producer cells were cultivated in supplemented RPMI 1640 medium containing 
100 μg/ml hygromycin B. Lentivirally transduced EBV producer cells were cultivated 
in supplemented RPMI cell culture medium and co-selected with 100 μg/ml 
hygromycin B and 3 μg/ml puromycin after initial selection with 10 μg/ml puromycin 
for 7 days. All cells were incubated in a 5% CO2 and water-saturated atmosphere at 
37°C.  
 
Preparation of extracellular vesicles depleted medium 
500 ml RPMI 1640 medium and 100 ml fetal bovine serum (FBS) were mixed and 
supplemented with 5 ml penicillin-streptomycin (10,000 U/ml), 5 ml sodium pyruvate 
(100 mM), 500 μl of 100 nm sodium selenite and 500 μl of 43.3% α-thioglycerols. The 
medium was ultracentrifuged using a SW32 or SW28 swinging-bucket rotor 
(Beckman) at 100,000 g at 4°C for at least 16 h. The supernatant was collected and 
filtrated using a 0.22 micron filter. The EV (exosome) depleted and filtered medium 
was mixed 1:1 (vol/vol) with plain RPMI 1640 medium to adjust the concentration to 
10% fetal bovine serum in the ready-to-use EV (exosome) depleted (ex-) RPMI 1640 
medium.  
 
Transient transfection of 2089 EBV producer cells 
6.5x105 EBV producer cells (Delecluse et al., 1998) were seeded in 6-well cluster 
plates. After overnight incubation, the cell medium was exchanged with 2 ml EV 
depleted (ex-) medium. 0.5 μg BZLF1 and 0.5 μg expression plasmid DNAs were 
mixed in a vial with 100 μl plain RPMI 1640. In another vial 100 μl plain RPMI 1640 
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was mixed with 6 μl PEI MAX® (6 μl PEI MAX® per 1 μg plasmid DNA). The content of 
both vials was combined rigorously mixed, the mixture was incubated at room 
temperature for 20 min and was added to the EBV producer cells in a single well of a 
six-well cluster plate.  
 
shRNA expression vector construction and sequence design of shRNAs 
The DNA sequences of selected EBV genes were obtained from the database of 
National Center for Biotechnology Information (NCBI). The FASTA format sequences 
were used for feeding the splashRNA tool (http://splashrna.mskcc.org) to predict 
potent shRNA sequences. According to the splashRNA score, the top three antisense 
guide sequences were chosen, ordered as synthetic oligonucleotides and inserted 
into the miR-3G frame of the basic shRNA construct (p6924 in our plasmid database). 
For each chosen EBV gene a knockdown pool of three shRNA constructs was 
designed and realized. The antisense guide sequences of individual EBV genes are 
marked in the entries shown in Table 7, which have compatible ends to be cloned 
into AvrII and EcoRI restriction sites in the basic shRNA construct p6924. The shRNA 
constructs contain the puromycin resistance gene as selection marker.  
 
Virus titer measurement (infectivity) 
The virus stocks were generated by transient DNA transfection of the 2089 EBV 
producer cells and the supernatants, harvested 3 days after transfection, were 
subsequently tested for infectious virus. Specifically, 5 μl virus stocks was added to 
1x105 Raji cells in a volume of 2 ml cell culture medium and incubated for 3 days. The 
infected cells which express green fluorescence protein were determined and the 
fraction of GFP-positive cells, termed green Raji unit (GRU), was quantified by flow 
cytometry (BD FACSCanto™).  
 
Bioparticle quantification (Elijah cell binding assay) 
2x105 Elijah cells were incubated with 20 μl of the harvested virus stocks. The mix 
was agitated on a mixing roller at 4 °C for 3 h. The cells were pelleted at 500 g at 4 °C 
for 10 min and washed with 1 ml ice-cold staining buffer (1% FBS and 2 mM EDTA in 
PBS). The anti-gp350 antibody (6G4) coupled to Alexa647 in 50 μl staining buffer 
(1:250 dilution) was added and the Elijah cells were incubated at 4 °C for 20 min. 1 
ml staining buffer was added and the cells were washed and resuspended in 300 μl 
staining buffer and analyzed by flow cytometry (BD FACSCanto™). The Elijah cells 
were analyzed for their fluorescence in the appropriate channel to obtain mean 
fluorescence intensity (MFI) data. MFI is an indirect measure of bound virus and 
correlates with the number of viral particles attached to the surface of Elijah cells.  
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Physical particles measurement (Nanoparticle tracking analysis)  
The physical particle concentration was measured using the ZetaView PMX 110 
instrument (Particle Metrix), which can perform nanoparticle tracking analysis (NTA). 
Harvested virus stocks were diluted with PBS to adjust the concentration of particles 
to about 107 – 108 particles per ml. Standard calibration beads (102.7±1.3 nm) 
(Polysciences) were used to confirm the range of linearity of the instrument. 1 ml 
diluted supernatant samples were injected for analysis. All samples in the chamber 
were recorded at 11 positions in three cycles. Pre-acquisition parameters were set to 
75 sensitivity, 50 shutter speed, a frame rate of 30 frames per second and 15 trace 
length. The post-acquisition parameters were set to a minimum brightness of 20, a 
minimum size of 5 pixels and a maximum size of 1000 pixels. Particle concentration 
and particle size were measured and documented and the images were analyzed 
using the ZetaView 8.04.02 software. 
 
Luciferase reporter construction 
Three corresponding target/sense sequences were inserted into the dual luciferase 
reporter plasmid psiCHECK2 (p5264). The sequences were inserted downstream of 
the Renilla luciferase coding sequence using the restriction enzyme sites XhoI and 
NotI. Firefly luciferase is used as internal control. The shRNA target sequences are 
shown in Table 8.  
 
Luciferase assay 
2x105 293T were seeded in a 24-well cluster plate. After overnight incubation, cells 
were co-transfected with 100 ng psiCHECK2 luciferase reporter plasmid and 300 ng 
individual corresponding pCDH shRNA expression plasmids. An empty pCDH shRNA 
expression plasmid (p6924) was transfected as control. Cells were lysed after 24 h 
and luciferase activity was measured using the Orion luminometer (Berthold). To 
detect the knockdown efficiency of stably shRNA transduced 2089 EBV producer 
cells, 1x105 producer cells were seeded in a 24-well cluster plate. After overnight 
incubation, cells were transfected with 100 ng corresponding psiCHECK2 luciferase 
reporter plasmid. An empty psiCHECK2 luciferase (p5264) reporter plasmid was 
transfected as control. After 24 h, cells were lysed and the luciferase activity was 
measured using the Orion luminometer.  
 
ß-lactamase (BlaM) fusion assay 
EBV particles equipped with CD63:BlaM were generated by co-transfecting 6x105 
2089 producer cells with expression plasmids encoding CD63:BlaM (p7200, 0.25 μg) 
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and BZLF1 (p509, 0.25 μg) together with 0.5 μg plasmid DNA encoding single EBV 
genes to generate virus supernatants for further testing. The open reading frame of 
human CD63 is C-terminally fused to a codon-optimized ß-lactamase via a G4S linker 
and cloned into the expression plasmid pcDNA3.1 (+) (p5267).  
For large scale production of CD63:BlaM equipped EVs, 1x107 cells (293T, Calu-3, 
Caco-2, HepG2 and Huh7 cells) were seeded in 13-cm dishes and the cells were 
transfected with 12 μg p7200 alone or together with 8 μg p5451 (VSV-G). One day 
after transfection, the medium was exchanged with plain DMEM cell culture medium 
with 4 g/L D-glucose. The supernatants were harvested after 72 h.  
To evaluate the fusogenic activities of different virus stocks, 2x105 human 
primary B cells were incubated with 5 μl virus supernatants. Alternatively, to evaluate 
the fusogenicity of EVs equipped with CD63:BlaM, 2x105 PBMCs or 17 different 
recipient cells were incubated with 500 μl EV containing supernatants harvested 
from the five different donor cell lines (293T, Calu-3, Caco-2, HepG2 and Huh7 cells) 
for 4 h at 37 °C. To assess the fraction of BlaM positive cells, primary B cells were 
analyzed directly but adherent cells were washed and trypsinized for further analysis. 
All cells were re-suspended in 100 μl of CCF4-AM staining solution in a 96-well plate. 
The staining solution consisted of 2 μl CCF4-AM (membrane-permeant ester forms of 
the negatively charged fluorescent ß-lactamase substrate), 8 μl Solution B (K1095, 
Thermo Fisher Scientific) and 10 μl of 250 mM Probenecid (P8761, Sigma) in 1 ml 
CO2-independent medium (18045-054, Thermo Fisher Scientific). After 16 h 
incubation in the dark at room temperature, the BlaM-positive recipient cells were 
analyzed by flow cytometry (BD LSRFortessa™). The CCF4 FRET substrate is excited 
with 409 nm wavelength laser (violet). The non-cleaved substrate emits light with 
520 nm wavelength (green) while the cleaved substrate emits light with a wavelength 
of 447 nm (blue).  
 
Isolation and preparation of human primary B cells from adenoids 
Human primary B cells were purified from adenoidal tissues, which were chopped 
with blades and washed with PBS. The mashed tissues were filtered with 100 μm 
sterile strainer (352360, Falcon®) and the cells were transferred to a sterile 50 ml 
tube. The volume was increased with PBS to 30 ml, 1 ml defibrinated sheep blood 
(SR0051D, Thermo Fisher Scientific) was added and mixed (to sediment T cells in the 
next step). The cell suspension was slowly layered on top of 15 ml Pancoll human 
(density: 1.077 g/ml) (P04-60500, PAN-Biotech) in a 50 ml tube. Samples were 
centrifuged at 1,900 rpm at room temperature for 30 min without brake. The 
interphase (white band) was collected and transferred to a new tube. The cells were 
washed three times with PBS and centrifuged at different speeds of 1,500, 1,400 and 
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1,200 rpm for 10 min.  
 
Preparation of peripheral blood mononuclear cells (PBMCs) 
20 ml freshly drawn human blood was mixed with 20 ml PBS. EDTA was added in the 
solution to have final concentration 2 mM to prevent coagulation. The cell 
suspension was added slowly on top of 10 ml Pancoll human (density: 1.077 g/ml). 
The two-step gradient was centrifuged at 2,000 rpm, no brake, for 30 min. The buffy 
coat layer (white interphase) containing monocytes, T and B cells was extracted 
carefully.  
 
Physical particle concentration of formulated cell culture media 
To investigate the concentration of extracellular vesicles (EVs) in fresh and spent 
media of different cell culture media were measured using a nanoparticle tracking 
analysis (NTA) instrument. The results are shown in Figure 12A in the appendix. 
Seven different formulated media and samples of cell culture media were analyzed. 
(i) ‘RPMI-‘ was plain RPMI 1640 medium purchased from the manufacturer; (ii) 
‘RPMI+’ was plain RPMI 1640 medium with all supplements for cell culture excluding 
fetal bovine serum (FBS). (iii) ‘Common medium’ consisted of ‘RPMI+’ and 10% FBS 
and was used to cultivate cells in vitro. (iv) ‘Ex- medium’ (exosome-depleted 
medium) was prepared by sedimenting 35 ml of ‘common medium’ by 
ultracentrifugation in a SW32 or SW28 swing-out rotor (Beckman) at 4 °C for at least 
16 h. 30 ml of the supernatant was harvested to yield ´Ex- medium’. (v) 5 ml of the 
remaining medium was used to resuspend the ‘medium pellet’ that had formed 
during sedimentation. To quantitate particles numbers, i.e., EVs, in conditioned, 
spent medium, 2 ml of ‘common medium’ or ‘ex- medium’ each were incubated with 
producer cells in 6-well cluster plates. Three days later, the media were collected 
and filtered using a 1.2 micron syringe filter and termed (vi) ‘conditioned com’ and 
(vii) ‘conditioned ex-‘, respectively.  
Using the NTA instrument, the particles contained in RPMI- could not be 
detected and RPMI+ was merely above the threshold level of the instrument of 107 
particles per ml (Fig. 12A). Unexpectedly, ‘ex- medium’ contained almost as many 
particles as ‘common medium’ (Fig. 12A), but particle concentration was about 
three-fold higher in the resuspended ‘medium pellet’ after ultracentrifugation of 
‘common medium’ indicating that physical depletion of EVs contained in FBS is 
partially effective, at least. After three days of cell culture with 2089 EBV producer 
cells, conditioned common medium (‘conditioned com’) and ‘conditioned ex-
‘ medium showed small increases in particle concentration as documented in Figure 
12A.  
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To analyze conditions of virus production, 2089 EBV producer cells were 
cultivated in 2 ml ‘ex- medium’ in individual wells of 6-well cluster plates for three 
days before physical particle concentration was measured. Different starting 
conditions were employed and the resulting particle concentrations are shown in 
Figure 12B. At the start of cell culture, (i) ‘ex- medium’, which was used to cultivate 
2089 producer cells in the subsequent experiments, was used at the start of the 
analysis also shown in Figure 12A (rightmost sample); (ii) 3 μl transfection reagent 
PEI Max, only, was added to 2 ml of ‘ex- medium’ (PEI); (iii) 0.5 μg empty pCMV 
vector (p6816) was complexed with 3 μl PEI Max and added (Vec); (iv) 0.5 μg BALF4 
(p6515) was complexed with 3 μl PEI Max and added (BALF4). To analyze virus stocks 
generated after lytic induction of the 2089 EBV producer cells for three days, (v) 0.5 
μg BZLF1 (p509) was complexed with 3 μl transfection reagent PEI Max and 
transfected (BZLF1); (vi) 0.25 μg p509 and 0.25 μg p6515 were complexed with 3 μl 
PEI Max and transfected (BZLF1 + BALF4). All conditioned media were harvested 
three days after transfection and filtered.  
The addition of 3 μl PEI Max led to a small increase of particle counts in all three 
samples of PEI, Vec and BALF4 compared to ‘conditioned ex-‘ medium. In induced 
2089 EBV producer cells transfection of BZLF1 alone or in combination with BALF4 
led to a clear gain in particle number probably because the supernatants contained 
viral particles and additional debris as a consequence of virus release and production 
by the lytically induced cells.  
 
Comparison of two cultivation conditions using different cell culture media  
To monitor possible differences when using ‘ex- medium’ for cultivating cells, 2089 
EBV producer cells were seeded in 6-well cluster plates. On the next day and prior to 
DNA transfection, the medium was exchanged with ‘common medium’ or ‘ex- 
medium’ (Fig. 12A). Under these two different conditions, cells were transfected 
with BALF4 (p6515), BZLF1 (p509), BZLF1 plus BALF4, or the transfection reagent PEI 
Max, only. The four types of conditioned media were harvested three days after 
transfection. The media were analyzed regarding virus titer (Raji cell infection assay; 
Fig. 2) and bioparticle concentration (Elijah cell binding assay; Fig. 3). The results are 
shown in panel A and B, respectively, of Figure 13 in the Appendix. No virus stocks 
were generated when the cells were treated with PEI Max, only, or transfected with 
BALF4 alone. When BZLF1 and BALF4 were co-transfected, the virus titer was clearly 
higher compared to cells transfected with only BZLF1 (Fig. 13A). Under all 
conditions, virus stocks generated from cells cultivated in ‘ex- medium’ showed 
slightly higher virus titer and bioparticle concentration compared with ‘common 
medium’ (Fig. 13B). 
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Flow cytometry (FACS) analysis of subpopulations of PBMC 
5x105 PBMCs were incubated with 1 μl antibody at 4°C for 30 min, when cells were 
washed with PBS and resuspended in staining buffer (1% FBS and 2 mM EDTA in 
PBS). The cells were analyzed by flow cytometry using a BD LSRFortessa™ 
instrument. 
 
Table 3. Antibodies used for the analysis of cellular subpopulations contained in 
PBMCs 
Antibody Clone and catalog no. Company 
CD19-APC HIB19, 17-0199-42 BD Biosciences 
CD3-APC SP34-2, 557597 BD Biosciences 
CD11c-APC 3.9, 301613 BioLegend 
CD14-PE MEM-15, 21279144 ImmunoTools 
CD303-APC AC144, 130-097-931 MACS 
CD304-PE REA774, 130-112-045 MACS 
 
Table 4. Medium, supplements and additional components for cell culture 
Medium Supplements  Catalog No. Company 




Sodium Pyruvate (100 
mM) 
11360070 Gibco® 
Sodium Selenite  
(stock: 100 nM) 
S5261 Sigma-Aldrich 




thioglycerols (43.3 μl 1-
Thioglycerol + 20 μl 10 








Hygromycin B (50 mg/ml) 10687010 Gibco® 
Puromycin (stock: 2 
mg/ml) 
A2856.0100 Applichem 




PEI MAX® - 
Polyethylenimine 





Pancoll human P04-60500 PAN-Biotech 
 
Table 5. Cell types of donor and recipient cells 
Cell type  Name  Disease 
B lymphocyte BJAB Burkitt’s lymphoma 
B lymphocyte DG-75 Burkitt’s lymphoma 
B lymphocyte Elijah Burkitt’s lymphoma 
B lymphocyte LCL  
B lymphocyte Raji Burkitt’s lymphoma 
Monocyte Mono-mac-6 Acute monocytic 
leukemia 
Monocyte THP-1 Acute monocytic 
leukemia 
Erythrocyte HEL Erythroleukemia 
Epithelial cells LN-18 Glioblastoma 
Epithelial cells U-251MG Astrocytoma 
Epithelial cells A549 Lung carcinoma 
Epithelial cells Calu-3 Lung adenocarcinoma 
Epithelial cells HepG2 Hepatocellular carcinoma 
Epithelial cells Huh7 Hepatocellular carcinoma 
Epithelial cells MDA-MB-231 Breast adenocarcinoma 
Epithelial cells Caco-2 Colorectal 
adenocarcinoma 
 
Software tools  
MacVector Version 18.0.0 (55) was used for in silico DNA cloning. FlowJo 10.4.2 was 
used for analysis and visualization of flow cytometry data. The ZetaView 8.04.02 
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software was used for nanoparticle tracking analysis. Prism 9 for macOS Version 9.0.1 
(128) and RStudio Version 1.2.5001 were used for statistical analysis and 
visualization. Microsoft Word for Mac Version 16.45 and Microsoft Excel for Mac 
Version 16.45 were used for documentation and analysis. Adobe Illustrator 25.1 was 
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Fig. 12 Concentration of physical particles in different cell culture media and in supernatants from 
induced 2089 EBV producer cells generated under various conditions. 
Concentrations of physical particles were determined with the aid of the nanoparticle tracking analysis 
(NTA) using the ZetaView PMX110 instrument. Mean and standard deviation of three replicates are 
shown. 
(A) Different cell culture medium preparations based on standard RPMI1640 medium were analyzed as 
follows:  
RPMI–: plain, non-supplemented commercial RMPI 1640 medium (Gibco). 
RPMI+: commercial RPMI1640 medium supplemented with 5 ml penicillin-streptomycin stock (10,000 
U/ml), 5 ml sodium pyruvate (100 mM), 500 μl of 10 nM sodium selenite, and 500 µl of 43.3% α-
thioglycerols.  
Common medium: RPMI+ with 10% fetal bovine serum (Bio&Sell) and the supplements listed above. 
Ex– medium (exosome-depleted medium): common medium with 10% fetal bovine serum (final 
concentration) after ultracentrifugation (100,000 g, 4 °C for more than 16 hours) and prepared as 
described in Materials and Methods. 
Medium pellet: Common medium was concentrated 7-fold by ultracentrifugation and analyzed. 
Technically, 35 ml common medium was ultracentrifuged (100,000 g, 4 °C for 16 hours) and 30 ml 
supernatant was removed and the pellet was resuspended.  
Conditioned com: Supernatant from non-induced 2089 EBV producer cells cultured in common medium 
for three days. 






































































































depleted medium (ex– medium) for three days. 
(B) Analysis of supernatants from non-induced and induced 2089 EBV producer cells including controls.  
Conditioned ex-: The conditioned ex- medium in panel A is used here to cultivate the cells. 
PEI: Non-induced 2089 EBV producer cells were cultured in exosome-depleted medium (ex– medium) 
for three days. 3 µl PEI MAX was added at the start of cell culture to mimic DNA transfection conditions.  
Vec: 2089 EBV producer cells were transfected with pCMV control plasmid DNA (0.5 µg; p6815) using 3 
µl PEI MAX and kept in exosome-depleted medium (ex– medium) for three days when the supernatant 
was harvested and analyzed. 
BALF4: same as above (Vec) but the cells were transfected with 0.5 µg of the BALF4 expression plasmid 
p6515. 
BZLF1: same as above (Vec), but the cells were transfected with 0.5 µg of the BZLF1 expression plasmid 
p509 to induce EBV production. 
BZLF1 + BALF4: same as above (Vec), but the cells were co-transfected with 0.25 µg each of the 
expression plasmids p509 and p6515 coding for BZLF1 and BALF4, respectively. 
 
 
Fig. 13 Comparison of virus production from 2089 EBV producer cells using common cell culture 
medium versus exosome-depleted medium (ex– medium). 
The 2089 EBV producer cell line was seeded in 6-well cluster plates (6.5x105 cells per well) and the 
medium was exchanged after overnight incubation with 2 ml common cell culture medium (fully 
supplemented RPMI1640 medium with 10% fetal bovine serum) or exosome-depleted (ex– medium). 
As a reference, cells were mock transfected with PEI MAX but no plasmid DNA was added (PEI). 
Alternatively, the EBV producer cell line 2089 was transfected with only the BALF4 encoding plasmid 
p6516 (0.5 µg), with the BZLF1 encoding plasmid p509 (0.5 µg) or with both BALF4 and BZLF1 plasmids 
(0.25 µg each) as indicated. Supernatants were harvested after three days and filtered (1.2 µm mesh 
size). (A) 1x105 Raji cells were infected with 10 µl of the different supernatants and analyzed by flow 
cytometry after three days. The percentage of GFP-positive cells is provided as ‘green Raji units’ (GRU). 





















































the Elijah cell binding assay (see Materials and Methods). Mean fluorescence intensity (MFI) values of 




Table 6. Synthetic oligonucleotides used to remove epitope tags from 76 expression plasmids to restore 
their open reading frames   
Gene (plasmid #) Primer/oligonucleotide 
BBRF3 (p6534) 6534_Top (Bgl2) 5’: GATCTTCCCCTAAAGTAACAGC 
6534_Bottom (Not1) 5’: GGCCGCTGTTACTTTAGGGGAA 
BDLF3 (p6535) 6535_Forward (Blp1) 5’: CCAATGCCACAAAAACAACTGC 
6535_Reverse (Not1) 5’: TTTTGCGGCCGCCTACACCAGTCCCTTGTAAAGC 
BILF2 (p6536) 6536_Forward (Esp31) 5’: GTAAATGACTCCAACACCTCC 
6536_Reverse (Not1) 5’: TTTTGCGGCCGCTCACAGGGGTATCCAGCCCTT 
BKRF2 (p6537) 6537_Top (Aju1) 5’: CTCAGTGGAAGACCTGTTTGGTGCCAACTTAAACAGATACGCATGGCAT 
CGCGGGGGCTAGGC 
6537_Bottom (Not1) 5’: 
GGCCGCCTAGCCCCCGCGATGCCATGCGTATCTGTTTAAGTTGGCACCAAACAGGTCTTCCACTGAGAATGA 
BLRF1 (p6538) 6538_Top (Bpu10l) 5’: 
TCAGCCATCTACCTGATGTACGTCTGCTTTAACAAGTTTGTGAACACGCTGCTGACGGATTAGGC 
6538_Bottom (Not1) 5’:  
GGCCGCCTAATCCGTCAGCAGCGTGTTCACAAACTTGTTAAAGCAGACGTACATCAGGTAGATGGC 
BMRF2 (p6539) 6539_Forward (Bpu10l) 5’: TTACTTTAGCGGGGTAGCGG 
6539_Reverse (Not1) 5’: TTTTGCGGCCGCTTTAGGATTTAATGAATGTCAC 
BXLF2 (p6540) 6540_Forward (Blp1) 5’: TGACCTCACACGAGACAAGC 
6540_Reverse (Not1) 5’: TTTTGCGGCCGCCTAAAGGAAAAACATAACAATCTTG 
BZLF2 (p6541) 6541_Forward (BamH1) 5’: CAAACCAAATGTAGAGGTCTGG 
6541_Reverse (Xba1) 5’: TTTTTCTAGATTAGCTATTTGATCTTTGACT 
BBLF1 (p6557) 6557_Forward (Nco1) 5’: AACAACTCCGCCCCATTGAC 
6557_Reverse (Not1) 5’: GGGGGCGGCCGCTTAGTTTGGTTTTTTATTTGGC 
BDLF2 (p6558) 6558_Top (Xho1) 5’: TCGAGGAGGTCATGTATGTGATGGTTCAGTAGGC 
6558_Bot (Not1) 5’: GGCCGCCTACTGAACCATCACATACATGACCTCC 
BGLF1 (p6559) 6559_Top (Mun1, Mfe1) 5’: 
AATTGGCACTCACCCCCGAGGAGAGGGGATATATTCTGGCACGTCATGGCATCCGCCGCGAACAGTAGGC 
6559_Bot (Not1) 5’: 
GGCCGCCTACTGTTCGCGGCGGATGCCATGACGTGCCAGAATATATCCCCTCTCCTCGGGGGTGAGTGCC 
BGLF2 (p6560) 6560_Top (Mun1, Mfe1) 5’: AATTGCCAAGTACTGAAACGTCAGGTCTTACATTCTTATTGAGC 
6560_Bot (Not1) 5’: GGCCGCTCAATAAGAATGTAAGACCTGACGTTTCAGTACTTGGC 
BGLF4 (p6561) 6561_Forward (Pst1) 5’: GCTCTATCGCCTCTATTGCC 
6561_Reverse (Not1) 5’: TTTTGCGGCCGCTCATCCACGTCGGCCATCTGGACC 
BKRF4 (p6562) 6562_Top (Mun1, Mfe1) 5’: AATTGGCCATGGCTGTAAGC 
6562_Bot (Not1) 5’: GGCCGCTTACAGCCATGGCC 
BLRF2 (p6563) 6563_Forward (Bpu101) 5’: TGTTCCTTCTGCTCCAGTGC 
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6563_Reverse (Not1) 5’: TTTTGCGGCCGCTTAATCAGAAATTTGCACTTTCTTTGC 
BNRF1 (p6564) 6564_Forward (BsrG1) 5’: TCATCTGGCTCTCCTGTGTG 
6564_Reverse (Not1) 5’: TTTTGCGGCCGCTCACTCGGAGGGGCGACCGTGCCTG 
BOLF1 (p6565) 6565_Forward (EcoR5) 5’: AGGAGGAGAAGGAGCATACG 
6565_Reverse (Xba1) 5’: TTTTCTAGATTACTCATCTTCGGCGGTGGGGCGGGG 
6565C_Top (Pml1) 5’:  
GTGACCATGGCGTCCGCTATGGAGAGTGACAGCAGCGGCGGTAGCGGAGGGGCAGACGCCCAGCCACCCCT
GGCAGAGGTGGACGGGGGGCTCGCCCGCGTGA 
6565C_Bot (Mlu1) 5’:  
CGCGTCACGCGGGCGAGCCCCCCGTCCACCTCTGCCAGGGGTGGCTGGGCGTCTGCCCCTCCGCTACCGCCGC
TGCTGTCACTCTCCATAGCGGACGCCATGGTCAC 
BORF2 (p6566) 6566_Forward (Blp1) 5’: AACAGAATGAGCGGAGTCC 
6566_Reverse (Not1) 5’: TTTTGCGGCCGCTTATTGGCAAGATTCACAGGCTCG 
BPLF1 (p6567) 6567_Top (Nhe1) 5’: 
CTAGCCGAGTACTGTCTCGCTTCGTGAGCCAGCTTCGCCGCAAGCTGGAGCGTTCCACCCACCGCCTCATCGCA
GACCTCGAGAGACTCAAGTTTTTGTATCTGTAAT 
6567_Bot (Xba1) 5’: 
CTAGATTACAGATACAAAAACTTGAGTCTCTCGAGGTCTGCGATGAGGCGGTGGGTGGAACGCTCCAGCTTGC
GGCGAAGCTGGCTCACGAAGCGAGACAGTACTCGG 
BRRF2 (p6568) 6568_Forward (Bpu101) 5’: TACCGTCCAGCAAAAAGGG 
6568_Reverse (Not1) 5’: TTTTGCGGCCGCTTAGACGACGCTCAGTGAATACAG 
BSRF1 (p6569) 6569_Forward (Age1) 5’: CGCTCAGTCATCTGGAATAC 
6569_Reverse (Not1) 5’: TTTTGCGGCCGCCTACGTTAACGCGAGCTCCGTGGG 
BVRF1 (p6570) 6570_Forward (Hind3) 5’: TCATCTCACCAGTGGAACC 
6570_Reverse (Not1) 5’: GGGGGCGGCCGCTCAGCTTGGGGCCACCGGGGAGG 
BXLF1 (p6571) 6571_Forward (Nhe1) 5’: TTTGTCTTGCGTTCACCC 
6571_Reverse (Not1) 5’: CCCCGCGGCCGCCTAGTCCCGATTTCCCCTCTCAAAATC 
BBRF1 (p6593) 6593_Forward (Age1) 5’: ATAATCAGGGGCAGCGTCTC 
6593_Reverse (Not1) 5’: TTTTGCGGCCGCTTAACTTCCAGCACCAGGCGGGGG 
BcLF1 (p6594) 6594_Forward (Cla1) 5’: AGTTTGTAGTGATTGCTGGC 
6594_Reverse (Not1) 5’: TTTTGCGGCCGCTCAAAAAACCACCTTATTTCCAAA 
BDLF1 (p6595) 6595_Forward (Pst1) 5’: TGTGGACATTGTTTTCCCC 
6595_Reverse (Not1) 5’: TTTTGCGGCCGCTTATCTTAACCAGCAAGTGGCCGT 
BdRF1 (p6596) 6596_Forward (BspE1) 5’: TGAATGAGTTACAGCACACG 
6596_Reverse (Not1) 5’: TTTTGCGGCCGCTCAAGCCACGCGTTTATTCAGCAA 
BFRF3 (p6597) 6597_Forward (Bpu101) 5’: CCATAGACAAGAGGCAGAGAG 
6597_Reverse (Not1) 5’: TTTTGCGGCCGCCTACTGTTTCTTACGTGCCCCGCG 
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BORF1 (p6598) 6598_Forward (Pst1) 5’: CAACTTCATCACCCCTGTG 
6598_Reverse (EcoR5) 5’: TTTTGATATCCTAGAGAATCACCTCCCAGTCAGA 
BALF1 (p6632) 6632_Forward (Pml1) 5’: TTTTCACGTGGCGATGAACCTGGCCATTG 
6632_Reverse (Not1) 5’: TTTTGCGGCCGCTTACAAAGATTTCAGGAAGTCAGT 
BALF3 (p6633) 6633_Forward (BsiW1) 5’: CGTGTCCCTCTACAACAAG 
6633_Reverse (Not1) 5’: TTTTGCGGCCGCCTACGCCGAGTCATCTCTCATTTG 
BALF5 (p6634) 6634_Forward (Nco1) 5’: GCTACCTGTGGGCTTTTTG 
6634_Reverse (Xba1) 5’: GGGGTCTAGATTAGAATGGTGGCCGGGCTGTAAA 
BARF1 (p6635) 6635_Forward (Bpu101) 5’: CCTTTCAGGGGCTTCTTTG 
6635_Reverse (Not1) 5’: AAAAGCGGCCGCTTATTGCGACAAGTATCCAGAAAC 
BaRF1 (p6636) 6636_Forward (BamH1) 5’: TGGCACCAAAATCAACGG 
6636_Reverse (Xba1) 5’: TTTTCTAGATCAAAGGTCATCTACCACCAGCAT 
BBLF2/BBLF3 
(p6637) 
6637_Top (EcoRV) 5’:  
ATCGGCCCTCCACCCCGGCTACACCATTCCTATGGAAATCACGCGAGAGACAGATTTACTGATGACTGTTCTCAG
TTTATTCTAGT 
6637_Bot (Xba1) 5’: 
CTAGACTAGAATAAACTGAGAACAGTCATCAGTAAATCTGTCTCTCGCGTGATTTCCATAGGAATGGTGTAGCCG
GGGTGGAGGGCCGAT 
BBLF4 (p6638) 6638_Forward (Pst1) 5’: GCTGCCTGGAACACAATAC 
6638_Reverse (Not1) 5’: TTTTGCGGCCGCTCAGTAAACCAGTAGTGCGCGTGA 
BBRF2 (p6639) 6639_Forward (Bsg1) 5’: GCAACAATCTGGACTCTCTG 
6639_Reverse (Not1) 5’: TTTTGCGGCCGCCTAGGGAATTATTTTTGAGACCGT 
BCRF1 (p6640) 6640_Forward (Nco1) 5’: CGGGACTTTCCAAAATGTCG 
6640_Reverse (Not1) 5’: TTTTGCGGCCGCTCACCTGGCTTTAATTGTCATGTA 
BcRF1 (p6641) 6641_Forward (Xho1) 5’: TACCAACTTTCCCTCGGTG 
6641_Reverse (Not1) 5’: TTTTGCGGCCGCTTACACTTGAGCATCACGGCAGTG 
BDLF4 (p6642) 6642_Forward (BamH1) 5’: CGGGACTTTCCAAAATGTCG 
6642_Reverse (Not1) 5’: TTTTGCGGCCGCTCAACACTTGGTTGTCAATGTGGA 
BFLF1 (p6643) 6643_Forward (Bpu101) 5’: CCTCATCAAGACCCAAAACAC 
6643_Reverse (Not1) 5’: TTTTGCGGCCGCTCACACGTAGACCTGGGAAGTTTG 
BFLF2 (p6644) 6644_Forward (Bsg1) 5’: TGTGCCTCAGGAGTTTAGC 
6644_Reverse (Not1) 5’: TTTGCGGCCGCCTACTGTTTATTTTCCAAAATGAG 
BFRF1 (p6645) 6645_Forward (Blp1) 5’: CGGATGTTGACCTACCAAAG 
6645_Reverse (Not1) 5’: TTTTGCGGCCGCTCAGGTCCACCTCAGAAACATCAG 
BFRF1A (p6646) 6646_Forward (Xho1) 5’: CGGGACTTTCCAAAATGTCG 
6646_Reverse (Not1) 5’: TTTTGCGGCCGCTTATTGAGCTCGTCTAGGAGCCTC 
BFRF2 (p6647) 6647_Forward (Blp1) 5’: CGGTTACTGCTTGAACTTTGG 
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6647_Reverse (Not1) 5’: TTTTGCGGCCGCTTAGGAAGCAGGGGACTGTCTGGA 
BGLF3 (p6648) 6648_Forward (Xho1) 5’: CGGGACTTTCCAAAATGTCG 
6648_Reverse (Not1) 5’: TTTTGCGGCCGCCTACTCATCTTCATAAGTCACCAT 
BGLF5 (p6649) 6649_Forward (Bsg1) 5’: GGGTGGAGTCTATGCTCTAC 
6649_Reverse (Not1) 5’: TTTTGCGGCCGCCTATGGAGTTGACTCGTCGTCGGC 
BGRF1/BDRF1 
(p6650) 
6650_Top (Asp7181) 5’:  
GTACCTACACCTACACCGGCAAGCAGCGCAACCTCTCTGACGACGTGCTGGTTGCGCTAGTCATGGCTCATTTT
CTCGCAACAACACAGAAGCACACGTTCAAGAAAGTTCATTAAGC 
6650_Bottom (Not1) 5’:  
GGCCGCTTAATGAACTTTCTTGAACGTGTGCTTCTGTGTTGTTGCGAGAAAATGAGCCATGACTAGCGCAACCA
GCACGTCGTCAGAGAGGTTGCGCTGCTTGCCGGTGTAGGTGTAG 
BHRF1 (p6651) 6651_Top (BamH1) 5’:  
GATCCAGAAGGTTTAGCTGGACTTTGTTTCTTGCTGGACTGACTTTGAGTCTGTTAGTTATATGTAGTTATTTATT
TATCTCCAGAGGAAGACACTAAGC 
6651_Bottom (Not1) 5’: 
GGCCGCTTAGTGTCTTCCTCTGGAGATAAATAAATAACTACATATAACTAACAGACTCAAAGTCAGTCCAGCAAG
AAACAAAGTCCAGCTAAACCTTCTG 
BILF1 (p6833) 6833_Forward (Bsg1) 5’: TGATGGGCGTGTTTTGTC 
6833_Reverse (Not1) 5’: TTTTGCGGCCGCTCAGGTGGACTGGCTAGGCACCCT 
6833C_Top (Pml1) 5’:  
GTGACCATGCTCTCCACCATGGCCCCCGGGTCCACCGTGGGGACCCTGGTGGCCAACATGACTTCCGTCAATGC
AACGGAAGATGCGTGCACTAAATCCTACAGCGCCTTCC 
6833C_Bot (BbvC1) 5’:  
TGAGGAAGGCGCTGTAGGATTTAGTGCACGCATCTTCCGTTGCATTGACGGAAGTCATGTTGGCCACCAGGGT
CCCCACGGTGGACCCGGGGGCCATGGTGGAGAGCATGGTCAC 
BKRF3 (p6834) 6834_Forward (Bsg1) 5’: GCATACGGCTTTCCAGTTC 
6834_Reverse (Not1) 5’: TTTTGCGGCCGCCTACAGCCTCCAATCTATCTCACC 
BLLF2 (p6835) 6835_Forward (Pml1) 5’: GAGAACCCACTGCTTACTG 
6835_Reverse (Not1) 5’: TTTTGCGGCCGCCTAGCATGGAGAGGTTTGAGAATC 
BLLF3 (p6836) 6836_Forward (Cla1) 5’: CCGATGAAGACCACAACTG 
6836_Reverse (Not1) 5’: AAAAGCGGCCGCTCATTGACCCGAGGATCCAAACCC 
BLRF3 (p6837) 6837_Top (Bgl2) 5’:  
GATCTAAGAACACTTCTTCAAGCGATTGGAGCCGCGGCTACGGTGAGCATCCCTATGGCCTAAGC 
6837_Bottom (Not1) 5’:  
GGCCGCTTAGGCCATAGGGATGCTCACCGTAGCCGCGGCTCCAATCGCTTGAAGAAGTGTTCTTA 
BMLF1 (p6838) 6838_Forward (Bpu101) 5’: TCTACATCACCTGTGCCACG 
6838_Reverse (Not1) 5’: AAAAGCGGCCGCTTATTGATTTAATCCAGGAACAAA 
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BNLF2a (p6839) 6839_Forward (Nco1) 5’: CGGGACTTTCCAAAATGTCG 
6839_Reverse (Not1) 5’: AAAAGCGGCCGCTTAGATGAGGAGCAGGCATAAAAG 
BNLF2b (p6840) 6840_Forward (Mlu1) 5’: CCAAAAGGTCAAAGAACAAGGC 
6840_Reverse (Not1) 5’: TTTTGCGGCCGCTTATCCACACCATCCCAATTCACA 
BRLF1 (p6841) 6841_Forward (Age1) 5’: TATGTTCCTGCCAAAGCCG 
6841_Reverse (Not1) 5’: AAAAGCGGCCGCCTAAAATAAGCTGGTGTCAAAAAT 
BRRF1 (p6842) 6842_Forward (Xho1) 5’: GGTATGAGGAAGGTAATCGC 
6842_Reverse (Not1) 5’: TTTTGCGGCCGCTTATTTGTATTGCATGGCAGAACA 
BSLF1 (p6843) 6843_Top (Nhe1) 5’: 
CTAGCCCGTCGTAGAGACAGACAAGATGGTTCCTTCTCAGAGACTCTCCCGAACTAGGC 




6844_Forward (Bpu101) 5’: CTTCTACATCACCTGTGCC 
6844_Reverse (Not1) 5’: AAAAGCGGCCGCTTATTGATTTAATCCAGGAACAAA 
BTRF1 (p6845) 6845_Top (Blp1) 5’: 
TGAGCTTGGCACCATGGCACAGTTTCTAGGAAAGTACATCAAGGTCAAGAAGGAAACTGGAATGTACACACTG
GTCAAGCTTTATTACCTGCTGCGCATCTAAGC 
6845_Bottom (Not1) 5’: 
GGCCGCTTAGATGCGCAGCAGGTAATAAAGCTTGACCAGTGTGTACATTCCAGTTTCCTTCTTGACCTTGATGTA
CTTTCCTAGAAACTGTGCCATGGTGCCAAGC 
BVLF1 (p6846)  6846_Top (Blp1) 5’: TCAGCTTGGGGCCACCGGGGAGGCCAGGTAGGC 
6846_Bottom (Not1) 5’: GGCCGCCTACCTGGCCTCCCCGGTGGCCCCAAGC 
BVRF2 (p6847) 6847_Forward (BbvC1) 5’: TACGAAGTGCCCAGATACG 
6847_Reverse (Not1) 5’: TTTTGCGGCCGCTCAAGCCACGCGTTTATTCAGCAA 
BXRF1 (p6848) 6848_Top (Xho1) 5’: 
TCGAGCTGGCAGAGCGGGAGGCCGAAAGGGCCAGGTCGGAGCGGTGGGACAGGTGTGCCCAGGTGCTCAA
AAATAGGC 
6848_Bottom (Not1) 5’:  
GGCCGCCTATTTTTGAGCACCTGGGCACACCTGTCCCACCGCTCCGACCTGGCCCTTTCGGCCTCCCGCTCTGC
CAGC 
BALF2 (p6927) 6927_Top (PspX1) 5’: TCGAGGTCTAGTCGATATCGCGGCCGCT 
6927_Bot (Xba1) 5’: CTAGAGCGGCCGCGATATCGACTAGACCTCGA 
BLLF1 (p7050) 7050_Forward (Bsu361) 5’: AAATGCCACCAACCACAC 
7050_Reverse (Not1) 5’: TTTTGCGGCCGCTTATACATAGGTCTCGGCGTCATC 
BDLF3.5 (p7078) 7078_Top (Bsg1) 5’: GCACCCTCCTGGACCTGGCCGGGGTGGAATGTCAGACCAAGGCCGATTGAAT 
7078_Bot (Xba1) 5’: CTAGATTCAATCGGCCTTGGTCTGACATTCCACCCCGGCCAGGTCCAGGAGGGTGCAA 
BGLF3.5 (p7079) 7079_Forward (Bgl2) 5’: CGGGACTTTCCAAAATGTCG 
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7079_Reverse (Xba1) 5’: AAAATCTAGATTCAATGACAGTCACCTTCCCCAAA 
BHLF1 (p7080) The sequence was restored with a PCR product using p2089 DNA as template 






LF1 (p7082) 7082_Forward (EcoR5) 5’: AGAGGAGATGTGGCACTCAG 
7082_Reverse (Xba1) 5’: TTTTTCTAGATTCAGTGCTGCATGGGCTCTTC 
LF2 (p7083) 7083_Forward (BspE1) 5’: ACAACAACACCTACGAGGC 
7083_Reverse (EcoR5) 5’: TTTTGATATCGATTACAGAGTGCCCTCGGAGG 
sLF3 (p7084) 7084_Forward (BstE2) 5’: ATCGGGGTGACCATCAACTG 
7084_Reverse (Xho1) 5’: TTTTCTCGAGTCAGAAGAGGAGGGGCAGCAG 
A73 (p7085) 7085_Forward (Bsp1201, BsrG1) 5’: TGAACAAGCCCCCAACAGTG 
7085_Reverse (Xba1) 5’: TTTTTCTAGATTACAGCTCCTCAGGGCTGG 






To restore the original genes of the EBV gene expression plasmid contained in the library provided by Dr. Josef 
Mautner, the EBNA1 and 6xHis tags were removed by conventional molecular cloning. The table lists primers 
designed for restoring the open reading frame of individual genes. Underlined sequences mark the stop codon 
of the open reading frame. The sequence of BHLF1 (p7080) was replaced with the sequence derived from B95-
8 strain EBV genome. The entire sequence of RPMS1 (p7086) was replaced with codon-optimized synthetic 




Table 7. Overview of synthetic oligonucleotides cloned into the basic lentiviral shRNA expression vector 
plasmid p6924 to be stably introduced into 2089 EBV producer cells 
Target gene 
(plasmid #)  
Oligonucleotide 
GFP shRNA 7272 top 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGAAGTTCACCTTGATGCCGTGTAGTGAAATAT
ATATTAAACACGGCATCAAGGTGAACTTCATTACGGTAACGCGG 
 shRNA 7272 bot 
AATTCCGCGTTACCGTAATGAAGTTCACCTTGATGCCGTGTTTAATATATATTTCACTACACGGCATCAAGGTGA
ACTTCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7273top 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTACTTGTACAGCTCGTCCATGGTAGTGAAATAT
ATATTAAACCATGGACGAGCTGTACAAGTATTACGGTAACGCGG 
 shRNA 7273 bot 
AATTCCGCGTTACCGTAATACTTGTACAGCTCGTCCATGGTTTAATATATATTTCACTACCATGGACGAGCTGTAC
AAGTAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC  
 shRNA 7274 top 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGTAGTTGTACTCCAGCTTGTGGTAGTGAAATAT
ATATTAAACCACAAGCTGGAGTACAACTACTTACGGTAACGCGG 
 shRNA 7274 bot 
AATTCCGCGTTACCGTAAGTAGTTGTACTCCAGCTTGTGGTTTAATATATATTTCACTACCACAAGCTGGAGTAC
AACTACAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BALF4 (p6515) shRNA 6954 for 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAATGTTGTCTTTAAACACCATGTAGTGAAATATA
TATTAAACATGGTGTTTAAAGACAACATTTTACGGTAACGCGG 
 shRNA 6954 rev 
AATTCCGCGTTACCGTAAAATGTTGTCTTTAAACACCATGTTTAATATATATTTCACTACATGGTGTTTAAAGACA
ACATTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6955 for 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTAGTGAGATGAAGGTCTGCAGTAGTGAAATA
TATATTAAACTGCAGACCTTCATCTCACTAATTACGGTAACGCGG 
 shRNA 6955 rev 
AATTCCGCGTTACCGTAATTAGTGAGATGAAGGTCTGCAGTTTAATATATATTTCACTACTGCAGACCTTCATCTC
ACTAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6956 for 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTATAAAATATGTAATGGCTTCGTAGTGAAATATA
TATTAAACGAAGCCATTACATATTTTATATTACGGTAACGCGG 
 shRNA 6956 rev 
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BKRF4 (p6562) shRNA 7296 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGTGTTTATTGTATGTATTGGGGTAGTGAAATATA
TATTAAACCCCAATACATACAATAAACACTTACGGTAACGCGG 
 shRNA 7296 bot  
AATTCCGCGTTACCGTAAGTGTTTATTGTATGTATTGGGGTTTAATATATATTTCACTACCCCAATACATACAATAA
ACACAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC  
 shRNA 7297 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTATTGTATGTATTGGGACTTGTAGTGAAATATA
TATTAAACAAGTCCCAATACATACAATAATTACGGTAACGCGG 
 shRNA 7297 bot  
AATTCCGCGTTACCGTAATTATTGTATGTATTGGGACTTGTTTAATATATATTTCACTACAAGTCCCAATACATACA
ATAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7298 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTATTGTATGTATTGGGACTTGAGTAGTGAAATATA
TATTAAACTCAAGTCCCAATACATACAATTTACGGTAACGCGG 
 shRNA 7298 bot  
AATTCCGCGTTACCGTAAATTGTATGTATTGGGACTTGAGTTTAATATATATTTCACTACTCAAGTCCCAATACATA
CAATAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BVLF1 (p6846) shRNA 7299 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAATAAACTCATCGCACGGGGGTAGTGAAATAT
ATATTAAACCCCCGTGCGATGAGTTTATTTTTACGGTAACGCGG 
 shRNA 7299 bot  
AATTCCGCGTTACCGTAAAAATAAACTCATCGCACGGGGGTTTAATATATATTTCACTACCCCCGTGCGATGAGT
TTATTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7300 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCTTTAGCATCTTCAGGAGGAGTAGTGAAATAT
ATATTAAACTCCTCCTGAAGATGCTAAAGATTACGGTAACGCGG 
 shRNA 7300 bot  
AATTCCGCGTTACCGTAATCTTTAGCATCTTCAGGAGGAGTTTAATATATATTTCACTACTCCTCCTGAAGATGCT
AAAGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7301 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAAAGTTAACACTTAGGGTCAGTAGTGAAATAT
ATATTAAACTGACCCTAAGTGTTAACTTTTTTACGGTAACGCGG 
 shRNA 7301 bot  
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BNLF2a (p6839) shRNA 7302 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTATTTATTGCATCACAAGTCGTAGTGAAATATA
TATTAAACGACTTGTGATGCAATAAATAATTACGGTAACGCGG 
 shRNA 7302 bot  
AATTCCGCGTTACCGTAATTATTTATTGCATCACAAGTCGTTTAATATATATTTCACTACGACTTGTGATGCAATAA
ATAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7303 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTATTTATTGCATCACAAGTCAGTAGTGAAATATA
TATTAAACTGACTTGTGATGCAATAAATATTACGGTAACGCGG 
 shRNA 7303 bot  
AATTCCGCGTTACCGTAATATTTATTGCATCACAAGTCAGTTTAATATATATTTCACTACTGACTTGTGATGCAATA
AATAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7304 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTATTGCATCACAAGTCACATGTAGTGAAATATA
TATTAAACATGTGACTTGTGATGCAATAATTACGGTAACGCGG 
 shRNA 7304 bot  
AATTCCGCGTTACCGTAATTATTGCATCACAAGTCACATGTTTAATATATATTTCACTACATGTGACTTGTGATGCA
ATAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BXRF1 (p6848) shRNA 7305 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGTAAATCTTATTGTCCGCGAGTAGTGAAATATA
TATTAAACTCGCGGACAATAAGATTTACATTACGGTAACGCGG 
 shRNA 7305 bot  
AATTCCGCGTTACCGTAATGTAAATCTTATTGTCCGCGAGTTTAATATATATTTCACTACTCGCGGACAATAAGAT
TTACAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7306 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTAAATTCTACAATATAACACCGTAGTGAAATATA
TATTAAACGGTGTTATATTGTAGAATTTATTACGGTAACGCGG 
 shRNA 7306 bot  
AATTCCGCGTTACCGTAATAAATTCTACAATATAACACCGTTTAATATATATTTCACTACGGTGTTATATTGTAGAAT
TTAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7307 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGATAATCTCAAAGAGGGTGTGTAGTGAAATAT
ATATTAAACACACCCTCTTTGAGATTATCATTACGGTAACGCGG 
 shRNA 7307 bot  
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BFLF2 (p6644) shRNA 7308 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTATTTTCCAAAATGAGCTGGGGTAGTGAAATAT
ATATTAAACCCCAGCTCATTTTGGAAAATATTACGGTAACGCGG 
 shRNA 7308 bot  
AATTCCGCGTTACCGTAATATTTTCCAAAATGAGCTGGGGTTTAATATATATTTCACTACCCCAGCTCATTTTGGA
AAATAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC  
 shRNA 7309 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTATTTTCCAAAATGAGCTGGGTAGTGAAATAT
ATATTAAACCCAGCTCATTTTGGAAAATAATTACGGTAACGCGG 
 shRNA 7309 bot  
AATTCCGCGTTACCGTAATTATTTTCCAAAATGAGCTGGGTTTAATATATATTTCACTACCCAGCTCATTTTGGAA
AATAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7310 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTGATAGGACTGTACCAGGTCGTAGTGAAATAT
ATATTAAACGACCTGGTACAGTCCTATCAATTACGGTAACGCGG 
 shRNA 7310 bot  
AATTCCGCGTTACCGTAATTGATAGGACTGTACCAGGTCGTTTAATATATATTTCACTACGACCTGGTACAGTCCT
ATCAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BMRF1 (p5106) shRNA 7311 top (same as 6963 for)  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAGGATTTAATGAATGTCACCAGTAGTGAAATAT
ATATTAAACTGGTGACATTCATTAAATCCTTTACGGTAACGCGG 
 shRNA 7311 bot (same as 6963 rev) 
AATTCCGCGTTACCGTAAAGGATTTAATGAATGTCACCAGTTTAATATATATTTCACTACTGGTGACATTCATTAA
ATCCTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7312 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAAATAACACTAAGATCCAACGTAGTGAAATAT
ATATTAAACGTTGGATCTTAGTGTTATTTTTTACGGTAACGCGG 
 shRNA 7312 bot  
AATTCCGCGTTACCGTAAAAAATAACACTAAGATCCAACGTTTAATATATATTTCACTACGTTGGATCTTAGTGTT
ATTTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7313 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTATCATCATATTCCATAGTGAGTAGTGAAATATAT
ATTAAACTCACTATGGAATATGATGATATTACGGTAACGCGG 
 shRNA 7313 bot  
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BHLF1 (p7080) shRNA 7314 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTAAACAGTTTATTGATAGGTGGTAGTGAAATAT
ATATTAAACCACCTATCAATAAACTGTTTATTACGGTAACGCGG 
 shRNA 7314 bot  
AATTCCGCGTTACCGTAATAAACAGTTTATTGATAGGTGGTTTAATATATATTTCACTACCACCTATCAATAAACTG
TTTAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC  
 shRNA 7315 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGACATGTAGGTGAGTAGTGTGTAGTGAAATAT
ATATTAAACACACTACTCACCTACATGTCATTACGGTAACGCGG 
 shRNA 7315 bot  
AATTCCGCGTTACCGTAATGACATGTAGGTGAGTAGTGTGTTTAATATATATTTCACTACACACTACTCACCTACA
TGTCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7316 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTACTTTTAGAGTGTAGTGTACGTAGTGAAATAT
ATATTAAACGTACACTACACTCTAAAAGTATTACGGTAACGCGG 
 shRNA 7316 bot  
AATTCCGCGTTACCGTAATACTTTTAGAGTGTAGTGTACGTTTAATATATATTTCACTACGTACACTACACTCTAAA
AGTAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BXLF1 (p6571) shRNA 7320 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTAAGTACACTAAAGATGCTGTGTAGTGAAATAT
ATATTAAACACAGCATCTTTAGTGTACTTATTACGGTAACGCGG 
 shRNA 7320 bot  
AATTCCGCGTTACCGTAATAAGTACACTAAAGATGCTGTGTTTAATATATATTTCACTACACAGCATCTTTAGTGT
ACTTAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7321 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGTAAATTAACTTGTAGCGGTGTAGTGAAATAT
ATATTAAACACCGCTACAAGTTAATTTACATTACGGTAACGCGG 
 shRNA 7321 bot  
AATTCCGCGTTACCGTAATGTAAATTAACTTGTAGCGGTGTTTAATATATATTTCACTACACCGCTACAAGTTAAT
TTACAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7322 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAACTTACTAAACTCGCGCCCAGTAGTGAAATAT
ATATTAAACTGGGCGCGAGTTTAGTAAGTTTTACGGTAACGCGG 
 shRNA 7322 bot  
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BVRF2 (p6847) shRNA 7264 top 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTAAATACGACTCGGCTGGGAGTAGTGAAATAT
ATATTAAACTCCCAGCCGAGTCGTATTTAATTACGGTAACGCGG 
 shRNA 7264 bot 
AATTCCGCGTTACCGTAATTAAATACGACTCGGCTGGGAGTTTAATATATATTTCACTACTCCCAGCCGAGTCGT
ATTTAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7265top 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAGTGTTAACTTTTACCTGTGGTAGTGAAATAT
ATATTAAACCACAGGTAAAAGTTAACACTTTTACGGTAACGCGG 
 shRNA 7265 bot 
AATTCCGCGTTACCGTAAAAGTGTTAACTTTTACCTGTGGTTTAATATATATTTCACTACCACAGGTAAAAGTTAA
CACTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7266 top 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTGATGAGGCTGAAATCCGTAGTAGTGAAATAT
ATATTAAACTACGGATTTCAGCCTCATCAATTACGGTAACGCGG 
 shRNA 7266 bot 
AATTCCGCGTTACCGTAATTGATGAGGCTGAAATCCGTAGTTTAATATATATTTCACTACTACGGATTTCAGCCTC
ATCAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BALF2 (p6927) shRNA 7323 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCTCAATCTCATATGTGGTCGGTAGTGAAATATA
TATTAAACCGACCACATATGAGATTGAGATTACGGTAACGCGG 
 shRNA 7323 bot  
AATTCCGCGTTACCGTAATCTCAATCTCATATGTGGTCGGTTTAATATATATTTCACTACCGACCACATATGAGATT
GAGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7324 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCTTGATCTTGATGTTCCTGGGTAGTGAAATATA
TATTAAACCCAGGAACATCAAGATCAAGATTACGGTAACGCGG 
 shRNA 7324 bot  
AATTCCGCGTTACCGTAATCTTGATCTTGATGTTCCTGGGTTTAATATATATTTCACTACCCAGGAACATCAAGAT
CAAGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7325 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCATAAACTGGACCACTTCGGGTAGTGAAATAT
ATATTAAACCCGAAGTGGTCCAGTTTATGATTACGGTAACGCGG 
 shRNA 7325 bot  
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BPLF1 (p6567) shRNA 6975 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTAATAAACAATTACAGATACAGTAGTGAAATATA
TATTAAACTGTATCTGTAATTGTTTATTATTACGGTAACGCGG 
 shRNA 6975 bot  
AATTCCGCGTTACCGTAATAATAAACAATTACAGATACAGTTTAATATATATTTCACTACTGTATCTGTAATTGTTTA
TTAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6976 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTATTAATAAACAATTACAGAGTAGTGAAATATA
TATTAAACTCTGTAATTGTTTATTAATAATTACGGTAACGCGG 
 shRNA 6976 bot  
AATTCCGCGTTACCGTAATTATTAATAAACAATTACAGAGTTTAATATATATTTCACTACTCTGTAATTGTTTATTAA
TAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6977 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCAATAGACAGAAATTGGGTGGTAGTGAAATA
TATATTAAACCACCCAATTTCTGTCTATTGATTACGGTAACGCGG 
 shRNA 6977 bot  
AATTCCGCGTTACCGTAATCAATAGACAGAAATTGGGTGGTTTAATATATATTTCACTACCACCCAATTTCTGTCT
ATTGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BBRF1 (p6593) shRNA 6978 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAAGAATCTTGATAAAACAGGGTAGTGAAATAT
ATATTAAACCCTGTTTTATCAAGATTCTTTTTACGGTAACGCGG 
 shRNA 6978 rev  
AATTCCGCGTTACCGTAAAAAGAATCTTGATAAAACAGGGTTTAATATATATTTCACTACCCTGTTTTATCAAGAT
TCTTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6979 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGGCATTCTCAATCATCGAGAGTAGTGAAATAT
ATATTAAACTCTCGATGATTGAGAATGCCATTACGGTAACGCGG 
 shRNA 6979 rev  
AATTCCGCGTTACCGTAATGGCATTCTCAATCATCGAGAGTTTAATATATATTTCACTACTCTCGATGATTGAGAA
TGCCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6980 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCATGTTGAACATGACCTCAGGTAGTGAAATAT
ATATTAAACCTGAGGTCATGTTCAACATGATTACGGTAACGCGG 
 shRNA 6980 rev  
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BGLF4 (p6561) shRNA 6969 top (same as 6966 top) 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGATGAAGATGTTGACTGGGAGTAGTGAAATA
TATATTAAACTCCCAGTCAACATCTTCATCATTACGGTAACGCGG 
 shRNA 6969 bot (same as 6966 bot) 
AATTCCGCGTTACCGTAATGATGAAGATGTTGACTGGGAGTTTAATATATATTTCACTACTCCCAGTCAACATCTT
CATCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6970 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAATCTGATAAATGACCTCTTGTAGTGAAATATA
TATTAAACAAGAGGTCATTTATCAGATTTTTACGGTAACGCGG 
 shRNA 6970 bot  
AATTCCGCGTTACCGTAAAAATCTGATAAATGACCTCTTGTTTAATATATATTTCACTACAAGAGGTCATTTATCA
GATTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6971 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGAAGTAATCAATGACAGTCACGTAGTGAAATAT
ATATTAAACGTGACTGTCATTGATTACTTCTTACGGTAACGCGG 
 shRNA 6971 bot  
AATTCCGCGTTACCGTAAGAAGTAATCAATGACAGTCACGTTTAATATATATTTCACTACGTGACTGTCATTGATT
ACTTCAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BFRF1 (p6645) shRNA 6992 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTATTAATAAAGTGCATACACGTAGTGAAATATA
TATTAAACGTGTATGCACTTTATTAATAATTACGGTAACGCGG 
 shRNA 6992 bot  
AATTCCGCGTTACCGTAATTATTAATAAAGTGCATACACGTTTAATATATATTTCACTACGTGTATGCACTTTATTAA
TAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6993 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGGATATCACAAACACGGGCGGTAGTGAAATA
TATATTAAACCGCCCGTGTTTGTGATATCCATTACGGTAACGCGG 
 shRNA 6993 bot  
AATTCCGCGTTACCGTAATGGATATCACAAACACGGGCGGTTTAATATATATTTCACTACCGCCCGTGTTTGTGA
TATCCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6994 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGAAATTTAGGAAGCAGGGGAGTAGTGAAATA
TATATTAAACTCCCCTGCTTCCTAAATTTCATTACGGTAACGCGG 
 shRNA 6994 bot  
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BSLF1 (p6843) shRNA 7001 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGATTTGAAAAAATAGACTGGGGTAGTGAAATA
TATATTAAACCCCAGTCTATTTTTTCAAATCTTACGGTAACGCGG 
 shRNA 7001 bot  
AATTCCGCGTTACCGTAAGATTTGAAAAAATAGACTGGGGTTTAATATATATTTCACTACCCCAGTCTATTTTTTC
AAATCAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7002 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCTGTGAATAGTACACTGGGGGTAGTGAAATAT
ATATTAAACCCCCAGTGTACTATTCACAGATTACGGTAACGCGG 
 shRNA 7002 bot  
AATTCCGCGTTACCGTAATCTGTGAATAGTACACTGGGGGTTTAATATATATTTCACTACCCCCAGTGTACTATTC
ACAGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7003 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGTCATTACAAAGTAGTGCCTGGTAGTGAAATAT
ATATTAAACCAGGCACTACTTTGTAATGACTTACGGTAACGCGG 
 shRNA 7003 bot  
AATTCCGCGTTACCGTAAGTCATTACAAAGTAGTGCCTGGTTTAATATATATTTCACTACCAGGCACTACTTTGTA
ATGACAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BTRF1 (p6845) shRNA 7004 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGACATTTCTCATAATGGTGCCGTAGTGAAATATA
TATTAAACGGCACCATTATGAGAAATGTCTTACGGTAACGCGG 
 shRNA 7004 bot  
AATTCCGCGTTACCGTAAGACATTTCTCATAATGGTGCCGTTTAATATATATTTCACTACGGCACCATTATGAGAA
ATGTCAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7005 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTCCTAGAAACTGTGCCATGGGTAGTGAAATAT
ATATTAAACCCATGGCACAGTTTCTAGGAATTACGGTAACGCGG 
 shRNA 7005 bot  
AATTCCGCGTTACCGTAATTCCTAGAAACTGTGCCATGGGTTTAATATATATTTCACTACCCATGGCACAGTTTCT
AGGAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7006 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGTGGAAGACAATCTGTCCCGAGTAGTGAAATA
TATATTAAACTCGGGACAGATTGTCTTCCACTTACGGTAACGCGG 
 shRNA 7006 bot  
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BMRF2 (p6539) shRNA 6963 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAGGATTTAATGAATGTCACCAGTAGTGAAATAT
ATATTAAACTGGTGACATTCATTAAATCCTTTACGGTAACGCGG 
 shRNA 6963 rev  
AATTCCGCGTTACCGTAAAGGATTTAATGAATGTCACCAGTTTAATATATATTTCACTACTGGTGACATTCATTAA
ATCCTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6964 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCACAAACTTCTTAAGCTTGTGTAGTGAAATAT
ATATTAAACACAAGCTTAAGAAGTTTGTGATTACGGTAACGCGG 
 shRNA 6964 rev  
AATTCCGCGTTACCGTAATCACAAACTTCTTAAGCTTGTGTTTAATATATATTTCACTACACAAGCTTAAGAAGTT
TGTGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6965 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTCACAAACTTCTTAAGCTTGTAGTAGTGAAATAT
ATATTAAACTACAAGCTTAAGAAGTTTGTGTTACGGTAACGCGG 
 shRNA 6965 rev  
AATTCCGCGTTACCGTAACACAAACTTCTTAAGCTTGTAGTTTAATATATATTTCACTACTACAAGCTTAAGAAGT
TTGTGAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BBRF3 (p6534) shRNA 6960 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAAGTAAAAGCTGTTGCCCAGGTAGTGAAATA
TATATTAAACCTGGGCAACAGCTTTTACTTTTTACGGTAACGCGG 
 shRNA 6960 rev  
AATTCCGCGTTACCGTAAAAAGTAAAAGCTGTTGCCCAGGTTTAATATATATTTCACTACCTGGGCAACAGCTTT
TACTTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6961 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAATAATTTGCAAAGGGCGTGGTAGTGAAATAT
ATATTAAACCACGCCCTTTGCAAATTATTTTTACGGTAACGCGG 
 shRNA 6961 rev  
AATTCCGCGTTACCGTAAAAATAATTTGCAAAGGGCGTGGTTTAATATATATTTCACTACCACGCCCTTTGCAAA
TTATTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6962 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTTAAATAATTTGCAAAGGGCGTAGTGAAATAT
ATATTAAACGCCCTTTGCAAATTATTTAAATTACGGTAACGCGG 
 shRNA 6962 rev  
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BNRF1 (p6564) shRNA 6972 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCAGTGTATGCATAGTCTGGAGTAGTGAAATAT
ATATTAAACTCCAGACTATGCATACACTGATTACGGTAACGCGG 
 shRNA 6972 bot  
AATTCCGCGTTACCGTAATCAGTGTATGCATAGTCTGGAGTTTAATATATATTTCACTACTCCAGACTATGCATACA
CTGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6973 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTGTAAATACAGCACACAGGTGTAGTGAAATAT
ATATTAAACACCTGTGTGCTGTATTTACAATTACGGTAACGCGG 
 shRNA 6973 bot  
AATTCCGCGTTACCGTAATTGTAAATACAGCACACAGGTGTTTAATATATATTTCACTACACCTGTGTGCTGTATT
TACAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6974 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGCTATTGCATTAACGAAGGGAGTAGTGAAATAT
ATATTAAACTCCCTTCGTTAATGCAATAGCTTACGGTAACGCGG 
 shRNA 6974 bot  
AATTCCGCGTTACCGTAAGCTATTGCATTAACGAAGGGAGTTTAATATATATTTCACTACTCCCTTCGTTAATGCA
ATAGCAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BBLF1 (p6557) shRNA 6966 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGATGAAGATGTTGACTGGGAGTAGTGAAATA
TATATTAAACTCCCAGTCAACATCTTCATCATTACGGTAACGCGG 
 shRNA 6966 rev  
AATTCCGCGTTACCGTAATGATGAAGATGTTGACTGGGAGTTTAATATATATTTCACTACTCCCAGTCAACATCTT
CATCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6967 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCATCATTTTCAGAGTCCTCAGTAGTGAAATATA
TATTAAACTGAGGACTCTGAAAATGATGATTACGGTAACGCGG 
 shRNA 6967 rev  
AATTCCGCGTTACCGTAATCATCATTTTCAGAGTCCTCAGTTTAATATATATTTCACTACTGAGGACTCTGAAAAT
GATGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6968 for  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTGTCAAAAGTATTGTCTGCGTAGTAGTGAAATAT
ATATTAAACTACGCAGACAATACTTTTGACTTACGGTAACGCGG 
 shRNA 6968 rev  
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BRLF1 (p6841) shRNA 6998 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTACTATAACTACATTCAGGGGTAGTGAAATATA
TATTAAACCCCTGAATGTAGTTATAGTAATTACGGTAACGCGG 
 shRNA 6998 bot  
AATTCCGCGTTACCGTAATTACTATAACTACATTCAGGGGTTTAATATATATTTCACTACCCCTGAATGTAGTTATA
GTAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6999 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTCATCATTTAGAAATGTATCCAGTAGTGAAATATA
TATTAAACTGGATACATTTCTAAATGATGTTACGGTAACGCGG 
 shRNA 6999 bot 
AATTCCGCGTTACCGTAACATCATTTAGAAATGTATCCAGTTTAATATATATTTCACTACTGGATACATTTCTAAAT
GATGAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 7000 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTACTATAACTACATTCAGGGATGTAGTGAAATATA
TATTAAACATCCCTGAATGTAGTTATAGTTTACGGTAACGCGG 
 shRNA 7000 bot  
AATTCCGCGTTACCGTAAACTATAACTACATTCAGGGATGTTTAATATATATTTCACTACATCCCTGAATGTAGTTA
TAGTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BALF1 (p6632) shRNA 6986 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCATTTACAAAGATTTCAGGAGTAGTGAAATAT
ATATTAAACTCCTGAAATCTTTGTAAATGATTACGGTAACGCGG 
 shRNA 6986 bot  
AATTCCGCGTTACCGTAATCATTTACAAAGATTTCAGGAGTTTAATATATATTTCACTACTCCTGAAATCTTTGTAA
ATGAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6987 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTATTCATTTACAAAGATTTCAGGTAGTGAAATATA
TATTAAACCTGAAATCTTTGTAAATGAATTTACGGTAACGCGG 
 shRNA 6987 bot  
AATTCCGCGTTACCGTAAATTCATTTACAAAGATTTCAGGTTTAATATATATTTCACTACCTGAAATCTTTGTAAAT
GAATAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6988 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTACAAAGATTTCAGGAAGTCGTAGTGAAATAT
ATATTAAACGACTTCCTGAAATCTTTGTAATTACGGTAACGCGG 
 shRNA 6988 bot  
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BBRF2 (p6639) shRNA 6989 top (same as 6978 top) 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTAAAGAATCTTGATAAAACAGGGTAGTGAAATAT
ATATTAAACCCTGTTTTATCAAGATTCTTTTTACGGTAACGCGG 
 shRNA 6989 bot (same as 6978 bot) 
AATTCCGCGTTACCGTAAAAAGAATCTTGATAAAACAGGGTTTAATATATATTTCACTACCCTGTTTTATCAAGAT
TCTTTAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6990 top (same as 6979 top) 
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGGCATTCTCAATCATCGAGAGTAGTGAAATAT
ATATTAAACTCTCGATGATTGAGAATGCCATTACGGTAACGCGG 
 shRNA 6990 bot (same as 6979 bot) 
AATTCCGCGTTACCGTAATGGCATTCTCAATCATCGAGAGTTTAATATATATTTCACTACTCTCGATGATTGAGAA
TGCCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6991 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGGTCAATAAAGAATCTTGATGTAGTGAAATAT
ATATTAAACATCAAGATTCTTTATTGACCATTACGGTAACGCGG 
 shRNA 6991 bot  
AATTCCGCGTTACCGTAATGGTCAATAAAGAATCTTGATGTTTAATATATATTTCACTACATCAAGATTCTTTATTG
ACCAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
BMLF1 (p6838) shRNA 6995 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTGTAATTCTTGATGTAGTGGCGTAGTGAAATAT
ATATTAAACGCCACTACATCAAGAATTACATTACGGTAACGCGG 
 shRNA 6995 bot  
AATTCCGCGTTACCGTAATGTAATTCTTGATGTAGTGGCGTTTAATATATATTTCACTACGCCACTACATCAAGAA
TTACAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6996 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTTATTGATTTAATCCAGGAACGTAGTGAAATATA
TATTAAACGTTCCTGGATTAAATCAATAATTACGGTAACGCGG 
 shRNA 6996 bot  
AATTCCGCGTTACCGTAATTATTGATTTAATCCAGGAACGTTTAATATATATTTCACTACGTTCCTGGATTAAATCA
ATAAAGACGGATACGCGTATGTCAGTTCATCCAAACATAAAC 
 shRNA 6997 top  
CTAGGTTTATGTTTGGATGAACTGACATACGCGTATCCGTCTTCACAAAGTTGTAGTCTCGCGGTAGTGAAATAT
ATATTAAACCGCGAGACTACAACTTTGTGATTACGGTAACGCGG 
 shRNA 6997 bot  
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Target gene 




 Antisense/target: red-colored (top, for) and brown-colored (bot, rev) 
Sense/passenger: green-colored (top, for) and blue-colored (bot, rev) 
Each shRNA sequence consists of a pair of oligonucleotides, encoding the forward and reverse strand. The 
antisense shRNA sequences are colored in red (forward) and brown (reverse) and the sense sequences are 
colored in green (forward) and blue (reverse). Additionally, the last nucleotide of oligonucleotide sequnences 
in sense orientation was replaced with thymine (T) to increase the knockdown efficiency of shRNAs (Watanabe 








GFP (p7275) 7275 for (shGFP)  
TCGAGACGGCATCAAGGTGAACTTCAAAATTCATGGACGAGCTGTACAAGTAAAATTCACAAGCTGGAGTA
CAACTACAGC 
 7275 rev (shGFP)  
GGCCGCTGTAGTTGTACTCCAGCTTGTGAATTTTACTTGTACAGCTCGTCCATGAATTTTGAAGTTCACCTTG
ATGCCGTC 
BALF4 (p7204) 7204 for (sh6515-2, BALF4)  
TCGAGATGGTGTTTAAAGACAACATTAAATTTGCAGACCTTCATCTCACTAAAAATTGAAGCCATTACATATTT
TATAAGC 
 7204 rev (sh6515-2, BALF4)  
GGCCGCTTATAAAATATGTAATGGCTTCAATTTTTAGTGAGATGAAGGTCTGCAAATTTAATGTTGTCTTTAAA
CACCATC 
BKRF4 (p7329) 7329 top (sh6562, BKRF4)  
TCGAGCCCAATACATACAATAAACACAAATTAAGTCCCAATACATACAATAAAAATTTCAAGTCCCAATACATA
CAATAGC 
 7329 bot (sh6562, BKRF4)  
GGCCGCTATTGTATGTATTGGGACTTGAAATTTTTATTGTATGTATTGGGACTTAATTTGTGTTTATTGTATGTAT
TGGGC  
BVLF1 (p7330) 7330 top (sh6846, BVLF1)  
TCGAGCCCCGTGCGATGAGTTTATTTAAATTTCCTCCTGAAGATGCTAAAGAAAATTTGACCCTAAGTGTTAA
CTTTTAGC 
 7330 bot (sh6846, BVLF1)  
GGCCGCTAAAAGTTAACACTTAGGGTCAAATTTTCTTTAGCATCTTCAGGAGGAAATTTAAATAAACTCATCG
CACGGGGC  
BNLF2a (p7331) 7331 top (sh6839, BNLF2a)  
TCGAGGACTTGTGATGCAATAAATAAAAATTTGACTTGTGATGCAATAAATAAAATTATGTGACTTGTGATGC
AATAAAGC 
 7331 bot (sh6839, BNLF2a)  
GGCCGCTTTATTGCATCACAAGTCACATAATTTTATTTATTGCATCACAAGTCAAATTTTTATTTATTGCATCAC
AAGTCC 
BXRF1 (p7332) 7332 top (sh6848, BXRF1)  
TCGAGTCGCGGACAATAAGATTTACAAAATTGGTGTTATATTGTAGAATTTAAAATTACACCCTCTTTGAGATT
ATCAAGC 







BFLF2 (p7333) 7333 top (sh6644, BFLF2)  
TCGAGCCCAGCTCATTTTGGAAAATAAAATTCCAGCTCATTTTGGAAAATAAAAATTGACCTGGTACAGTCCT
ATCAAAGC 
 7333 bot (sh6644, BFLF2)  
GGCCGCTTTGATAGGACTGTACCAGGTCAATTTTTATTTTCCAAAATGAGCTGGAATTTTATTTTCCAAAATG
AGCTGGGC 
BMRF1 (p7334) 7334 top (sh5106, BMRF1)  
TCGAGTGGTGACATTCATTAAATCCTAAATTGTTGGATCTTAGTGTTATTTTAAATTTCACTATGGAATATGATG
ATAAGC 
 7334 bot (sh5106, BMRF1)  
GGCCGCTTATCATCATATTCCATAGTGAAATTTAAAATAACACTAAGATCCAACAATTTAGGATTTAATGAATGT
CACCAC  
BHLF1 (p7335) 7335 top (sh7080, BHLF1)  
TCGAGCACCTATCAATAAACTGTTTAAAATTACACTACTCACCTACATGTCAAAATTGTACACTACACTCTAAA
AGTAAGC 
 7335 bot (sh7080, BHLF1)  
GGCCGCTTACTTTTAGAGTGTAGTGTACAATTTTGACATGTAGGTGAGTAGTGTAATTTTAAACAGTTTATTG
ATAGGTGC 
BXLF1 (p7337) 7337 top (sh6571, BXLF1)  
TCGAGACAGCATCTTTAGTGTACTTAAAATTACCGCTACAAGTTAATTTACAAAATTTGGGCGCGAGTTTAGT
AAGTTAGC 
 7337 bot (sh6571, BXLF1)  
GGCCGCTAACTTACTAAACTCGCGCCCAAATTTTGTAAATTAACTTGTAGCGGTAATTTTAAGTACACTAAAG
ATGCTGTC 
BVRF2 (p7267) 7267 for (sh6847, BVRF2)  
TCGAGTCCCAGCCGAGTCGTATTTAAAAATTCACAGGTAAAAGTTAACACTTAAATTTACGGATTTCAGCCTC
ATCAAAGC 
 7267 rev (sh6847, BVRF2)  
GGCCGCTTTGATGAGGCTGAAATCCGTAAATTTAAGTGTTAACTTTTACCTGTGAATTTTTAAATACGACTCG
GCTGGGAC  
BALF2 (p7338) 7338 top (sh6927, BALF2)  
TCGAGCGACCACATATGAGATTGAGAAAATTCCAGGAACATCAAGATCAAGAAAATTCCGAAGTGGTCCAG
TTTATGAAGC 







BPLF1 (p7211) 7211 for (sh6567-2, BPLF1)  
TCGAGTGTATCTGTAATTGTTTATTAAAATTTCTGTAATTGTTTATTAATAAAAATTCACCCAATTTCTGTCTATT
GAAGC 
 7211 rev (sh6567-2, BPLF1)  
GGCCGCTTCAATAGACAGAAATTGGGTGAATTTTTATTAATAAACAATTACAGAAATTTTAATAAACAATTACA
GATACAC 
BBRF1 (p7212) 7212 for (sh6593-4, BRRF1)  
TCGAGCCTGTTTTATCAAGATTCTTTAAATTTCTCGATGATTGAGAATGCCAAAATTCTGAGGTCATGTTCAAC
ATGAAGC 
 7212 rev (sh6593-4, BRRF1)  
GGCCGCTTCATGTTGAACATGACCTCAGAATTTTGGCATTCTCAATCATCGAGAAATTTAAAGAATCTTGATA
AAACAGGC 
BGLF4 (p7209) 7209 for (sh6561-2, BGLF4)  
TCGAGTCCCAGTCAACATCTTCATCAAAATTAAGAGGTCATTTATCAGATTTAAATTGTGACTGTCATTGATTA
CTTCAGC  
 7209 rev (sh6561-2, BGLF4)  
GGCCGCTGAAGTAATCAATGACAGTCACAATTTAAATCTGATAAATGACCTCTTAATTTTGATGAAGATGTTG
ACTGGGAC 
BFRF1 (p7215) 7215 for (sh6645-2, BFRF1)  
TCGAGGTGTATGCACTTTATTAATAAAAATTCGCCCGTGTTTGTGATATCCAAAATTTCCCCTGCTTCCTAAATT
TCAAGC  
 7215 rev (sh6645-2, BFRF1)  
GGCCGCTTGAAATTTAGGAAGCAGGGGAAATTTTGGATATCACAAACACGGGCGAATTTTTATTAATAAAGT
GCATACACC 
BSLF1 (p7218) 7218 for (sh6843-2, BSLF1)  
TCGAGCCCAGTCTATTTTTTCAAATCAAATTCCCCAGTGTACTATTCACAGAAAATTCAGGCACTACTTTGTAA
TGACAGC 
 7218 rev (sh6843-2, BSLF1)  
GGCCGCTGTCATTACAAAGTAGTGCCTGAATTTTCTGTGAATAGTACACTGGGGAATTTGATTTGAAAAAATA
GACTGGGC 
BTRF1 (p7219) 7219 for (sh6845-2, BTRF1)  
TCGAGGGCACCATTATGAGAAATGTCAAATTCCATGGCACAGTTTCTAGGAAAAATTTCGGGACAGATTGTC
TTCCACAGC 







BMRF2 (p7207) 7207 for (sh6539-2, BMRF2)  
TCGAGTGGTGACATTCATTAAATCCTAAATTACAAGCTTAAGAAGTTTGTGAAAATTTACAAGCTTAAGAAGT
TTGTGAGC 
 7207 rev (sh6539-2, BMRF2)  
GGCCGCTCACAAACTTCTTAAGCTTGTAAATTTTCACAAACTTCTTAAGCTTGTAATTTAGGATTTAATGAATG
TCACCAC 
BBRF3 (p7206) 7206 for (sh6534-4, BRRF3)  
TCGAGCTGGGCAACAGCTTTTACTTTAAATTCACGCCCTTTGCAAATTATTTAAATTGCCCTTTGCAAATTATT
TAAAAGC 
 7206 rev (sh6534-4, BRRF3)  
GGCCGCTTTTAAATAATTTGCAAAGGGCAATTTAAATAATTTGCAAAGGGCGTGAATTTAAAGTAAAAGCTG
TTGCCCAGC 
BNRF1 (p7210) 7210 for (sh6564-2, BNRF1)  
TCGAGTCCAGACTATGCATACACTGAAAATTACCTGTGTGCTGTATTTACAAAAATTTCCCTTCGTTAATGCAA
TAGCAGC 
 7210 rev (sh6564-2, BNRF1)  
GGCCGCTGCTATTGCATTAACGAAGGGAAATTTTTGTAAATACAGCACACAGGTAATTTTCAGTGTATGCATA
GTCTGGAC 
BBLF1 (p7208) 7208 for (sh6557-2, BBLF1)  
TCGAGTCCCAGTCAACATCTTCATCAAAATTTGAGGACTCTGAAAATGATGAAAATTTACGCAGACAATACTT
TTGACAGC 
 7208 rev (sh6557-2, BBLF1)  
GGCCGCTGTCAAAAGTATTGTCTGCGTAAATTTTCATCATTTTCAGAGTCCTCAAATTTTGATGAAGATGTTG
ACTGGGAC 
BRLF1 (p7217) 7217 for (sh6841-2, BRLF1)  
TCGAGCCCTGAATGTAGTTATAGTAAAAATTTGGATACATTTCTAAATGATGAAATTATCCCTGAATGTAGTTAT
AGTAGC 
 7217 rev (sh6841-2, BRLF1)  
GGCCGCTACTATAACTACATTCAGGGATAATTTCATCATTTAGAAATGTATCCAAATTTTTACTATAACTACATTC
AGGGC 
BALF1 (p7213) 7213 for (sh6632-2, BALF1)  
TCGAGTCCTGAAATCTTTGTAAATGAAAATTCTGAAATCTTTGTAAATGAATAAATTGACTTCCTGAAATCTTT
GTAAAGC 







BBRF2 (p7214) 7214 for (sh6639-2, BBRF2)  
TCGAGCCTGTTTTATCAAGATTCTTTAAATTTCTCGATGATTGAGAATGCCAAAATTATCAAGATTCTTTATTGA
CCAAGC  
 7214 rev (sh6639-2, BBRF2)  
GGCCGCTTGGTCAATAAAGAATCTTGATAATTTTGGCATTCTCAATCATCGAGAAATTTAAAGAATCTTGATAA
AACAGGC 
BMLF1 (p7216) 7216 for (sh6838-2, BMLF1)  
TCGAGGCCACTACATCAAGAATTACAAAATTGTTCCTGGATTAAATCAATAAAAATTCGCGAGACTACAACTT
TGTGAAGC 
 7216 rev (sh6838-2, BMLF1)  
GGCCGCTTCACAAAGTTGTAGTCTCGCGAATTTTTATTGATTTAATCCAGGAACAATTTTGTAATTCTTGATGT
AGTGGCC 
 Sense/target: three individual red-colored sequences 
Antisense: three individual brown-colored sequences 
Each luciferase reporter contains a pair (sense and antisense orientation) of oligonucleotides, which 
encompass three corresponding perfect-match target sequences corresponding to each of the three shRNAs 
per viral transcript as listed in Table 7. The shRNA target sequences are colored in red (forward, sense 
orientation) or brown (reverse orientation).  
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